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Abstract 
Inborn errors of metabolism (IEMs) constitute a major class of genetic disorder. Most of 
IEMs are transmitted recessively, so consanguinity has a huge impact on disease 
prevalence, particularly in societies like Saudi Arabia, where consanguineous marriage is 
common. Understanding and treatment are very important in genetic diseases, and simple 
models would be helpful. Thus, the feasibility of applying the fruit fly, Drosophila 
melanogaster, as a model for a human renal genetic disease - xanthinuria - was investigated. 
Xanthinuria is a rare human genetic disease, caused by mutations in xanthine oxidase or 
molybdenum cofactor sulphurase; in Drosophila, the homologous genes are rosy (ry) and 
maroon-like (mal), respectively. 
The new Orbitrap technology of mass spectrometry has the potential to determine levels of 
many metabolites simultaneously by exact mass, and a major part of this thesis was to 
investigate the utility of Orbitrap technology in metabolomics of both wild-type and 
Drosophila mutant. Repeatable significant differences were identified between ry and wild-
type flies, which recapitulated painstaking analytical biochemical determinations of the 
1950s, but with greater precision. Additionally, completely novel impacts of the ry mutation 
(on pyrimidine metabolism, the urea cycle and osmolyte biosynthesis) were identified. 
As expected mal mutants showed more similar changes as ry, but with widespread 
metabolic perturbations.. 
The online resource, FlyAtlas.org, provides detailed microarray-based expression data for 
multiple tissues and life-stages of Drosophila. Downstream genes, such as urate oxidase, 
are utterly tubule-specific. Accordingly, the utility of Orbitrap technology in elucidating 
tissue-specific metabolomes was also investigated. Additionally, genetic interventions using 
designed RNAi constructs were also made and validated by QPCR and metabolomics. As 
urate is a potent antioxidant, survival of urate oxidase knockdowns was tested in vivo, and a 
significant impact on survival identified. 
An Affymetrix microarray was performed, comparing ry506 mutant flies against wild-type 
and differences were identified in a second experiment, the anti-gout drug allopurinol was 
used to phenocopy the effects of ry. 
Overall, the thesis showed that Orbitrap technology was highly suitable for metabolomic 
analysis of both wild-type and mutant Drosophila, and had potential in the analysis of 
metabolomes of single tissues. The possibility of using Orbitrap-based metabolomics in 
human diagnosis is discussed. 
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Chapter 1 Introduction 
 2 
1.1 Human genetic disease 
Many human diseases are either genetic or have a genetic contribution (Goh et al., 
2007). Scientists have classified genetic diseases into subcategories, namely; multi-
factorial, chromosomal, mitochondrial and single gene disorders.  Multi-factorial 
diseases are caused by a mixture of environmental factors and mutations (or 
polymorphisms) in multiple genes. Some examples include diabetes, cancer, and 
obesity. Because of their nature, management of multifactorial diseases is more 
complicated than the other types. Chromosomal diseases are caused by abnormalities in 
chromosomal number or structure. Usually several or many genes are defective, for 
example in Down syndrome (trisomy 21). In mitochondrial diseases, chromosomal 
DNA is intact but rather the mitochondrial DNA carries mutations. Each mitochondrion 
contains 5 to 10 circular pieces of maternally-inherited DNA. An example is Leber’s 
hereditary optic neuropathy (LHON), caused by defects in genes encoding subunits of 
mitochondrial complex I.  The fourth category (single gene disorder) is of particular 
relevance to this thesis. Single gene disorders are classified into further groups 
according to mode of inheritance, into autosomal, dominant or recessive, or X-linked 
recessive.  
Diseases of dominant or mitochondrial inheritance are rarely found in the neonatal 
period; however, autosomal or X-lined recessive inheritance constitute the major causes 
of disease development (Ellaway et al., 2002).  
As previously mentioned, all categories of genetic disease are found worldwide; 
however, the autosomal recessive mode of inheritance is particularly favoured by 
factors (for example, geographical isolation, close tribal affiliations, large family size 
and a culture of consanguineous marriage (Al-Gazali et al., 2006)) that are common in 
the Arab countries (Figure  1-1). 
In Saudi Arabia, for example, certain inborn errors of metabolism (IEM) are far more 
common than in the western world (Table  1-1), and neonatal screening must thus be 
more comprehensive. These unique inborn errors of metabolism are attributed to the 
consanguineous marriages practiced in the Arab world, especially in a country like 
Saudi Arabia (Al-Odaib et al., 2003).  
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Figure  1-1. Distribution of consanguineous (second cousin or closer) marriages 
worldwide. (Tadmouri et al., 2009). 
 
Table  1-1. Incidence of selected IEMs in Saudi Arabia compared to Europe and USA.  
Personal communication from Dr. Hazem Ghneim: (Ghneim, 2010) 
Disease  KSA Germany USA 
PKU 1: 10,528 1:10,400 1: 19,000 
MSUD 1: 6,016 1: 250,000 1: 940,000 
ASL 1: 8,423 1: 250,000 1: 940,000 
ADSL 1: 16,845 No cases 1: 190,000 
HMG 1: 42,113 No cases No cases 
IVA 1: 42,113 1: 62,500 1: 130,000 
MMA 1: 5,615 1: 125,000 1: 90,000 
PA 1: 42,113 1: 250,000 1:300,000 
BKT 1:84,226 No cases 1: 470,000 
GA-I 1: 42,113 1: 83,300 1:190,000 
MCAD 1:1:12,032 1: 20,800 1:13,000 
3MCC 1:10,528 1: 125,000 1:36,000 
    
Total screened 84,226 250,000 940,000 
Overall incidence 1: 732 1: 2,400 1: 4,300 
PKU; Phenylketonuria; MSUD, Maple syrup urine disease; ASL, Argininosuccinate 
lyase; ADSL, Adenylosuccinate Lyase deficiency; HMG, 3-hydroxy-3-methylglutaryl-
coenzyme A lyase deficiency (also known as HMG-CoA lyase deficiency); IVA,  
Isovaleric Acidemia; MMA, Methylmalonic Acidemia; PA, Propionic Acidemia; BKT, 
Ketothiolase Deficiency; GA-I, Glutaric Acidemia  Type 1; MCAD, Medium-chain 
acyl-coenzyme A dehydrogenase deficiency; 3MCC, 3-methylcrotonyl-coenzyme A 
carboxylase deficiency. 
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1.2 Consanguinity in the Arab world 
All humans are heterozygous for several lethal recessive mutations (Consortium, 2010). 
In an outbred genetic system this is not a severe problem. However, in societies with 
high levels of consanguineous marriage, the impact will be severe. In Arabic 
communities for example, first or second cousin marriages are very common (Figure 
 1-2). Consequently, autosomal recessive disorders, when present, are unsurprisingly 
going to spread in this community. So when parents are both heterozygous for a given 
mutation, any child has a 25% likelihood of being affected. In Saudi Arabia, in 
particular, consanguinity rates are about 50%, of which 60% are at a first-cousin level of 
consanguinity (El Mouzan et al., 2008); furthermore, the Kingdom is considered to have 
one of the highest birth rates in the Middle East and North Africa (Saadallah and 
Rashed, 2007).  
 
Figure  1-2. High level of consanguinity among Arabs (Al-Gazali et al., 2006). Two 
Arab family pedigrees, showing intermarriages over several generations. 
So premarital screening programmes for congenital diseases could help significantly to 
limit the incidence and impact of inborn errors of metabolism. In the Jewish population, 
for example, Tay-Sachs disease incidence is ten times higher when compared with other 
races (Myerowitz and Costigan, 1988). Thus, an effective premarital screening program 
(Kaback et al., 1993) and carrier detection (Kronn et al., 1998) are very important 
(Kaback et al., 1993). At the same time, global population screening-based programs are 
also indicated (Kaback, 2000) and (Bach et al., 2001).  
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Although premarital screening is an ideal solution, it is not always practical or 
economic; so in practice both diagnosis and treatment must also be researched. In order 
to have better understanding, and to improve management of human genetic disorders, 
good animal models are desirable. The requirements of such models are discussed 
further in section  1.5. 
 
1.3 Inborn errors of metabolism (IEMs) 
This term was coined by Sir Archibald Garrod, the British physician, to describe a 
group of disorders which result from failure of steps in a biochemical pathway (Houten, 
2009). Inborn errors of metabolism (IEMs) consist of a group of largely monogenic 
disorders. The clinical manifestations appear as results of an enzyme malfunction a few 
examples can be seen in Table  1-2 and Figure  1-3.  
Table  1-2. Possible impacts of inborn errors of metabolism. 
No. Type of disease Example Defective enzyme 
1 Lack of immediate product GSD-I G6P  
2 Accumulation of immediate precursor Galactosemia  GALT 
3 Accumulation of remote precursor G6PD, PKU G6PDH, PAH 
4 Failure of feedback inhibition LNS HGPRT 
GSD-I;   Glycogen storage disease type I , G6P; Glucose-6-phosphatase, GALT; galactose-1- phosphate 
uridyl transferase, G6PD; Glucose-6-phosphate dehydrogenase deficiency, G6PDH; Glucose-6-phosphate 
dehydrogenase, PKU; Phenylketonuria, PAH; phenylalanine hydroxylase, LNS; Lesch-Nyhan syndrome, 
HGPRT; Hypoxanthine-guanine phosphoribosyltransferase. (Pinksy, 1972).  
 
 
Figure  1-3. Possible impacts of biochemical inhibition (Pinksy, 1972) 
In some inborn errors of metabolism, one or more of these biochemical effects produce 
the final metabolic and pathological picture. For example, in glycogen storage disease 
type I (GSD-I), glycogen is accumulated in different tissues, namely liver, intestinal 
mucosa and kidney. This happens as a remote effect of the absence of G6P, the enzyme 
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responsible for converting glucose-1-phosphate (G1P) to glucose, as shown (number 3) 
in Figure  1-3. Furthermore, the same enzyme is also responsible from producing 
glucose from its precursor G3P, which then will be taken into erythrocytes.  Absence of 
the enzyme G6PDH reduces the glucose supply to erythrocytes. This makes the RBCs 
susceptible to haemolytic anaemia; this is represented as number 1 in Figure  1-3. The 
GSD disease pathway is summarized in Figure  1-4. 
 
Figure  1-4. Glycogen storage disease type I. 
Another example of a metabolic disease that arises as a result of accumulation of an 
immediate precursor (number 2 in Figure  1-3), is galactosemia. It is an autosomal 
recessive monogenic metabolic disorder, in which it is not possible to convert galactose 
to glucose because of the absence of galactose-1-phosphate uridyltransferase (GALT). 
If not functioning, accumulation of the immediate precursor, which is Gal-1-P, will be 
obvious. The later, when precipitated within tissues, becomes toxic.  
Also, accumulation of chemical compound as a result of a mutated enzyme sometime 
leads to toxicity. For example, in phenylketonuria, the absence of phenylalanine 
hydroxylase enzyme leads to accumulation of phenylalanine, which leads to progressive 
mental retardation.  
Metabolic diseases can also result from defects in feedback inhibition Figure  1-5, for 
example in Lesch-Nyhan syndrome. The defective enzyme is hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), which is part of the purine salvage pathway. It 
inhibits the biosynthesis of purine from hypoxanthine and guanine. Thus in the absence 
of this inhibition feedback mechanism, excessive uric acid production takes place. This 
can lead to disorders such as gout.  
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Figure  1-5. Purine biosynthesis -Salvage pathway.    
 
1.3.1 Clinical classification of IEMs 
IEMs can be clinically classified into two main categories; I and II (Martins, 1999). 
Diseases which affect the functional or anatomical system are categorized as category I. 
The symptoms are clearer and less complicated than category II. Diseases in this 
category usually affect a specific functional or anatomical system for example the 
endocrine system, immune system or coagulation factors. The symptoms are consistent 
and can easily direct the physician to the defective biochemical pathway. For example, a 
prolonged coagulation time can be a clear indicator of a defect in one of the coagulation 
factors (Martins, 1999).  
On the other hand, category II diseases need careful and thorough investigation. This 
occurs when the affected metabolic pathway is responsible for a common job in 
multiple different cells and organs. Diseases from this category have wide clinical 
diversity, and the disease can manifest as either primary or even as secondary effect of a 
metabolic pathway. They can be divided into three groups (Figure 1-6). Disturbance of 
biosynthesis or catabolism constitute the first group.  As a result of this disturbance, 
complex molecules accumulate in some vital sites, such as lysosomes. Thus they are 
called lysosomal disorders, such as Gaucher disease.  Diseases from group two, lead to 
acute or chronic intoxication. Amino acids related-disorders are the main cause of this 
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group. Examples are: cystinuria, phenylketonuria and Maple syrup urine disease. The 
last, group three, is related to energy deficiency or production diseases. This group 
includes disturbance in the glycolysis and gluconeogenesis defects (Martins, 1999).  
 
Figure  1-6. Clinical classification of IEMs according to Martins, 1999. 
 
1.3.2 Sample selection for diagnosis  
Sample selection varies differently according the metabolic diseases being investigated. 
Samples could be of whole blood, serum, plasma and even urine. Samples are typically 
collected into a collection tube with or without anticoagulant. Recently, Guthrie card 
blood spots for sample collection for inborn errors of metabolism have formed the basis 
for neonatal screening programs.  
The analysis principles and application, later on, varied widely using different detection 
methods; spectrophotometric, radiochemical, or mass-spectrometric methods. These 
detection methods provided a powerful selective screening tool for different inherited 
disorders. However, the above methods for neonatal screening of metabolic disorders 
have common disadvantages: limited diseases covered by each method, high false-
positive rates, and low specificity or sensitivity (Rashed et al., 1997).  
All of those and others disorders are nowadays are mostly diagnosed using mass 
spectrometry. This method is increasingly updated and new analyzers being discovered 
in order to have better and early diagnosis.  
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1.4 Congenital kidney disease 
Most of the genetic renal diseases in human are related to polycystic kidney disease 
(PKD). The frequency was estimated to be between 1 in 500 and 1 in 1,000 live births 
(Rossetti et al., 2007). It is characterized by accumulation of fluids containing cysts in 
the renal parenchyma. This diseases can be inherited either as dominant or recessive 
autosomal forms. The dominant form of the disease mainly affects adults and is caused 
by defective proteins polycystin 1 or polycystin 2, which are encoded by the PKD1 and 
PKD2 genes respectively (Figure 1-7). However, the onset of the recessive form is 
earlier, either in infancy or in early childhood. It is mainly caused by a defective protein 
called fibrocytin, which is encoded by polycystic kidney and hepatic disease  (PKHD) 
gene (Patel et al., 2009).  
Recently, a study suggested that a cellular organelle, the cilium, has a major role in the 
cause of the PKD in all previously mentioned forms of inheritance (Yoder, 2007). It is 
located in the top of most body cells and it is hair-like structure. It has an important role 
in cell proliferation and growth by transducing mechanosensory signals. Thus, any 
mutation in the genes which are involved in ciliary function will lead to PKD (Figure 
 1-8). As a result, fluid transport will also affected; and with time, cells become full with 
fluids. Consequently, with gradual swollen cells become full with fluids and cyst. 
Finally the whole kidney becomes enlarged and end-stage polycystic diseases arises 
(Patel et al., 2009). This particular disorder is an example of one that cannot be 
modelled in Drosophila MT, as Drosophila cells (with the exceptions of sperm and 
some sensory cells) lack primary cilia (Zhang et al., 2004). 
 
Figure  1-7. Structure of PKD 1and 2 after (Stayner and Zhou, 2001). 
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Figure  1-8. Signal transduction by cilium. The function of the cilia is to sense fluid 
movement. PC1, acts as a sensory molecule for fluid that transmits the signal from the 
extracellular to PC2, it also produces sufficient Ca2+ influx to activate intracellular 
ryanodine receptors (RyR). This leading to local increase in the cytosolic Ca2+ 
concentration. This increase in the cystolic Ca2+, regulates numerous molecular 
activities inside the cell that contribute to tissue development (Nauli et al., 2003). 
 
Figure  1-9. Mechanism of progression of PKD. Mutation in PKD 1 & 2 genes which 
encoding the proteins polycystin 1 and 2 leads to abnormalities in tubular fluid secretion 
(A), cell proliferation (B) and tubular basement membranes (C), all of these are give 
rises in renal cysts  (Bennett, 2009). 
 
However, many IEMs also have renal consequences. This can be because the kidney is 
unable to clear sufficient quantities of accumulating metabolite; this can typically 
precipitate to form concretions called kidney stones, and so block the kidney. The term 
nephrolithiasis refers to stone formation within the kidney itself, and urolithiasis to 
formation within the broader urinary tract; both are possible consequences. An example 
of a congenital inherited disorder which affects the kidneys is Xanthinuria type I. It is an 
autosomal recessive genetic disease where the enzyme xanthine oxidase is absent. This 
enzyme is responsible for converting hypoxanthine to xanthine and then to uric acid. In 
the absence of this enzyme, uric acid production is reduced sharply; and as a result the 
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substrates, hypoxanthine and xanthine, accumulate. The consequences of this disorder is 
explained in detail in (Dent and Philpot, 1954).  
 
1.5 Animal models for IEMs 
When the human genome project started, it was thought that answers about human 
hereditary diseases would emerge rapidly (Collins and Mansoura, 2001). However, this 
massive effort mostly produced the sequence of the genome, and did not of itself cure 
any human disease (Sachidanandam et al., 2001). It became clear around a third of all 
genes were entirely novel. How could their function be elucidated?  
So for this reason the approach of reverse genetics has emerged. Reverse genetics, 
unlike forward genetics, is moving from the genotype to phenotype (Lewin, 1986; 
Orkin, 1986; Ruddle, 1982). This means selecting a target gene, then mutating it either 
by knockdown or overexpression, then looking for a phenotype. If a suitable model is 
available, it is possible to perform physiological, behavioural or metabolomic 
experiments.  
 
1.5.1 Mouse 
The mouse is the closest related genetically tractable model to human. It is a mammal, 
and it has defined body organs such as kidneys, heart, lungs and blood. Transgenic lines 
are available in several genomic centres around the world (Dow, 2007). All of these 
characteristics make it a very useful animal model. Furthermore, the whole mouse 
genome has been sequenced. However, can all of these features make it the exclusive 
candidate for all research purposes including genetic studies? The answer is not 
necessarily “yes”.  
Different models have different advantages depending on the question to be addressed. 
For example, when studying DNA replication, E. coli is the best model, as it reproduces 
every 20 minutes. Thus, it is not surprising that the Nobel prize for the study of DNA 
replication was awarded for work on bacteria (Berg and Lehman, 2007) (Dow, 2007).  
Furthermore, in the genetic study, transgenic technique is crucially important to produce 
mutations of specific genes and to intervene in a tissue-specific way. In mouse, this 
procedure it must be planned carefully in terms of cost and time. Constructing a 
transgenic mouse needs several years. There is a huge financial outlay that can reach 
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$100,000 and continuing cost of $10,000 per year to maintain a single line (Dow, 2007). 
Therefore, mouse is not automatically always the best choice as an animal model for 
genetic diseases.  
 
1.5.2 Drosophila  
So we argue that Drosophila melanogaster has clear advantages for studying some 
human disease genes, applying the reverse genetic approach. This is based on the rich 
information available for researchers. For example, availability of the completed 
Drosophila genome sequence (Adams MD, 2000), the tens of thousands of available 
classical mutants in stock centres, RNAi stocks for nearly every gene (Dietzl et al., 
2007), and the FlyAtlas.org (Chintapalli et al., 2007) and Homophila (Reiter et al., 
2001) websites. The last two web sites are for finding the best tissue to select for 
studying, and the fly gene homologues to human disease genes respectively. 
In contrast with mouse, a transgenic fruit-fly line can be made for approximately $500 
in only three months and costs $30 per year to maintain (Dow, 2007). Further details of 
Drosophila melanogaster as genetic model are discussed in section (1.6 Droso. As a 
genetic model)  1.6.    
On the other hand, Drosophila as an invertebrate, suffers from some limitations 
particularly when trying to model genes involved in specifying specifically vertebrate or 
mammalian characteristics, for example creating the four-chambered heart, ducts of 
mammary glands or bone calcification  diseases (Bier, 2005). 
    
1.5.3 When to choose Drosophila vs. mouse 
Despite all of this, all experimentally animal models are vitally important for research. 
However, answering some specific biological questions which will persuade an 
individual to select one over the other (Figure  1-10). For example, some inherited 
metabolic disorders, like Xanthinuria type I, cannot be studied in mouse. The reason 
behind that is the defective xanthine oxidase enzyme, which is responsible for 
xanthinuria, also interferes with milk production in mouse (Wu et al., 1994), (Vorbach 
et al., 2002). Thus, mutated female lines are unable to produce the necessary milk to 
their progenies. While, in Drosophila, it is not only easy to find a mutant, but 
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constructing a transgenic line and targeting the effect specifically to Malpighian tubules 
can be done relatively easily. 
 
Figure  1-10. Trade-off between genetic power and biochemical relevance (Dow, 2007). 
 
1.6 Drosophila as a genetic model 
Drosophila melanogaster has drawn scientists’ attention for approximately 100 years, 
since T.H. Morgan described the first ever discovered white mutant. Since that time, 
Drosophila melanogaster has been extensively used to research biological status in 
health and disease conditions.   
Drosophila, or fruit fly as others call it, is one of the best and powerful genetic animal 
models being used; this is due to its short life cycle, which allows multiple generations 
to be screened quickly. The availability of full Drosophila genome sequence is another 
advantage. The small size of the insect makes it better than many other animal models 
in terms of space in the lab and food requirements.  
At the molecular level, balancers and P-elements provide powerful genetic tools for 
gene transformation and phenotype selection.  Interfering RNA is also one of the 
important molecular genetic tools which helps in field of functional genomics, 
specifically reverse genetics. 
 
1.6.1 P-elements  
There are many transposon families naturally found in the Drosophila genome, the best 
known of which is the P-element. They are important because they are extensively used 
in constructing and generating transgenic flies. The P-element normally contains one 
gene, which encodes the transposase enzyme, required for transposition to take place.  
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This transposable element is autonomous, and is 2.9 kb in size, so they have the ability 
to jump from plasmids into the germlines of the fly. At the same time in the genome, 
smaller incomplete P-elements are present and it is believed that they were generated as 
a result of deletions in the original P-element. The difference between the two P-
elements apart from the size is that the smaller ones are non-autonomous (Rubin and 
Spradling, 1983). 
 
1.6.2 Enhancer trapping 
Enhancer trapping provides a powerful method to map patterns of gene expression in a 
fly or embryo. It also allows the identification of genes that are expressed in a particular 
pattern (O'Hare and Rubin, 1983) (Brand and Perrimon, 1993).  
In most engineered P-elements, the transposase gene is substituted with a genetic cargo 
of choice, together with a reporter gene, mini-white, downstream or a ubiquitous 
promoter, allowing the presence of a P-element to be scored visually in a w- 
background. So this line has a non-motile or trapped P-element. These flies are then 
crossed with another line carrying germline-expressed transposase, mostly from the 
∆2,3 line which contains an incompletely excised (and thus immotile) P-element. So in 
such a cross, the P-element is going to jump only in the germline of the progeny. In 
subsequent generations, flies with red eyed colour are selected for further 
experimentation (Guo, 1996).  
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Figure  1-11 Schematic diagram of first generation enhancer trap. A) The main features of the Drosophila 
transposons. B) Transposon could be inserted between the gene regulatory elements and a gene. C)The 
gene specific regulatory elements can drive the expression of LacZ.  
 
 
1.6.3 GAL4-UAS system 
Using P-elements with a marker gene like white, the transgenes are introduced into the 
flies with the help of a helper plasmid encoding transposase into w- flies to visibly 
identify transgenesis. However, some random insertions show lethality when they were 
made homozygous. This is because of the insertion of the P-element into an essential 
place in the genome. 
In this case these flies will be made heterozygous using the help of balancer 
chromosomes that do not allow recombination. 
 
GAL4 is a transcription factor that is naturally found in yeast ((O'Kane and Gehring, 
1987)). It has been applied to be used in activating the gene transcription in Drosophila. 
By itself, GAL4 has no target gene in the Drosophila but will specifically drive 
expression of the transgenes under the control of upstream activating sequence (UAS). 
Both GAL4 and UAS comes in a bipatriate system developed by brand and perrimon 
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(1993). The GAL4 is either randomly inserted in the genome of the fly or fused 
downstream of a promoter sequence which constitute one component. The other 
component is the transgene of interest cloned under the control of UAS. 
 
When these two systems or in other words flies are mated they will give rise to the 
progeny that have both components. This in turn activate the transgene under the control 
of UAS by the GAL4-specific expression manner. As the GAL4 expression depend on 
the upstream elements it was inserted or fused with, this system is useful in elucidating 
tissue- and cell-specific functions. For example, GAL4 can be placed under the control 
of the urate oxidase gene promoter as this gene is expressed exclusively in the 
Malpighian tubules, the Uro-GAL4 line drives transgene expression with exquisite 
precision  in these tissues (Terhzaz et al., 2010).  This is not as easy as it sounds, it have 
some problems and do not always work because some gene’s promoters not necessarily 
at the start of the gene    , so enhancer trap do not always reflect expression of the gene. 
Another possibility, inserts may unintentntially disrupt a gene. Also, RNAi may not be 
effective, or may have off-target effects.  
 
 
Figure  1-12. The GAL4 UAS system. This diagram showing the GAL4-UAS system in 
gene expression. The expressed gene in this case is an inverted repeat that gives a 
hairpin-like dsRNA which silences a targeted gene (Brand and Perrimon, 1993).  
 
1.6.4 Balancer chromosomes 
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As recessive lethal mutations must be kept alive by providing a functional gene in trans, 
in most species it is necessary to select for the mutant gene in every generation, so 
adding hugely to the cost and complexity of genetic research. A key advantage of 
Drosophila is the relative ease of keeping recessive lethal alleles alive, so allowing large 
stock centres to be built. Here comes the usefulness of balancer chromosomes. A 
balancer is a region which prevents recombination between homologous chromosomes 
during meiosis. This feature is gained from the presence of an inverted region or a series 
of inversions on it. 
 
Typically, balancer chromosomes in the Drosophila melanogaster contain three 
important features: (i) multiple inversions to suppress the recovery of viable 
recombination products over the length of the chromosome; (ii) a dominant visible 
phenotype that enables the inheritance of the chromosome to be tracked easily in 
progenies; and (iii) a recessive lethal mutation that eliminates the homozygous balancer 
from the population of breeding flies. 
 
The inverted regions entirely prevent crossover. The markers also make it very clear 
where the balancer is, even if it is visually indistinguishable from wild-type. This makes 
genetic crosses with balancers totally predictable. 
 
Even though mutations are often detrimental, if left in a stock of flies with a wild-type 
counterpart, after a number of generations they will be lost. Some can be kept on their 
own, if they are viable enough, but some mutations are poorly viable, or totally lethal. 
In this case, in order for the stock of flies to persist, a wild-type copy of the gene must 
be present to rescue the lethality. If present on a wild-type chromosome, the mutation 
will be lost from the stock as the wild-type chromosome takes over. However, if the 
wild-type copy is present on a balancer, the balancer cannot take over as they are 
homozygous lethal.  
 
In the case of a recessive lethal mutation, only files containing the lethal chromosome 
and the balancer can survive. 
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1.6.5 Heritable RNAi 
The complete sequencing of Drosophila melanogaster has encouraged researchers to 
investigate the function of each gene (Adams MD, 2000).  The reverse genetic approach 
is considered as the best choice of elucidating gene function by generating loss of 
function phenotype. To cause a gene malfunction, RNA interference (RNAi) technique 
may be the best choice, because it tends to produce viable hypomorph, rather than 
(possibly lethal) nulls. This then allows physiological studies. Double-stranded RNAi is 
widely used to inactivate genes of interest and provide a powerful tool for gene function 
studies (Fire et al., 1998).  
However, gene silencing by injected dsRNA is transient and consequently is not going 
to be heritable. So heritable dsRNA is highly desirable as an experimental tool. So more 
advanced methods were developed to construct plasmids that are able to express dsRNA 
into transgenic fly. Furthermore, those plasmids or vectors after transcription produce 
inverted repeats or hairpin RNA loops that are substrates for the RISC complex, so 
generating dsRNA (Kennerdell and Carthew, 2000).  
However, cloning long inverted repeats into a plasmid is known to be problematic. This 
is because of the internal deletions that happened as a result of bacterial culturing. To 
solve this problem, a short linker (like a functional intron) must be introduced between 
the repeated sequence (Lee and Carthew, 2003).  
A contemporary vector for the efficient construction of RNAi lines is pRISE (Kondo et 
al., 2006), with the characteristic repeat of the Gateway recombination cassette (Akbari 
et al., 2009) and (Boy et al., 2010). This vector enables the gene silencing effect to be 
achieved more easily and with great efficiency (Kondo et al., 2006).  Further details are 
found in (2.7.6 The pRISE vector for RNAi ) 
 
1.6.6 Malpighian tubules 
Renal function in Drosophila is performed by the Malpighian tubules. Part of this thesis 
is devoted to testing their suitability as a model of mammalian renal dysfunction.    
 
1.6.6.1 History 
The tubules are named after Marcelo Malpighi, who was a physician of the Pope, 500 
years ago. Beside his work as comparative anatomist, he was a pioneer in the use of 
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microscopy. This interest allowed him to apply his skills in microscopy to investigate 
insect anatomy. As a result of this interest he discovered the Malpighian tubules. 
However, it was not demonstrated until the 20th century, that they can produce urine 
(reviewed in Dow and Davies, 2003). Since then, tubules have been extensively studied 
for their excretory and osmoregulatory functions. 
 
1.6.6.2 The Drosophila Malpighian tubules 
The Malpighian tubules are simple, cylinders, closed at one end. They connect to the 
junction of mid-gut and hindgut by the ureters. They are two pairs, anterior and 
posterior and each contribute equally to the function  (Figure  1-13) (Dow and Davies, 
2003). They are among the smallest insects tubules to be studied. They measure 
approximately 2 mm long, 35 µm in diameter and consist of nearly 150 cells. Each 
tubule is divided into multiple segments, namely; initial, transitional and main 
segments, and lower tubule and upper and lower ureter (Sozen et al., 1997).  
 
Each segment in this simple epithelial tube does a specialised function. The initial 
segment of the anterior tubule absorbs calcium and stores it. The main segment is a 
secretory segment heavily involved in fluid transport and other key funcitons of redox 
homeostasis. The lower tubule involved in the reabsorption of the fluid. The ureter joins 
two tubules and opens up into the hindgut.  
 
The main segment of the tubules is composed of two cell types; the columnar epithelial 
principal cells and the star-shaped stellate cells. The principal cells have deep basal 
infoldings and long apical microvilli, and are more abundant than the stellate cells  
(Cabrero et al., 2004). The stellate cells are comparatively small and thin, with shallow 
basal infoldings and short apical microvilli (Wessing, 1978; Wessing and Eichelberg, 
1978). Enhancer trapping has been used to investigate the Malpighian tubule’s 
morphology with great insights identifying a distinct lower segment in both the anterior 
and posterior tubules. Bar-shaped cells and tiny cells in the tubule were discovered by 
Sozen et al., in 1997. The bar-shaped cells are thought to be the equivalent of stellate 
cells in the initial segment, and the tiny cells may be stem cells (Sozen et al., 1997). 
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1.6.6.3 Physiology 
The Malpighian tubules perform various  physiological roles in Drosophila, from the 
expected renal and hepatic roles, to a surprising role in immune response as well as 
osmoregulation.  Active cation transport by the tubules is described by the Wieczorek 
model (Wieczorek et al., 1991). The model suggests that the principal cells use the 
apical proton-pumping activity of the Vacuolar ATPase (V-ATPase) to build a 
favourable transport gradient. Apical alkali metal-proton exchangers are then able to 
drive potassium into the tubule lumen, with water following the potassium due to the 
osmotic gradient. The Wieczorek model seems to fit the tubule experimental data in 
Drosophila, as V-ATPase inhibitors prevent fluid secretion (Dow et al., 1994), and the 
V-ATPase subunits are highly enriched and expressed in the principal cells (Wang et 
al., 2004). The principal cells are also involved in the active transport of cations and 
anions (O'Donnell et al., 1996; Torrie et al., 2004).  
The stellate cells appear to be the site of transcellular chloride shunt and therefore water 
movement (Dow and Davies, 2003). Chloride shunt is controlled by the hormone 
Drosokinin and the second messenger intracellular Ca2+, which increase transcellular 
conductance through chloride channels (O'Donnell et al., 1998). 
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Figure  1-13. Regional differentiation of adult Drosophila Malpighian tubules. After 
(Wessing and Eichelberg, 1978)  and (Singh et al., 2007). 
 
1.7 The human kidney 
 
1.7.1 Introduction  
The kidneys play a dominant role in regulating the composition and volume of the 
extracellular fluid (ECF). They normally maintain a stable internal environment by 
generating the urine and excreting many solutes. These substances include not only 
waste products and foreign compounds, but also many useful substances that are present 
in excess as a result of eating, drinking, or metabolism.  
 
The kidneys perform a variety of important functions: 
1. They regulate the osmotic pressure (osmolality) of the body fluids by excreting 
osmotically dilute or concentrated urine, as appropriate, under hormonal control.   
 
2. They regulate the concentrations of numerous ions in blood plasma, including Na+, 
K+, Ca2+, Mg2+, Cl- , bicarbonate (HCO3−), phosphate, and sulphate. 
 
3. They play an essential role in acid–base balance, by excreting H+ when there is 
excess acid, or HCO3− when there is excess base, to protect against acidosis or alkalosis, 
respectively. 
 
4. They regulate the volume of the ECF by controlling Na+ and water excretion. 
5. They help regulate arterial blood pressure by adjusting Na+ excretion and producing 
various substances (e.g., renin) that can affect blood pressure. 
 
6. They eliminate the waste products of metabolism, including urea (the main nitrogen-
containing end product of protein metabolism in humans), uric acid (an end product of 
purine metabolism), and creatinine (an end product of muscle metabolism). 
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7. They remove many drugs (e.g., penicillin) and foreign or toxic compounds. 
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1.7.2 Functional renal anatomy 
Each kidney in an adult weighs about 150 g and is roughly the size of a fist. If the 
kidney is sectioned, two regions are seen: an outer part, called the cortex (1), and an 
inner part, called the medulla (2).  
All the glomeruli, convoluted tubules, and cortical collecting ducts are located in the 
cortex.  
The medulla has a striated appearance that results from the parallel arrangement of 
loops of Henle, medullary collecting ducts, and blood vessels of the medulla.  
The medulla can be further subdivided into an outer medulla (a), which is closer to the 
cortex, and an inner medulla (b). 
 
 
 
Figure  1-14 Mammalian kidney. 
(Modified from Smith HW. Principles of Renal Physiology. New York: Oxford University Press, 
1956. 
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1.7.3 The nephron is the basic unit of renal  structure and function 
 
Each human kidney contains about one million nephrons, each of which consists of a 
renal corpuscle (1) and a renal tubule (2). The renal corpuscle consists of a tuft of 
capillaries, the glomerulus (a), surrounded by Bowman’s capsule (b).  The renal 
tubule is divided into several segments. The part of the tubule nearest the glomerulus is 
the proximal tubule (2a). This is subdivided into a proximal convoluted tubule (2a1) 
and proximal straight tubule (2a2). The straight portion heads toward the medulla, 
away from the surface of the kidney. The loop of Henle includes (3) the proximal 
straight tubule, thin limb, and thick ascending limb. Connecting tubules (4) connect the 
next segment, the short distal convoluted tubule, to the collecting duct system. Several 
nephrons drain into a cortical collecting duct, which passes into an outer medullary 
collecting duct. In the inner medulla, inner medullary collecting ducts unite to form 
large papillary ducts. 
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Figure  1-15 Components of the nephron and the collecting duct system. (Modified from 
Kriz W, Bankir L. A standard nomenclature for structures of the kidney. Am J Physiol 
1988;254:F1–F8.) 
 
The glomerulus of the nephron (Figure  1-16a) in the mammalian kidney is responsible 
for blood filtration.   The filtration barrier is constituted by specialized epithelial cells 
called podocytes, which surround the glomerular capillaries. These cells are paved on a 
basement membrane, and arranged closely to each other with 30-50nm spaces or slits 
(Figure  1-16b).  Theses slits together with the basement membrane control and 
constitute the filtration barrier. Disruption of this barrier leads to leakage of blood 
proteins into the urinary space (proteinuria), and is diagnostic of kidney dysfunction. 
Insects’ excretory systems lack nephrons; however, nephron-like components such 
filtration cells (nephrocytes) and ducts (MT) are present (Figure  1-16c). On the other 
side, insect nephrocytes (Figure  1-16d), which absorb potentially harmful substances. It 
has been found by  (Weavers et al., 2009), infoldings in the plasma membranes forming 
small cavities. Similar to the situation in podocytes, the cavities’ entrances are narrow 
gaps, 30 nm width, that are bridged by cell surface proteins forming the nephrocyte 
diaphragm. The nephrocyte diaphragm and basement membrane both behave as a 
selectively permeable barrier (Figure  1-16d), and filtrate is endocytosed from the sides 
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of the lacunae. Significantly, the anatomies of the nephrocyte and podocyte filtration 
barriers are remarkably similar, because both contain neprhrin, the characteristic protein 
of the slit diaphragm. Weavers et al. 2009 have thus postulated that the insect excretory 
system is an intermediate step towards the formation of  a glomerular filtration system. 
It is not that the insect system is more primitive (both insects and vertebrates are 
successful classes of organism); it is that the small size of insects has rendered the 
formation of an elaborate vascular system, and a glomerular kidney, unnecessary. 
 
 
Figure  1-16 The glomerular and nephrocyte filteration barriers. a–d, Diagram of the 
vertebrate nephron (a), glomerular filtration barrier (b), insect excretory system (c) 
nephrocyte filtration barrier (d). bm, basement membrane; nd, nephrocyte diaphragm; 
sd, slit diaphragm.  
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1.8 Metabolomics 
1.8.1 Introduction 
Clearly, understanding the impacts of inborn errors of metabolism invites the study of 
the broader metabolism of an organism or tissue. As a global technique, metabolomics 
is a new emerging part of the ‘omics’ approach (Dettmer and Hammock, 2004). 
Genomics deals with genes, transcriptomics deals with mRNA and proteomics deals 
with the proteins. The crucial advantage of the metabolome is that it can potentially 
provide a ‘fingerprint’ of the entire metabolic status of a cell or tissue and so help in 
closing the gap between genotype and phenotype. Metabolomics is the “systematic 
study of the unique chemical fingerprints that specific cellular processes leave behind - 
specifically, the study of their small-molecule metabolite profiles” (Daviss, 2005).  
 
Figure  1-17. The 'Omics' Cascade.  (Dettmer et al., 2007) 
 
The metabolome can be considered as the end-point of the OMICS cascade (Figure 
 1-17). In view of its importance, metabolomics has rapidly developed in the last few 
years (Figure  1-18) (Oldiges et al., 2007).  
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Increasing number of publication in  metabolomics 
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Figure  1-18. This graph  shows the rapid increase in publications in the field of 
metabolomics (Oldiges et al., 2007).  
 
1.8.2 The basic MS principle 
Metabolomic analysis can potentially be performed with almost any analytical 
technique, but the power of mass spectroscopy (MS), means that this has rapidly 
become the standard for such studies. The basic principle of MS is thus covered here 
Figure  1-19. 
 
Figure  1-19 Operation of a spectrometer mass analyzer (Revesz et al., 2002). 
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Consider a sample contains two metabolites A and B that are introduced into the high 
vacuum of an MS instrument on a “target”. Firstly, in the ion source, the sample is 
converted from the liquid status into gas status i.e. vaporized, for example by heat or 
laser.  Then, with the ionization step, each metabolite becomes electrically charged, and 
may be fragmented into smaller charged molecules.  
In the analyser part of the spectrometer, electrical and magnetic fields are applied as 
each samples passes through. When an electrical or magnetic current is applied, each 
metabolite behaves differently from other metabolites according to its mass to charge 
(m/z) ratio. Thus the electrical force accelerates the particles through the machine, and 
particles and the magnetic field will affect the ion direction. Finally, the arrival of 
charged molecules is measured in a detector. There is thus the potential to resolve 
multiple molecular species from a single specimen. 
Metabolomic experiments, utilizing MS, were first performed in 1971 (Horning and 
Horning, 1971) and (Mamer et al., 1971). Although the first papers did not mention the 
word “metabolomics”, more than 250 metabolites  were measured in a single 
experiment in the same year  (Pauling et al., 1971). However, the term metabolomics 
started to appear in the literature after Oliver and colleagues conducted a systematic 
functional analysis of the yeast genome (Oliver et al., 1998).  
Metabolomics can be applied in many research and diagnostics fields and the analytical 
samples vary widely depending on the biological question researchers want to address.  
The samples studied in metabolomics include dried blood specimens (Chace et al., 
2003),  serum (Brindle et al., 2002), urine (Salek et al., 2007), wide range of fluids, like 
seminal fluid, amniotic fluid, cerebrospinal fluid (Lindon et al., 2006), tissue extracts 
(Kamleh et al., 2008) or microorganisms (Mashego et al., 2007).  
In the field of agriculture, plants have been modified genetically or environmentally in 
order to improve diet, health and nutrition. This leads to alteration in the genomic and 
metabolomic levels, thus newly produced metabolites should precisely and effectively 
monitored by metabolomic study (Fiehn et al., 2001). 
In the pharmaceutical field, metabolomics has been used in the application of drug 
discovery, development, toxicology and pathophysiology of diseases (Wishart, 2008).  
In bacteriology, the application of metabolomics focuses on the understanding of 
genetics and physiology of the bacterium to improve human health, drug effectiveness 
and resistance and bacterial effects on the environmental health (Mashego et al., 2007).  
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Also these bacteria could be engineered to ordered them to make new compounds or 
enzymes that are not normally produced by them, this is an emerging field called 
synthetic biology. It is a relatively new field of study, combining biological science and 
engineering. A good example for this approach is the bacteria that produce different 
light in specific  status and so called the Escherichia coli that can see light (Levskaya et 
al., 2005). 
In the diagnosis of inborn errors of metabolism, metabolic analysis was used many 
years ago by Sir Archibald Garrod (Lanpher et al., 2006). With the recent technological 
advances, metabolomic profiling has long been applied with high success in all 
previously mentioned fields. However, issues like accuracy and reproducibility are still 
waiting to be addressed. 
Metabolic analysis was first used for simple detection of changes in black urine from 
alkaptonuric patients (Houten 2009). After this and after further advances in sensitivity, 
it was used to detect more smaller and specific metabolites, such as glucose, from 
different human biological fluids like serum and plasma samples.  
As more metabolites are studied simultaneously, it becomes harder to separate them and 
resolve them from each other, so it was important to find a method for separating those 
metabolites. So liquid chromatography was developed and coupled to a range of 
analyzers in order to improve separation and detection. Coupling the liquid 
chromatographic column will be explained in detailed later. 
 
1.8.3 Technologies available for metabolomic studies  
1.8.3.1 Gas chromatography MS (GC-MS) 
GC-MS is a common type of chromatographic detection, applied in the field of 
analytical chemistry, for volatile metabolites. The basic principle of the technique relies 
on the mobile phase which in this case is the gas to carry the molecules over the 
stationary phase, which is the inner side of the glass tube. Helium or nitrogen are the 
most widely gases used in this method. The inner side of the column is sometimes 
coated with different materials that interact differently with other metabolites and may 
delay or increase the retention time for molecules. Molecules are typically ionised by 
electrospray ionization (ESI). 
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1.8.3.2 Liquid chromatography MS (LC-MS) 
This is another technique for metabolic detection branching from analytical chemistry. 
Separation principle is based on the physical and molecular mass properties of the 
molecules being separated. Interfacing the output of this liquid chromatographic column 
with the MS is usually accomplished by ESI.   
LC-MS has been considered as a powerful metabolic technique, and is widely used in 
field of analytical chemistry. It offers a reasonable extent of sensitivity and specificity 
for targeted detection molecules.  
In the LC-MS the diameter of the separation column, usually 1 mm and the flow rate are 
both small. This is considered a limitation of this technique, as it thus permits only a 
limited injection into the MS instrument, and so limits sensitivity.  
 
1.8.3.3 Fourier transform ion cyclotron resonance (FT-ICR) 
FT-ICR offers the best resolving power and the best accuracy among all MS analysers 
(McLuckey and Wells, 2001). In this type of detection, the principle is based on the 
measuring the frequency of oscillating ions in a spindle-shaped detector. The Orbitrap 
mass analyser is one of the best of this type, with the potential to measure mass to better 
than 1 part in 1 million, and will be used extensively in this thesis.   
 
1.8.4 Mass spectrometry technology  
1.8.4.1 Ion generation, positive mode electrospray ionization (PIESI)  
Samples are to be analysed should be first dissolved into a polar volatile solvent before 
it can be transported into a high potential electrospray needle. Due to the very high 
voltage inside the needle, all molecules become charged with the addition of 1 H+ ion or 
more; to calculate these adducts, calculations such as those  shown in Table  1-3 are 
used. This additive has the mass of 1.0073, thus adding this mass number to the total 
mass expected to each molecular species. At the point where the liquid leaves the 
needle, a cone shape is formed which is called Taylor cone as shown in Figure  1-20 . 
This Taylor cone slowly bursts into smaller fine sprays due to solvent evaporations 
under the effect of heat. These smaller sprays droplets, which contain metabolites shrink 
until they reach the gas phase, with ions moving individually through the mass analyser.  
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Positive ion electrospray ionisation (PIESI) is the most common ionisation technique, 
and generally works well for both low and high molecular weights molecules. Although 
the technique has been improving and developing since its discovery, the basic working 
principles have remained the same. 
The PIESI is the widely method applied and is considered very sensitive for compounds 
separation containing an amine group, amides, etc. On the contrary, PIESI does not 
work well for polar acids such as Krebs cycle acids or for neutral sugars. 
 
 
Figure  1-20. Taylor cone. In this diagram a spraying needle tip is shown. Due to the 
high voltage all molecules are charged. As the sprayed liquid leaving the needle and at 
just where the liquid leaves the needle a cone shape is formed which is called Taylor 
cone (Gates, 2004).  
 
1.8.4.2 Ion generation, negative mode electrospray ionization (NIESI)  
On the opposite to PIESI, negative ion electrospray ionisation (NIESI) is generally 
somewhat less sensitive than PIESI and consequently detects fewer compounds. The 
main groups of compounds which can be detected exclusively in negative ion mode are 
neutral sugars and organic acids such as the Krebs cycle acids. Table  1-3 is useful table 
to help in accurately deduce metabolites. 
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Table  1-3. Expected adducts generated as a result of ionization. Where M = any 
metabolites detected  (Kind, 2010). 
Ion name Ion mass 
C
ha
rg
e 
 
Ion name Ion mass 
C
ha
rg
e 
1. Positive ion mode 
 
2. Negative ion mode 
M+3H  M/3 + 1.0073 3+  M-3H  M/3 - 1.0073 3- 
M+2H+Na  M/3 + 8.3346 3+  M-2H  M/2 - 1.0073 2- 
M+H+2Na  M/3 + 15.7662 3+  M-H2O-H M- 19.0184 1- 
M+3Na  M/3 + 22.9893 3+  M-H  M - 1.0073 1- 
M+2H  M/2 + 1.0073 2+  M+Na-2H  M + 20.9747 1- 
M+H+NH4  M/2 + 9.5206 2+  M+Cl  M + 34.9694 1- 
M+H+Na  M/2 + 11.9983 2+  M+K-2H  M + 36.9486 1- 
M+H+K  M/2 + 19.9852 2+  M+FA-H  M + 44.9982 1- 
M+ACN+2H M/2 + 21.5205 2+  M+Hac-H  M + 59.0139 1- 
M+2Na  M/2 + 22.9892 2+  M+Br  M + 78.91889 1- 
M+2ACN+2H M/2 + 42.0338 2+  M+TFA-H  M + 112.9856 1- 
M+3ACN+2H M/2 + 62.5471 2+  2M-H  2M - 1.0073 1- 
M+H  M + 1.0073 1+  2M+FA-H  2M + 44.9982 1- 
M+NH4  M + 18.0338 1+  2M+Hac-H  2M + 59.014 1- 
M+Na  M + 22.9892 1+  3M-H  3M - 1.0073 1- 
M+CH3OH+H  M + 33.0335 1+  
   
M+K  M + 38.9632 1+  
   
M+ACN+H  M + 42.0338 1+  
   
M+2Na-H  M + 44.9712 1+  
   
M+Propanol+H M + 61.0653 1+  
   
M+ACN+Na  M + 64.0158 1+  
   
M+2K-H  M + 76.9190 1+  
   
M+DMSO+H  M + 79.0212 1+  
   
M+2ACN+H  M + 83.0604 1+  
   
2M+H  2M + 1.0073 1+  
   
2M+NH4  2M + 18.0338 1+  
   
2M+Na  2M + 22.9892 1+  
   
2M+K  2M + 38.9632 1+     
2M+ACN+H  2M + 42.0338 1+     
2M+ACN+Na  2M + 64.0158 1+     
1.8.5 Ion separation methods 
A very wide range of mass analysers can be used to separate the ions generated by ESI. 
In this thesis particular attention will be given to the Orbitrap analyser.  
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1.8.5.1 The Orbitrap mass spectrometer 
The Orbitrap analyser was invented in 2005 by Makarov and then was available in the 
markets by Thermo Electron Corporation  (Hu et al., 2005). The detection principle is 
based on the trapping the injected ions into the trap between the inner spindle-like 
electrode and the outer barrel like electrode Figure  1-21 (Bateman et al., 2009).  
The analyser is consists of an outer barrel-like shape electrode divided into two exact 
halves, and an inner spindle-like shape electrode.   
As group of ions enters the trap, the electric field is switched ON and then attracts the 
ions between the barrel-like and the spindle-like central electrodes, then the ions will 
start moving in a circular movement around the spindle-like electrode. This shape of the 
electrodes give advantages of giving a modified electric field which permits to the ions 
to move into angular, radial and axial oscillation movements regularly (Makarov et al., 
2006).  The frequency of this oscillation movement is proportional to the mass over 
charge ratio (m/z). Then the readings are output as chromatograms (electrographs) 
(Breitling et al., 2006; Makarov et al., 2006). 
 
Figure  1-21. The LTQ-Orbitrap working mechanism. A, transfer octopole; B, curved 
RF-only quadrupole (c-trap); C, gate electrode; D, trap electrode; E; ion optics, F; inner 
orbitrap electrode (centeral electrode), G; outer orbitrap electrode. In ESI, the analytes 
is pumped into the source in solution via the eluent flow LC that interfaced with mass 
spectrometer. The analyte solution flowing through the electrospray needle to form 
droplets. These droplets travel between needle tip and counter electrode to evaporate 
solvents before sample injected into mass spectrometer. When a high voltage is applied, 
Taylor cone is produced and spray charged droplet is formed. Then charged ions pass 
through stages of differential pumping through RF only multipoles into a curved RF 
only quadruple then to the C-trap. Ions in the C-trap accumulate and their energy is 
dampened using nitrogen gas. They are then injected by a curved lens system which 
provides further areas of differential pumping before being passed into Orbitrap 
detector. Then mass spectra are acquired by image current detection. The Orbitrap mass 
spectrometer consists of : ESI ionization source, (I) heated capillary, followed by (II) 
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multi-pole focusing devices, (III) a gating lens, followed by a focusing octapole, linear 
ion trap (LTQ) following by focusing multi-pole (IV) which leads to new bent 
quadrupole (C-trap), and finally the Orbitrap mass analyser (Makarov et al., 2006).  
 
Because of this working principle, this Orbitrap analyser ensures vary high mass 
accuracy; with internal lock mass, it can resolve to better than 2 parts in 1,000,000. This 
makes it the most precise mass spectrometry currently available (Olsen et al., 2005).    
The Orbitrap has several advantages, when compared with other analysers, as it is 
relatively cheaper and with lower maintenance cost. It also, does not have a huge 
magnetic sector and consequently a complicated cooling system is not required.  
To explain this high mass accuracy, molecules having the same integer mass but with 
different molecular formulae will have slightly different exact masses. For example 
ethanol (C2H4O) and methyl hydrazine (CH4N2) both have the same mass of 44, but the 
exact masses are 44.02622 and 44.03744 respectively (Figure 1-19). The Orbitrap, but 
not the other analysers, has sufficient precision to differentiate between them (Breitling 
et al., 2006). 
 
     Figure  1-22. Ultra-high accuracy and resolution are required to discriminate 
metabolites of near-identical mass. The masses of metabolite A (blue) and metabolite B 
(green) differ by only 0.004 Da (1 ppm). This is one of the most extreme cases observed 
in small-molecule databases. No other organic chemical has a similar mass; therefore, 
accurate mass measurement enables unambiguous assignment of a molecular formula. If 
the Orbitrap analyzer was set at high enough resolution (around 1 000 000 full-width 
half-maximum resolution), the two compounds could even be distinguished in the same 
mixture. 
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1.8.6 Further separation methods 
In order to have accurate metabolite detection, and isomers to be accurately 
distinguished, an efficient chromatographic separation is highly recommended. 
Generally, a chromatographic step minimizes the risk of ion suppression effects and can 
help distinguish between isomers. Thus, an extra separation method at the beginning of 
the process, can decrease of interfering compounds, and can help in identifying a larger 
number of metabolites. 
 
1.8.6.1 Hydrophilic Interaction Chromatography (HILIC) 
HILIC provides an excellent separation chromatographic method. On the zwitterionic 
(ZIC-HILIC) column, the water layer associated with column surface acts as a pseudo 
stationary phase Figure  1-23. The zwitterion coating in theory is charge neutral thus 
minimising ion exchange interactions with the analyte and the chain length separating 
the positive and negative charges of the ZICHILIC column is optimised so that the 
charges on the column surface can fold round and interact to neutralise each other. The 
column is used with a high organic solvent content in the mobile phase which favours 
ionisation under ESI conditions (Watson, 2010) and (Alpert, 1990). 
 
 
Figure  1-23 The chemistry of the ZIC-HILIC column. A) HILIC is a high-performance 
liquid chromatographic (HPLC) technique for separation of polar and hydrophilic 
compounds. It is based on the HILIC retention, which is based on partitioning of the 
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injected analyte solute molecules between the mobile phase eluent and a water-enriched 
layer in the hydrophilic HILIC stationary phase. The more hydrophilic the analyte is, 
the more is the partitioning equilibrium shifted towards the immobilized water layer in 
the stationary phase, thus the more is the analyte retained. The hydrophilic surface holds 
water when exposed to mixtures of organic solvent and water. Compounds such as, 
acids, bases, ions, sugars, and other charged and neutral hydrophilic compounds that are 
annoying to separate in ordinary separation techniques. They are much easier to be 
separated in HILIC due to the different separation selectivity. Some compounds are 
possible to separate by more than one chromatographic technique, and HILIC does them 
all.  B) HILIC partly overlap with RPLC (reverse phase liquid chromatography), NPLC 
(Normal Phase Liquid Chromatography) and IC (Ion Chromatography) and it fills the 
gap in the chromatographic toolbox and perfectly fits in-between other separation 
techniques (Appelblad et al., 2008).   
 
 
Figure  1-24 Comparison of advantages and disadvantages for different MS techniques  
(Shulaev, 2006). 
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1.8.7  Data Processing  
The greatest amount of time in metabolomic experiments is devoted to data processing.  
 
1.8.7.1 Sieve Software 
Most commercial data processing software aims to plot extracted ion chromatograms 
across the full scan range of the mass spectrometer. In order to do this the Sieve 
software is widely used. Sieve  is a software developed by a collaboration between Vast 
Scientific and Thermo Scientific (Vast_Scientific_Inc., 2010). It takes the data 
generated by the Orbitrap mass spectrometers and aligns it, extracts the relative ion 
chromatograms (RICs) and tabulates them. Further details of the software analysis used 
in this thesis are provided in chapter 2.  
 
1.8.8 Microarray 
The function of a cell depends on the genes which it expresses. Measurement of gene 
expression, for example by Northern blot, is a cornerstone of molecular biology. Most 
recently, microarray technology has allowed the simultaneous measurement of tens of 
thousands of genes from a single sample. The reconciliation of microarray and 
metabolomic data is thus potentially extremely powerful. 
 
1.8.8.1 Technology 
Microarray principle is highly dependent in its work on the principle of hybridization 
following the reverse Northern blot principle. In other words, oligonucleotide probes, 
corresponding to every gene or transcript that is to be measured, are arrayed on a solid 
substratum in a known pattern. Labelled mRNA is hybridised to the slide, and the signal 
attached to each probe is measured- typically by confocal microscopy or some variant 
thereof. This will tell researchers which genes are being expressed in each sample, and 
at what levels the transcripts are found. A typical microarray chip contains tens of 
thousands of probes attached to the glass slide. In the Affymetrix system (Figure  1-25), 
each gene has multiple probes, each of approximately 28 nt length. Half the probes are 
perfect matches to the known sequence (PM probes), and half (MM probes) have single 
base changes from the corresponding PM probes. The proprietary analysis software uses 
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the difference between PM and MM signals to control for nonspecific hybridisation, and 
so potentially yield more quantitative results (Wu and Irizarry, 2004) 
 
 
Figure  1-25. Probe distribution on an Affymetrix gene chip. From  
http://www.mun.ca/biology/scarr/Human_mtDNA_re-sequencing_microarray.html  
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Figure  1-26. A typical microarray workflow for the identification of clusters of 
differentially expressed genes. http://www.stathis.co.uk/art/infographics/infographics-
gallery/?pid=96  
 
The availability of Affymetrix microarrays has helped the Drosophila community 
hugely. Among applications of the technology, the FlyAtlas.org resource has clearly 
helped in closing the phenotype gap between human diseases and Drosophila 
(Chintapalli et al., 2007) by directing researchers to the specific Drosophila tissues in 
which their genes of interest are mostly expressed. This is particularly useful when 
looking for the best fly tissues to start investigating for human disease homology.  
Microarrays are widely employed to explore differences between samples (healthy vs. 
diseased, experimental vs. control, etc.), as shown in Figure  1-26. In this work, we will 
be using microarrays to analyse the differences between rosy and wild type flies, and 
additionally to perform a time-course gene expression analysis of drug action. 
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1.8.8.2 Validation of microarray results 
Although Affymetrix arrays are considered to be highly reliable, it is considered prudent 
to validate changed expression of genes of particular interest before publication. This 
could be by several techniques (for example Northern blotting, or Western blotting for 
protein levels); but is usually performed by quantitative reverse transcriptase PCR (Q-
RT-PCR). 
 
1.8.9 Aims of the thesis 
The main aims of this thesis is to  
• Test the feasibility of Drosophila melanogaster ‘kidney’ (Malpighian tubules) as 
genetic model. 
• Applying the Drosophila to give insights informative information about inborn 
errors of metabolism.  
• Test the Drosophila as a model for disease related to congenital renal diseases. 
• How beneficial this would be to the field resulting from the powerful genetic 
tools that Drosophila acquired over the years.  
• Integrating the omics approach; genomics, transcriptomics and maybe 
metabolomics may provide novel insights into the disease state or even its 
amelioration. 
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Chapter 2 Materials and Methods 
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2.1 Drosophila melanogaster 
2.1.1 Drosophila stocks 
Name From Used for Phenotype 
Oregon R Bloomington stock 
center (BSC) 
Control for all 
studies 
 
wild type 
Canton S BSC control for all 
studies 
 
wild type 
w1118 (Hazelrigg et al., 
1984) 
background for P-
element insertions 
 
white eyes 
mal 37 BSC Metabolomics brown eyes 
cho  BSC Metabolomics brown inclusions 
in tubules 
ry 506 BSC Metabolomics 
 
brownish eyes 
w1 BSC Alternative white 
allele 
 
white eyes 
w93 BSC Alternative white 
allele 
 
white eyes 
5’ HIUH VDRC UAS-RNA line 
 
Carries mini-w+ 
uro- GAL 4 Made in lab, 
(Terhzaz et al., 
2010) 
Drives expression 
in principal cells 
Carries mini-w+ 
Actin-GAL 4/CyO BSC Drives ubiquitous 
expression 
 
Carries mini-w+ 
and CyO balancer 
TM3, Sb, (Ser) BSC Balancer for 
Chromosome 3 
Stubbly bristles; 
(some variants 
have serrate 
wings) 
w1118; {w+mC=WH}PBac 
uro
f04888 
 
Bloomington Survival assay Normal 
CyO Bloomington Balancer for 
Chromosome 2 
Curly wings 
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2.1.2 Drosophila rearing 
All flies were kept in small ventilated plastic vials on standard Drosophila medium  (at 
section  8.1) (Ashburner, 1989). The room temperature was between 20 – 22 ºC in a 
12:12 light: dark cycle and between 35 – 40 % relative humidity. When large quantities 
of Drosophila were needed, large bottles were used under the same conditions. Flies 
were tipped as required on to new medium, approximately every two weeks. 
 
2.1.3 Dissection of Drosophila  
Adult flies, usually 5 to 7 days old, were first anaesthetized on ice before they were 
transferred to a Petri dish containing an appropriate volume of Schneider’s medium. Fly 
Malpighian tubules can be easily dissected intact without complicated equipment (Dow 
et al., 1994). For dissecting Malpighian tubules, a fly is firmly held by a forceps from 
the thorax region and with the other hand, forceps pulling the very end part of the fly 
gently and slowly. At this point the Malpighian tubules will start to appear - attached, 
however, to the midgut (MG). Then they need to be freed by using the forceps with 
great care, gently hold the tubules from the ureter by separating them from the MG at 
the ureter (Figure  2-1). In case of head sampling, the head was separated from the body 
by applying two forceps on the neck and pulling in opposite directions. The number of 
flies dissected varied depending on each experiment. This method was adopted after 
(Dow et al., 1994; Sullivan and Sullivan, 1975). 
 
Figure  2-1 Malpighian tubule dissection method  (Dow et al., 1994). 
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2.1.4 Generation of transgenic flies 
After constructing appropriate plasmids and providing the required amount of at least 50 
µg, DNA samples were sent to Bestgene Drosophila Injection Services, USA. for 
microinjection into white background (w1118) flies along with a helper plasmid supplied 
by Bestgene. The newly generated flies (G0) were crossed with w1118 again. This service 
included microinjection, transfomant identification and –optionally- balancing.  
 
2.1.5 Characterization of transgenic flies 
 
Figure  2-2. Germline transformation of Drosophila. 
The germline transformation process is conducted by injecting embryos from the w1118 
strains with a P-element shuttle vector that contains the gene of interest and a marker 
mini-white gene, along with a ∆2-3 helper plasmid. Emerged flies from these embryos 
are crossed with w1118. Progeny of this cross are then screened for red eyes, implying 
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that they carry mini-white, and thus transgenes. Only those red-eyed adult flies are 
backcrossed again to w1118, and selected to produce a stably transformed line. Figure is 
after (Guo, 1996).  
 
2.1.6 Crossing and rearing crosses 
The GAL4/UAS system provides a powerful tool for cell-specific expression of 
transgenic payloads (Sentry and Kaiser, 1992). Typically, a UAS-RNAi line was tested 
for effectiveness by crossing to the Actin-GAL4 driver, to determine whether ubiquitous 
expression of the construct has an effect on fly development, survival, or any other 
detectable phenotype.  For finer spatial control, UAS lines were also crossed to the uro-
GAL4 driver, which directs expression to only tubule principal cells of only third instar 
and adult flies (Terhzaz et al., 2010). This was achieved by collecting between 20 to 30 
virgin flies of the uro-GAL4 into small vials. Each vial contained one virgin fly and was 
kept for 2 to 3 days, to ensure that fertilized eggs were not being laid. Any vial 
containing fertilized eggs was discarded. After making sure only virgins were present, 
each was crossed to uro or ry RNAi lines males. The reciprocal crosses were also made, 
to test for sex-specificity of expression, though this was not observed in this project. 
 
 Example: UAS line on Chromosome III 
 
 
 
X 
 
 Uro GAL4 expression driver 
 
 
Use for experiments 
 
 
↓ 
& 
Flies carrying the designed content (P) 
with red eyes, short bristles phenotype. 
 
 
 Flies with long bristles were only selected from this cross. 
 
 Example: UAS line on Chromosome II 
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X 
 
 
Flies from constructed lines UAS-uro 
with red eyes and curly wings phenotype 
curly wings. 
 
 
Use for experiments 
 
and 
 
 
 
Flies with straight wings were only selected from this cross.  
Figure  2-3 Some typical examples of GAL4-UAS crosses and selection of 
appropriate progeny. 
 
After mating took place and sufficient eggs were laid, adults were transferred into new 
fly food bottles leaving the first bottles with only larvae. The newly transferred flies 
were left for several days until sufficient eggs were laid then again transferred as 
desired. This process took approximately between five to ten days.  
 
2.1.7 Survival food preparation 
To test for survival under oxidative stress conditions, a special peroxide diet was 
prepared. The food contained 1% agarose, 1% sucrose and 1% H2O2 into a final volume 
of 10 ml per vial. 
 
2.1.8 Oxidative stress survival assays 
Freshly emerged adults were placed in mixed-sex groups of 20 flies on normal diet in 
tubes, until egg-laying was established, then transferred to vials with H2O2, freshly 
prepared as described above. To ensure that the oxidative challenge was maintained, 
flies were transferred to fresh H2O2 vials every 2 days. The time to emergence of adult 
progeny was carefully noted. Then the percentage of survivors were calculated using the 
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(GraphPad) using the Kaplan-Meier survival curve as means ± SEM. Experiments were 
always performed in which progeny of a cross (typically a GAL4/UAS cross) were 
compared with each parental line,  i.e. two different parents and the progeny. 
 
2.2 RNA extraction 
Messenger RNAs (mRNAs) were extracted using the Qiagen RNeasy Mini extraction 
kits following the manufacturer’s instructions. For Malpighian tubules, mRNA was 
extracted from 25 to 35 flies, depending on the experiment. Tubules were then collected 
into 2.0 ml eppendorf tubes with 350 µl lysis (RLT) buffer containing 10% β-
mercaptoethanol, prepared freshly. For long-term storage, lysates were immediately 
frozen in liquid nitrogen and then transferred to a -80 ºC freezer, where it could be 
stored for several months until needed.  Once extracted according the manufacturer’s 
protocol, mRNA concentration and purity were checked using the NanodropTM 1000 
spectrophotometer. First strand cDNA synthesis 
Complementary DNA (cDNA) was prepared from mRNA with the help of the 
Superscript II reverse transcriptase (Invitrogen) according to the manufacturer’s 
protocol. Then the DNA concentration and purity were checked using the NanodropTM 
1000 spectrophotometer. 
 
2.3 Quantification of nucleic acid 
Quantification of mRNA and DNA are important steps in any molecular experiment. 
This was carried out using the NanodropTM 1000 analyzer. At the same time sample 
purity was also monitored. The measurements were based on the assumption that an OD 
of 1 at 260 nm corresponds to 50 µg/ ml for DNA and 40 µg/ ml for RNA. The analyzer 
was zeroed by the same elution solution used in the samples. 
The purity was calculated by the ratio of A260/280. Values of 1.8 for DNA and 2.0 for 
RNA were considered pure.  
2.4 Oligonucleotide synthesis 
All primers in this thesis were designed using MacVector 10.0 software. The selected 
pairs were then sent to the MWG Biotech where they were synthesized. Primer quality 
was controlled and assessed by MWG Biotech using Trityl monitoring, OD 
 49 
measurement and MALDI-TOF MS. Primers were supplied as lyophilized pellets, and 
reconstituted with the appropriate volume of ultrapure sterile water to produce a stock 
of 100 pmol/µl. Further dilution was needed to produce a working PCR primer 
concentration of 6.6 µM. When not in use, primer stocks were stored at -20 ºC.     
 
2.5 Polymerase chain reaction (PCR) 
2.5.1 Standard PCR using Taq DNA polymerase 
Volumes (in µl) for a typical PCR reaction are shown below: 
10 x PCR buffer 5 
MgCl2  1.5 
dNTPs 2 
Forward primer 1 
Reverse primer 1 
Taq DNA polymerase 0.4 
cDNA 2 (or as needed to yield 50-100 ng template) 
H2O To 20 µl 
 
2.5.2 Reverse-transcription (RT) PCR 
Reverse transcription PCR (RT-PCR) is a technique to measure abundance of 
expression. It is a two-step process, in which mRNA is first reverse transcribed to 
cDNA, then amplified with gene-specific primers. Reverse transcription was carried out 
using Superscript II reverse transcriptase kit (Invitrogen), dNTPs and oligo-dT. The 
reaction volumes were 20 µl following the company instruction’s protocol. Then 
appropriate aliquots were made and stored at – 20 ºC for further use. 
 
2.5.3 Quantitative (Q)-PCR 
Quantitative PCR technique is a powerful tool for gene expression analysis. In this 
thesis the analysis was carried out into a 96 well plate. Each tube contains mixture 
solution of 12 µl of Sybr green, 1 µl of each forward and reverse primers. Water was 
 50 
added to a final volume of 24 µl/ sample. Then in each qPCR tube an equal 
concentration of cDNA template was added. A no-template blank was included to 
ensure the integrity of the master mix. 
The absolute quantitation of gene expression method used to measure the gene 
expression. For this method, a standard curve was generated to estimate the sample 
copy number. This led to make a serial dilution of the corresponding gene being 
analyzed. At the same time, an internal quality checking was also analysed using  the α- 
tubulin housekeeping gene (Chintapalli et al., 2007) with specific primer set. After 
aliquotting the master mix and the addition of samples, tubes were carefully covered 
with special caps. To ensure the content is completely mixed together and it is at bottom 
of the tubes, centrifugation for each strip was necessary .  
The protocol used was the following: 
Denaturation  95 ºC  10 min 
Denaturation  95 ºC  10 s 
Annealing 50-60 ºC  30 s (according to primers) 
Extension  72 ºC  30 s 
Absorption reading  76 ºC  10 s 
Incubation  72 ºC  5 min 
Melting curve  63 - 90 ºC  read every 0.2 ºC   
 
2.5.4 Agarose gel electrophoresis 
Agarose gel electrophoresis is historically the method of choice for DNA detection in 
research labs. The principle of DNA separation relies on the negative charge that DNA 
possesses and its size. Small DNA fragments migrate faster towards the positive anode.  
The mixture prepared in 1% agarose in 0.5x TBE and ethidium bromide. After certain 
period of time the visualization took place under the UV light, the gel was photographed 
and the fragment sizes were compared with 1kb ladder (Sambrook and Russell, 2001).   
 
2.5.5 PCR purification 
When the DNA generated from a PCR run is needed for further experiments (such as 
cloning), it is necessary to remove any unutilized dNTPs, primers or Taq enzyme to 
leave only pure DNA fragments. For this task, the Qiagen DNA purification kit was 
used according the manufacturer’s instructions. 
30-40 x 
 51 
 
2.5.6 Gel purification 
After running a gel and observing a DNA fragment of the desired size, it is sometimes 
necessary to select that particular fragment for further analysis. For such needs, one 
specific band was excised using a scalpel blade under UV illumination on the 
transilluminator, taking care to protect the eyes from UV.  This fragment would be 
transferred to an eppendorf tube, weighed, then processed according to the Qiagen Gel 
Extraction Kit manufacturer’s instructions. 
 
2.6 DNA cloning 
2.6.1 E. coli strains and plasmids 
One Shot® Top 10 chemically competent E. coli were used for the pENTR directional 
TOPO cloning.  
The DH5α TM were used for general transformation, for example with  the pRISE2 
dsRNA  vector. 
E.coli 
Strain Genotype 
One Shot® Top10 ( F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacΧ74 recA1 
araD139 ∆(ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG λ- ) 
DH5αTM subcloning efficiency 
competent cells (Invitrogen) 
(F- φ80dlacZ ∆M15, ∆(lacZYA-argF), U169, deoR, recA1, endA1, 
hsdR17 (rK-,mK+), phoA, supE44,λ-, thi-1, gyrA96, relA1). 
Plasmids 
Name Purpose 
pRISE 
(Invitrogen) 
Used to clone DNA fragment of interest downstream of the UAS 
sequence, to generate RNAi. Also contains the AmpR gene to confer 
ampicillin resistance when transformed into E.coli. 
pENTR Gateway cloning system 
 (Invitrogen) 
Plasmid used to express the effects of RNA interfering. Also 
contains the AmpR gene to confer ampicillin resistance when 
transformed into E.coli. 
 
2.6.2 Topo cloning of PCR products 
The Invitrogen Topo-Directional cloning kit was used. It allows efficient directional 
cloning into a vector. Many issues should be taken into account. This starts with the 
primers design, where CACC bases at the 5’ end of the forward primer should be added. 
Then the blunt-end PCR product generated should be used freshly, and cloned into 
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Topo-D vector in 1:1 molar ratio. To complete the cloning, this then needed to be 
transformed into One Shot Top 10 chemically competent E. coli and incubated with 
SOC medium for an a hour then plated overnight onto L-amp X-GAL IPTG agar  
(Katzen, 2007).  
 
2.6.3 Restriction digests 
New England Biolab restriction enzymes were used in this project. Generally 1-10 µg of 
DNA was digested with 1 µl of a particular enzyme in 20 µl of the corresponding buffer 
for 1 h at 37 ºC. If purification of the resulting DNA was required, this was 
accomplished either by DNA pruficaton (2.5.5.) or gel excision (2.5.6). 
 
2.6.4 DNA ligation 
DNA ligation was required when cloning a DNA fragment into a vector was needed. 
Before this, both vector and insert had to digested with appropriate compatible 
restriction enzymes, and the resulting DNAs purified and quantified. To prevent the 
vector from religating to itself, a treatment with alkaline phosphatase at the end of the 
restriction digest incubation period was occasionally performed; this need was reduced 
by designing directional cloning strategies with two enzymes that produced 
incompatible sticky ends. Then a specific molar ratio of insert to vector was used 
according to the instruction’s manual according to Roche rapid DNA kit ligation kit.  
 
2.6.5 Transformation into E. coli 
Two µl of plasmids were transformed into E. coli competent cells by incubating on ice 
for 5 to 30 min. The mixture was then heat-shocked for 30 sec at 42 ºC then placed on 
ice immediately. The reaction volume then added into 250 µl of SOC medium before 
incubated at 37ºC for one hour with shaking at 250 rpm. The final step of 
transformation 100 µl was spread on selective bacterial plates containing 50 µg/ml 
kanamycin or 60 µg/ml ampicillin, as appropriate.   
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2.6.6 The pRISE vector for RNAi 
Several “RNAi” vectors for constructing RNA inverted repeat sequence are available, 
and some are designed for germline transformation into Drosophila. One of them is 
pRISE II. The pRISE II vector contains two attR1-ccdB-attR2 recombination cassettes 
in inverted orientation separated by a functional intron from the ftz gene. So this will 
help to insert any DNA sequence into two different orientations with the help of another 
vector contains the recombination sites like the pENTR/D from Invitrogen.  This 
pENTR/D contains attL1 and attL2 recombination sequence. So when we clone our 
DNA into the pENTR vector, between the attL1 and attL2 positions, it can be easily 
transferred into the pRISE vector by an enzyme called LR Clonase Figure  2-4. This 
enzyme recognizes the attL and attR target sites (Kondo et al., 2006).  
The pRISE also contains the UAS promoter region which allows the cell-type specific 
expression of dsRNA under the control of appropriate GAL4 drivers.  
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Figure  2-4 The pRISE  plasmid vector and principle of generating an inverted repeat for 
gene silencing construct generation.  a) The pRISE vector. b) Steps of constructing an 
inverted repeat using pENTR and pRISE vectors with the help of LR Clonase enzyme. 
After (Kondo et al., 2006). 
 
2.6.7 GatewayTM cloning 
The first step in gene cloning for gene silencing with the Gateway kit, the DNA 
fragment of interest must me first cloned into an entry clone. This enter clone will 
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contain the gene of interest flacked by attL sequences, which later can be easily 
recombine with the destination victor particularly in the attR sequences.  
This technology insures fast, efficient directional cloning that ligates the DNA fragment 
with desired orientation for gene expression (Figure  2-5).  
 
 
Figure  2-5 The pENTR vector  (Invitrogen, 2002). 
 
2.6.8 LR Clonase 
The Gateway LR Clonase enzyme mix is an enzyme responsible for the facilitating the 
recombination between an entry clone into a destination vector. In this thesis it was 
responsible to transfer the DNA sequence in the pENTR to the destination vector pRISE 
to constructing an inverted repeat to produce RNAi effects when driven by GAL4. 
This based on the site recombination between the attL and attR site in each vector. 
An equal molar ratio (1:1) of the insect entry clone was added to the destination vector 
with LR Clonase buffer. TE buffer (pH 8), was added to a final volume of 16 µl.  Then 
4 µl LR ClonaseTM enzyme was added to the reaction and mixed by brief vortexing.  All 
previous steps were carried out at room temperature. Then the reaction tube was 
incubated at room temperature for 60 min before the Proteinase K was added. This was 
incubated for further 10 min at 37 ºC.  The next step was transform it to DH5α  as in 
section  2.6.1 .  
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Figure  2-6 The Gateway LR in vitro recombination reaction (Invitrogen, 2010). 
 
2.6.9 Colony screening and selection 
2.6.9.1 Plasmid selection 
The DNA plasmids utilised during this study contained either the ampicillin or 
kanamycin resistance genes, which were used as transformation selection factors. 
Colonies transformed with the plasmid were selected by the addition of ampicillin (100 
µg ml-1) or kanamycin (50 µg ml-1) to the L-Agar or L-Broth growth medium. 
Ampicillin was stored as a 100 mg ml-1 stock solution (w/v) in 50% H2O, 50% ethanol, 
at -20 °C. Kanamycin was purchased in a 50 mg ml-1 solution (Sigma-Aldrich, UK) and 
stored at 4 °C. 
 
2.6.9.2 Diagnostic PCR for plasmid selection 
To identify the presence and orientation of a DNA insert in a vector, bacterial colonies 
on a plate were tested using PCR (before overnight cultures were set up). PCR reactions 
were sat up with one primer that bound to the insert and one primer that bound to the 
vector (facing into the cloning site). The colony was touched with a sterilised tip and 
then the tip was used to pipette the PCR solution up and down several times. 
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2.6.9.3 Preservation of selected  bacterial cultures  
Equal amounts of bacterial cultures and 30 % glycerol were added to a screw-top 
cryovial tube with gentle stirring with the pipette tip. This was immediately snap- frozen 
in liquid nitrogen before the stocks were stored in the – 70 °C freezer.  
 
2.7 Affymetrix microarray experiments 
2.7.1 Fly preparation and Allopurinol treatment scheme 
Fly food used in this experiment was freshly prepared and all vials used were from the 
same fly food stock. Allopurinol was added in the concentration of 110 µg/ml as it was 
found in pilot experiments that this concentration can phenocopy the ry mutant. The 
drug was added on the surface of the fly food. To prevent evaporation, vials was 
immediately closed with cotton and left for overnight to dry. Four different time course 
samples were prepared as zero, 6, 24 and 48 hours along with the ry506 mutant.  
 
Figure  2-7 Schematic diagram for preparation of fly food with Allopurinol. In this 
sample preparation, allopurinol was added to fly food. The drug concentration  was 110 
µg/ml (Keller and Glassman, 1965) . After adding the drug, vials were left for 24 hours 
to make sure that all was absorbed by the food and that no residue remained to cause the 
fly to stick to the diet, and thus die. Was drawn by me.  
 
2.7.2 Sample preparation  
Malpighian tubules were dissected from flies aged between 5 to 7 days after emergence. 
Tubules from between 25 to 30 flies were used for each sample. Malpighian tubule 
dissection was followed as described in section  2.1.3 and as in Figure  2-1. In order to 
minimize the chance of RNA degradations, each dissected MT were immediately 
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transferred into the RLT buffer that was kept on ice. For total-RNA extractions the 
Qiagen-RNeasy Mini Kit was used following the manufacturer protocol. The goal of 
this experiment was to test the transcriptomic changes elicited on the MT by allopurinol, 
and to compare with the authentic rosy mutation. For reasons of cost, the experiment 
was designed as a time course, with samples taken in triplicate at 0 h (control), and at 
six, twenty four and forty eight hours, together with a t=0 h rosy506 mutant for 
comparison.  
 
2.7.3 RNA target preparation 
Total RNA was extracted with Qiagen minicolumns according to the manufacturer’s 
protocols, and quality verified using the Agilent Bioanalyzer, which is a computer 
assisted nanogel electrophoresis for total or complementary RNA. A GeneChip® IVT 
Expression Kit, based on linear RNA amplification and T7 in vitro transcription 
technology, was used to prepare cRNA for microarray. 
In this process, the total RNA undergoes reverse transcription to synthesize the first 
strand cDNA, this then converted into a double strand DNA template for transcription. 
In vitro transcription synthesis an amplified RNA (aRNA) and incorporates a biotin-
conjugated nucleotide, washing step taken place to remove unconjugated NTPs , salt 
and enzymes. Next is fragmentation of the biotin-labelled aRNA in preparation for 
hybridization onto the array chip.   
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2.8 Metabolomics 
2.8.1 The control animal model strains 
An Oregon R wild type strain was used as a control in these experiments. These flies 
were cultured on standard food at 25 C° and 55% r.h. on a 12:12 photoperiod as 
described in the section on Drosophila rearing  2.1.2. 
 
2.8.2 Chemicals  
The allopurinol used for this study was purchased from Sigma Chemical Co. (St Louis, 
MO, USA). Acetonitrile was from Fisher Scientific (Leicestershire, UK), formic acid 
(UWR, Pool, UK) and methanol. All chemicals used were analytical reagent grade. A 
Direct Q-3 water purification system (Millipore, Watford, UK) was used to produce the 
HPLC water that was in all of the analyses. All other chemicals used were obtained 
from Sigma Chemicals (Poole, Dorset), or Fisher Scientific Co. 
 
2.8.3 Dissection and sample preparation 
Different fly tissues were dissected the same way as in section  2.1.3 except where 
otherwise mentioned. Then all following steps were carried out on ice. Next in order to 
homogenize the contents, each sample were then sonicated very well for 2-3 s for three 
times.  
Samples then were centrifuged at 10,000 rpm at 4ºC for 10 min in a cooled 
microcentrifuge, and the supernatants were collected into new 2.0 ml eppendorf tubes 
and kept at – 80 ºC (Figure  2-8).   
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Figure  2-8 Metabolite sample preparation methodology. Was drawn by me. 
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2.8.4 Operation of the Orbitrap 
 
Figure  2-9 Diagram showing the steps taken for metabolomic investigation. Was drawn 
by me. 
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2.9 Metabolite extraction strategies  
2.9.1 Methanol-water (MW) solvent 
Solvent used in this experiment was a mixture of methanol and water in the ratio (1:1), 
which was suggested by (Kamleh et al., 2008). Ten whole flies (male and female) were 
added into 500 µl of the mixture solvent in eppendorf tubes and then homogenized by 
sonication for 2-3 seconds for three times; the mixtures tubes were then spun in a cooled 
microcentrifuge at 10 000 rpm at 4 ˚C. The filtered extracts were then kept in the freezer 
at -80 ˚C prior to analysis. On the day of analysis, samples were brought to RT 
temperature and placed into chromatograph glass vials. 
 
2.9.2 Chloroform-methanol-water (MCW) solvent 
An alternative method method of extraction was also tested. Methanol/chloroform/water 
solvents were also used in the sample extraction method in the ratio was 3:1:1. Ten 
adult flies from both genders were collected and anesthetized under CO2, they were then 
transferred into the mixed solvents and well homogenized for 2-3 seconds by sonication 
for three times. The sample was then centrifuged for 10 minutes at 4˚C, and 
supernatants were then transferred into new eppendorf tubes and then were stored in the 
freezer at -80˚C until required. Prior to analysis, samples were kept at room temperature 
and were placed into chromatograph glass vials. 
 
2.10 Allopurinol containing-fly food preparation 
This was prepared as described for the microarray experiments, to allow comparison 
between corresponding transcriptomes and metabolomes of the tubule. 
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2.11 Software and applied libraries used 
In the following, all software used and applied libraries are listed in table 4 
Software     Description 
Excel 2007                   Microsoft spreadsheet 
Xcalibur v. 2.0             Analysis of LC/MS data 
Sieve software v.1.2            Converts raw data to appropriate format 
Sieve Extractor                        Automates metabolites identification 
SIMCA-P+11                  Evaluates and displays LC/MS data 
KEGG Encyclopaedia            Works as identifier to  provide  metabolite  names 
(http://www.genome.jp/kegg/)    Works as identifier to provide  metabolite  names 
PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed       
Works as identifier to provide literature for 
metabolite  names 
Metlin (http://metlin.scripps.edu/) database            Works as identifier to provide metabolite  names 
Human Metabolome Database 
(http://www.hmdb.ca/)     
Works as identifier to provide  metabolite  names 
                 
 
Figure  2-10 Workflow of metabolic software used. 
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2.12 High resolution mass spectrometry adjustments  
LC-MS data were obtained from experiments that were carried out at Strathclyde 
University (Department of Pharmaceutical Analysis) using a Finnegan LTQ Orbitrap 
(Thermo Fisher, Hempstead, UK). Orbitrap analyser resolution was set up at 30000.  
Samples was analysed in positive mode with a capillary temperature of 250˚C, Sheath 
gas flow 40ml/min and auxiliary gas was 10, while the mass scanning range was (50-
1250) m/z. The whole instrument was controlled by Xcalibur software version 2.0 
(copyright© Thermo Fisher Co).  
ZIC–HILIC column 5µm (150 × 4.6mm) was used in all analyses and a method was 
developed which produced good separation for a broad spectrum of metabolites. Solvent 
A was 0.1 % formic acid in HPLC grade water, and solvent B was 0.1 % formic acid in 
acetonitrile. A flow rate of 300 µl/min was used and the injection volume was 10 µl. 
Samples were in a vial tray which was set at constant temperature at 3 ˚C to avoid any 
possible degradation of samples. 
2.13 Metabolite identification 
Samples within an experimental set were analysed on the same day and in a single run. 
This means that the differences in instrument response from run to run due to 
independent manual tunings were limited.  
LC-MS data obtained from Xcalibur software version 2.0 composed of retention time 
and the mass/charge ratio of metabolite. Several steps of the metabolite identification 
and data analysis were carried out in this thesis and are worth describing here. 
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2.14  Step by step data analysis 
2.14.1 Xcalibur  
Firstly, the Xcalibur sample files were loaded into Sieve software 1.2 (Thermo Fisher 
Co) to convert raw data obtained from Xcalibur software to a common format that 
allows use for further data processing.  
The software shows only 2 dimensions. 
 
Figure  2-11 Typical raw data produced by the Xcalibur software. The upper trace shows 
total current chromatograms, and the lower trace,  mass spectrogram peaks from 50 – 
1200 dalton. Was captured by me. 
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2.14.2 Sieve software 
Secondly, samples are uploaded to the Sieve program as two groups: control and test 
samples. Sieve software was tasked with the alignment and framing of chromatograms. 
The software shows retention time, observed mass, ratio for the mean peak areas, mass 
intensity and P-value or t-test between ion chromatograms of the control group (normal 
wild type) and those of the test group.  
The importance of this program is mainly to align data obtained from the Xcalibur. Data 
alignment is important to bring peaks widths within the limit of reading range, and to 
minimise the analyser’s reading errors. 
 
 
Figure  2-12 Typical screenshot of the alignment step in Sieve. The control and 
experimental traces are coloured blue and red. Was captured by me. 
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The second step of the Sieve software is to analyse the aligned peaks Figure  2-13. 
 
Figure  2-13 Detail of aligned peaks in Sieve. Each trace represents an individual 
experimental sample. In this case, the record is for the metabolite kynurenine its 
molecular weight, compared with the m/z ratio, retention time , P-value. (Five 
dimensions). 
 
2.14.3 Sieve Extractor  
Thirdly, a large number of extracted mass results from the Sieve program were not 
annotated automatically with the name of the metabolite. Sieve Extractor software can 
help in naming metabolites. Following classification by Sieve software, data obtained 
were copied and pasted into Sieve Extractor (SE), a programme designed by Strathclyde 
University – Pharmaceutical Analysis Department in-house for automated metabolite 
identification. Briefly, Sieve data were manipulated by SE according to ion 
chromatogram mass width and R.T Width. Two chemical structure databases, Metlin 
and KEGG were searched to establish identity for peaks by exact mass. New 
identifications were manually curated for specificity and plausibility before being 
accepted (discussed below). 
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Figure  2-14 Sample output from Sieve Extractor (SE) Programme. Was captured by me. 
 
In a few cases some metabolites suggested by the software make no sense, thus manual 
checking is always required. In most cases several formula are possible but one or more 
of these do not make sense in biological classification and can be rejected. Chemical 
databases such as PubChem, Human Metabolome and Metlin database were associated 
with metabolite naming when the possible formula within mass accuracy limit was 
used.  
Misidentification or incomplete identification of metabolites was occurring during data 
analysis for several different reasons. In such cases, MS2 fragmentation is one of the 
metabolite identification approaches that can help in confirming the identity of 
compounds especially when distinguishing structurally similar constituents such as 
isomers. Loss of the lower mass range occurs during the fragmentation mechanism. An 
additional approach for distinguishing isomer ions is possible on the basis of the 
retention time of metabolites in the ZIC-HILIC column stationary phase. Metabolite 
identification based on retention time depends on understanding of the chemical 
properties of a metabolite which reacts with  ZIC-HILIC column. In HILIC columns, 
metabolites which are classified as cations are retained more than anions. 
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In this thesis, hypoxanthine and allopurinol are isomer compounds. Although the 
Orbitrap and Xcalibur showed no difference in mass and elemental composition 
between hypoxanthine and allopurinol, a separation between them was observed by 
chromatographic column according to physicochemical properties. An example is 
shown in Figure  2-15. 
 
 
Figure  2-15 Extraction chromatograms from TIC of isomeric compounds using the 
HILIC-column. 
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Sometimes differences in retention times do not tell the whole story. Thus MS/MS 
fragmentation is mandatory to get an informative answer for some isomeric compounds, 
for example hypoxanthine and allopurinol or oxypurinol. Another step is using 
standards to differentiate between metabolites which produce the same observed 
molecular mass in the analyzer.  
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2.15 Microscopy 
2.15.1 Polarizing microscope  
Is a simple bright field microscope equipped with polarizer, located between light 
source and specimen, and analyzer, placed in the optical pathway before the eyepieces. 
Although polarizing microscopy has a range of uses, it was particularly useful in this 
thesis for the visualization of uric acid crystals in situ. Uric acid is a metabolite of 
Xanthine, and so presence of urate crystals implies a functional purine metabolism 
pathway. Uric acid crystals are brightly birefringent (that is, they appear bright under 
crossed polaroizing filters). 
See the chapter 5 on uro 5.4.1 for more details. 
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Chapter 3 The rosy  (ry) 
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3.1 History 
The mutant rosy (ry) is the second Drosophila mutant ever identified, just after the 
white mutant was discovered by T.H. Morgan in 1910. Although the exact date is not 
clear, it is likely that rosy was first isolated in 1912 (Dow, 2007). The rosy mutant is 
characterized by a red-dull eye colour (Figure  3-1), due to the absence of the enzyme 
Xanthine dehydrogenase  (XDH) (Hadorn and Schwinck, 1956). This enzyme has an 
important role in the eye pigmentation reaction in Drosophila. Chemically, flies lacking 
this enzyme possess high levels of 2-amino-4-hydroxypteridine, which is a precursor of 
isoxanthopterin (Glassman and Mitchell, 1959). Moreover, ry flies show high levels of 
hypoxanthine and xanthine, which are precursors of uric acid, so rosy clearly affects the 
purine metabolism pathway. The ry mutants are sensitive to purine-rich diet; ry mutants’ 
life span is shown to be directly reduced by a purine enriched diet when compared to 
wild type flies (Collins et al., 1970).   
Strikingly, this phenotype is not found only in ry. Several other mutants, like mal, cin, 
lxd, are described having the same eye colour defects, and subsequent investigation has 
shown that they encode other genes which impinge on the purine metabolism pathway 
(Table  3-1). 
  
Table  3-1. Comparison between selected Drosophila mutants with defective eye-colour.  
Gene sym chr Eye colour Enzyme activity References  
rosy ry 3 Brown, Red dull Absent or low XDH (Hadorn and Schwinck, 
1956) 
maroon-like mal 1 Brown red dull Present, inactive Co-F. 
 
(Forrest et al., 1956) 
(Wahl et al., 1982) 
cinnamon cin  1 Reddish-brown AO, PO, XDH, SO.  (Baker, 1973) 
chocolate  cho 1 Brown 2-amino-4-hydroxypteridine 
absent 
(Sturtevant, 1955) 
(McKay, 1972) 
AO; Aldehyde oxidase, PO; pyridoxal oxidase, XDH; xanthine dehydrogenase, SO; 
sulfite oxidase.  
 
There is also a renal phenotype; in the ry mutants: as an result of XDH absence, the 
enzyme’s substrates, xanthine and hypoxanthine are found at much higher levels than 
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normal. Consequently, xanthine calculi form in the Malpighian tubules (MT), which 
become enlarged and malformed (Figure  3-2).  
 
 
Figure  3-1. Showing the characteristic red-
dull eye colour of ry mutant against white-
eyed flies (w1118) and Canton S wildtype 
(WT). 
 
 
 
Figure  3-2. Inflated MT in ry and 
compared with WT (Wang et al., 2004). 
A; MT from a wild type fly, B; shows 
inflated MT from homozygous ry mutant 
blocked with xanthine orange particles. 
  
As the mutant is best known for its dull-red eye colour (Figure  3-1), one might expect 
that the main location of the XDH enzyme is in the eyes. Reaume et al (1989) stated that 
XDH enzyme is transported to the eye but not expressed; however by looking at the 
Flyatlas.org one can see the gene is expressed almost everywhere in the fly, including 
the eyes, but mainly in the MT.  Also, XDH is mainly cytoplasmic, so transportation is 
unlikely.  
3.2 Xanthine dehydrogenase vs. oxidase 
Xanthine oxidoreductase is the generic name for the house keeping gene enzyme; 
namely Xanthine dehydrogenase (XDH) and Xanthine oxidase (XO) (Meneshian and 
Bulkley, 2002). 
WT 
ry 506 
W1118 
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Figure  3-3. Xanthine Oxidoreductase (XOR ) structure and interchangable mechanism 
(Meneshian and Bulkley, 2002). 
 
Both the dehydrogenase and oxidase use hypoxanthine and xanthine as substrates to 
produce uric acid; however, different cofactors are utilized in each reaction. The 
dehydrogenase uses NAD+ as an electron acceptor and produces NADH. However, the 
oxidase utilizes O2 as a cofactor and produces more reactive oxygen species (ROS), 
namely H2O2 and O2-. These in turn can form further radicals. So the XO is known to be 
a source of free radicals as seen in the reaction (A) in (Figure  3-4). 
 
 
 
A) 
 
  
 
B) 
 
 
Figure  3-4. Xanthine dehydrogenase and oxidase reactions. 
Xanthine dehydrogenase 
Xanthine oxidase 
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Furthermore, both enzymes are encoded by the same gene and exist as interchangeable 
forms. Usually it is found in the dehydrogenase form; however under some 
pathophysiological conditions or in injuries such as ischemic reperfusion, it is converted 
into the oxidase form, using the excessive O2 present as a cofactor and thus producing 
ROS as a result of the oxidative stress. This switch could thus be thought of as a defence 
mechanism in ischemia, where the body suffers from severe O2 loss; on recovery, the 
body is trying to provide an immediate supply of O2 to the affected tissue. This huge 
supply of O2 gained into cells, from increased blood flow, can causes sometimes 
unwanted effects like cellular damage of proteins, DNA and plasma membrane (Martin 
et al., 2004). Thus, in order to prevent cell death, conversion of XDH to XO helps to 
utilize the excessive O2 present. However, although this mechanism rescues the body 
from oxidative stress, it is at the cost of generating high levels of ROS.  
This interconversion can also be either reversible  when sulfhydrylated; or irreversible, 
when proteolysed (Figure  3-5)   (Chung et al., 1997).  
Thus, the enzyme XDH/OX has an important role in cellular defence against oxidative 
stress. 
 
 
Figure  3-5. Interconversion between XDH and XO (Modified from  Chung et al., 
1997).This figure shows the interconversion between XDH and XO. The original form 
is the dehydrogenase form, which can be converted to the oxidised form by 
sulfoxidation and converted back to the dehydrogenase form by reduction. However, 
conversion to XO by proteolysis is irreversible.  
 
Furthermore, XO plays an important role against free radicals, because its main product 
is uric acid, a very well known reducing agent (electron donor). Urate can thus act as a 
free radical scavenger by donating electrons to be coupled to ROS. Moreover, XDH/XO 
could modulate the immune response, as ROS, in the form of O2-, OH- and H2O2; and 
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RNS, in the form of NO, in the presence of bacteria, can act as antibacterial and 
cytotoxic agents against various pathogens and tumour cells (Vorbach et al., 2003).  
In humans, the interconversion between XDH and XO is known to occur, leading to its 
naming as XOR. Such interconversion has not been demonstrated in Drosophila, where 
the gene product has been called XDH since 1956. Thus, to avoid misunderstanding, in 
this thesis I am going to call the enzyme XDH in Drosophila and XOR when discussing 
in mammal particularly humans.  
3.2.1 Basic biochemistry  
Both enzymes are composed of two identical subunits with a total size of 300 kDa. Each 
subunit consists of one molybdenum (85kDa), two non-identical Fe2S2 centres (20kDa) 
and flavin adenine dinucleotide (FAD) (40kDa), producing a total molecular weight of 
150kDa (Chung et al., 1997).  
3.3 Results 
3.3.1 Tissue-specific knockdown of XDH activity 
Although a wide range of rosy alleles have been characterised, and many are still 
available in stock centres, we wished to investigate the role of rosy in further detail, 
dissecting its enzymic and defence roles in individual tissues – for example, the 
Malpighian tubules, the tissue in which ry is most abundantly expressed. As both rosy 
and the corresponding human disease (Xanthinuria type I) both show similar defects, 
this would allow a more detailed modelling of the human condition in flies, and so test 
the implicit hypothesis of the thesis (that human renal disease could usefully be 
modelled in Drosophila). Accordingly, we tried to develop new alleles of rosy, and new 
analytical techniques to study their impact.  
3.3.2 RNA interference (RNAi)  
RNAi is a method widely used as a powerful tool for reverse genetics in gene silencing. 
The method first was used in C. elegans, then was adapted into Drosophila 
melanogaster for gene silencing (Kennerdell and Carthew, 2000). Since then, many 
elegant RNAi vectors have been developed. For our purposes, the RNAi inducing 
silencing vector (pRISE) is an effective tool to generate constructs that can be used in 
Drosophila RNA silencing technique (Kondo et al., 2006).  
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This approach is based on constructing a plasmid including an inverted repeat of the ry 
target sequence separated by a functional intron to form double stranded RNA (Figure 
2-4 B). This plasmid also uses a characteristic repeat sequence of the Gateway 
recombination cassette which helps in avoiding multiple restriction digest and ligation 
steps. To accomplish the ry gene silencing, our DNA fragment has first to be cloned 
into an appropriate entry vector, which is the pENTR/D-TOPO from Invitrogen. Once 
the cloning is done then this will be transferred or subcloned easily into the pRISE by 
the help of an enzyme recognising the Gateway cassette site by recombination reaction 
(Figure 2.6 LR clonase). This enzyme is the LR Clonase, also from Invitrogen.   
In principle, the use of clonase rather than ligase offers very high frequency of ligation, 
and the approach was successful elsewhere in this project. However, after several 
attempts, it proved impossible to clone the open reading frame for ry into pENTR in-
house (Figure  3-6).  
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 Primer testing Direct colony 
PCR screening 
Further 
screening 
 1 2 3 
A 
 
 
 
 
Primer testing. 
Lane 3 for ry. Lane 
5 for uro. 
 
Upper samples 
were for ry 
screening. Lower 
samples were for 
uro screening. Lane 
4,5 & 7 showed 
success insertion 
for uro. 
 
In this particular gel 
picture only the 
positive control was 
shown. 
    
New primer set.   
B 
 
 
 
  The newly ry  
primer set tested on 
both lanes 3 &5. 
 
Upper lane 1 
ladder, 2 to 12 
samples. 
Lowe lane 1 ladder, 
2-10 samples, 11 
+ve cont 
 
Restriction digest. 
Lane 1 ladder, 2-5 
samples  
 
 
Figure  3-6 Gel pictures showing ry cloning. 
All column 1 gel pictures are for primer testing. A1 ry and uro primer testing. 
While in B1 a new ry primer set was used. Column 2 gel pictures were for direct 
colony screening. Same steps in row B were repeated several times.  
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During the course of the project, comprehensive libraries of transgenic Drosophila 
containing RNAi constructs downstream of UAS, have become available from several 
stock centres. Accordingly, the transformant 25172 was also ordered from the 
Drosophila Genomic Resource Centre in Vienna. 
3.3.2.1 Validation by qPCR.  
Flies were crossed with urate oxidase-GAL4 line, which drives RNAi expression 
exclusively in the principal cells of the main segment of the tubules of third instar larvae 
and adults (Terhzaz et al., 2010). Then week-old adult progeny were selected, tubules 
were dissected, total mRNA were extracted, cDNA were also generated and then gene 
expression validation of the knockdown took place.  
QPCR method is considered the method of choice for gene expression validation. So 
primers were designed to amplify a DNA fragment of 196 bp (primers qPCR ry II F and 
R see appendix 9.5) in the ry gene. Then the annealing temperature was optimised. 
Results were normalized against the housekeeping gene, α-tubulin (Chintapalli et al., 
2007). 
Malpighian tubules were dissected from both parents and progeny then total mRNAs 
were checked for quality as well as for quantity. Then cDNA was generated and then 
checked for quality and quantity, next this was used as a template for the gene 
expression validation reaction. It was found that the RNAi line, when driven by the 
tubule-specific driver uro-GAL4, reduced expression of the ry in the tubules 
significantly, by 70 %  compared to parental lines (Figure  3-7). 
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Figure  3-7. The ry RNAi knockdown validated by qPCR 
The ry gene knockdown expression is compared to uro-GAL4 and ry RNAi parents. 
Data mean ± SEM, N=4. Significance of changes was assessed by Student’s t-test (two 
tailed) taking P=0.05 as the critical level: significant changes are marked with *.   
 
Accordingly, it was concluded that the Vienna UAS-ry(RNAi) line provided a suitable 
resource – a strong, cell-specific hypomorphic allele of ry – and in-house cloning efforts 
were discontinued. 
3.3.3 Metabolomics 
The metabolomic approach has emerged as a new branch of the omics era. With the 
advances in bioinformatics and unparalleled sensitivity in detection, it has potential 
applications for simple model organisms like Drosophila.  
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The Orbitrap was known to be able to detect relevant metabolites, from manufacturer 
standards. However, we set out to establish whether they could be resolved with 
sufficient sensitivity in real extracts of flies.  
Thus we tried to use the Drosophila rosy mutant to find out whether metabolomics, and 
specifically the Orbitrap, are useful tools in flies. Oregon R also was used as a control. 
In a brief pilot study 10 flies were grind up and run. As it can be seen in (Figure  3-8) the 
desired peaks of purine metabolism related metabolites were seen.  
 
 
 
Figure  3-8 Narrow-range extracted ion traces extracted across a range of 0.02 amu 
showing the metabolites related to uric acid biosynthesis from female wild-type 
Drosophila. Along with their retention time as well as mass/charge ratio. 
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3.3.3.1 Validation by Orbitrap 
For further validation, and as a new method for gene knockdown validation, we tried to 
apply metabolomics to measure relevant metabolites that should be directly affected by 
ry gene silencing.  
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Figure  3-9. RNAi knockdown of rosy phenotypically validated by Orbitrap. It shows 
comparisons between the major metabolites involved in the absence of XDH in different 
lines. Uro-GAL4 drivers parents, ry RNAi parents and progenies. Data are shown as 
mean ±SEM for N=3 independent experiments. Data that differ significantly are marked 
with asterisks are analyzed by Student’s t-test two tailed.  
 
So from the data presented, the RNAi line produces a useful knockdown of rosy, 
assessed both by gene expression and metabolomic pathway disruption; and the 
Orbitrap technology provides a useful screen for knockdown of a metabolic enzyme. 
 
3.3.4 Whole fly metabolomics 
Could this technology also be useful for classical mutations (of which there are many 
thousands in stock centres worldwide)? A pilot experiment was performed on extracts 
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pooled from 10 flies. Male and females were kept separate using the ry506 mutant, 
known for as XDH enzyme deficient and Oregon R wild type as a control. Initially we 
were looking for key metabolite changes like xanthine, hypoxanthine and urate, a 
targeted rather than global metabolomic approach (Figure  3-10). 
 
 
 
Hy
px
an
thi
ne
 
M
Hy
px
an
thi
ne
 
F
Xa
nth
ine
 
M
Xa
nth
ine
 
F
0 
1000 
2000 
3000 
4000 
ns
ns Male
Female
Ar
bi
tr
a
ry
 
u
in
its
 
Figure  3-10 A pilot study for male and female rosy mutant. It shows no differences 
between male and female involved the two main metabolites in purine metabolism  
pathway. Data are shown as mean ±SEM for N=5 independent experiments. Data that 
differ significantly analyzed by Student’s t-test two tailed are marked with asterisks. 
 
 
From classical biochemistry, it was expected to find that both xanthine and 
hypoxanthine are elevated in the ry506 mutant (Hadorn and Schwinck, 1956) and 
(Glassman and Mitchell, 1959). This was clearly observed in both males and females, 
with both producing similar results. These results both confirm the classical data, and 
validate the accuracy of the Orbitrap in reproducing similar results with a fundamental 
technology. The Orbitrap is thus a useful tool for targeted metabolomics in Drosophila. 
Having obtained the expected results, the analyzer was challenged further, to see to 
what extent that it would be useful in specific fly tissues. This experiment is much more 
demanding in terms of low metabolite concentrations. Consequently, we carried out 
another experiment using different fly tissues, like heads and Malpighian tubules. 
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Empirically, 15-20 heads and tubules for 20-30 flies were found to give good results 
(Figure  3-11). 
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Figure  3-11. Comparison in the rosy mutant between heads and MT. Uric acid levels in 
both head and tubule were too low to be measured. Data are shown as mean ±SEM for 
N=5 independent experiments. Data that differ significantly are marked with asterisks 
are analyzed by Student’s t-test two tailed. This graph shows that xanthine is much 
more significantly higher than hypoxanthine in the MT. While in the heads samples, 
although hypoxanthine level is higher than xanthine, it is not statistically significantly.  
 
Accordingly, tissue-specific differences were analysed in more detail, as shown in 
(Figure  3-12) and (Figure  3-13).  In both heads and tubules, hypoxanthine and xanthine 
levels were strongly elevated, and uric acid and allantoin depleted; but these effects 
were much more marked in the tubules. This is consistent with microarray expression 
data, as ry is expressed in the whole fly, with higher levels particularly in MT. The 
metabolites viewed in different tissues thus reflect gene expression level in those 
individual tissues (Chintapalli et al., 2007), suggesting that it may ultimately be possible 
to build models linking transcriptome and metabolome. 
The results were encouraging, as they showed that the Orbitrap is very useful tool not 
only in fly metabolomics but also in small tissues as well. Very clear metabolite 
differences were seen between ry and WT in tubules as well as in the heads (Figure 
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 3-11). Thus metabolomics of individual tissues can provide more detailed insights than 
whole-organism studies, in a manner exactly analogous with  the single-tissue 
microarrays that underpin the FlyAtlas.org resource (Chintapalli et al., 2007). 
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Figure  3-12. Wild type vs. rosy heads. Comparisons between key metabolites in purine 
metabolism pathway to their counterpart in WT in heads samples. Data for each 
metabolite are expressed as a percentage relative to the wild-type levels. Data are shown 
as mean ±SEM for N=5 independent experiments. Data that differ significantly are 
marked with asterisks are analyzed by Student’s t-test two tailed.  
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Figure  3-13. Wild type vs. rosy Malpighian tubules. This graph shows the comparisons 
between key metabolites in purine metabolism pathway to their counterpart in WT in 
MT samples. Data for each metabolite are expressed as a percentage relative to the 
wild-type levels. Data are shown as mean ±SEM for N=5 independent experiments. 
Data that differ significantly are marked with asterisks are analyzed by Student’s t-test 
two tailed.. 
 
3.3.5 Global metabolomics of rosy and wild-type flies 
After validating the technology, by looking for specific metabolites in ry, (so called 
‘targeted’ analysis,) and by comparison with historical data, the approach was extended 
to all metabolites that could be resolved in the Orbitrap, the so-called ‘global 
metabolomic analysis’. 
Initially we broadened our analysis to those metabolites associated with purine 
metabolism biosynthesis and metabolism (Table  3-2). This confirmed the classical 
findings for rosy, but also extended it to several further metabolites.  
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Table  3-2. A broader view of the purine metabolism pathway.  
Metabolite 
P Value 
(Paired t-Test) 
Ratio 
ROSY/WT 
Remarks 
Allantoin 0.00 0.002  
Uric acid 0.00 0.0041  
Leucylarginine 0.00 0.1107  
Thymine 0.12 0.2296 NS 
Uridine 0.02 0.2996  
Aspartic acid 0.02 0.5576  
Valineyl valine  0.41 0.5734 NS 
Uracil 0.00 0.7721  
Guanine 0.01 0.8169  
Guanosine 0.07 0.8713 NS 
Glutamine 0.75 1.0403 NS 
Inosine 0.59 1.0565 NS 
Glutamic acid 0.41 1.0895 NS 
Cytosine 0.14 1.4403 NS 
Adenosine 0.00 2.1464  
Deoxyguanosine 0.00 2.1464  
Cytidine 0.18 2.2857 NS 
Amp 0.00 2.3137  
Xanthine 0.00 19.870  
Hypoxanthine 0.00 36.006  
NS, non significant. P-value less than 0.05  is significant. 
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3.3.6 The main study (male and female) 
As the approach was clearly working well, the analysis was extended globally. Table 
 3-3 shows all significantly changed metabolites detected, arranged into putative 
metabolic pathways. 
 
Table  3-3 Significantly changed metabolites seen in ry506  males and females. Analyzed 
by Student’s t-test two tailed. 
Female Male 
Metabolite/Metabolic 
pathway Formula 
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) ratio 
ry/WT 
P.value 
ratio 
ry/WT 
P.value 
Purine / uric Acid related   
Uric Acid C5H4N4O3 169.0356 1 5.65E-04 7.62E-04 2.5E-09 5.96E-04 
Allantoin C4H6N4O3 159.013 1 0.047 1.19E-04 0.018 0.002 
Hypoxanthine  C5H4N4O 137.0458 1 15.66 1.92E-04 10.844 4.90E-05 
Xanthine C5H4N4O2 153.0407 1 25.2 3.19E-04 20.665 5.5E-07 
Guanine C5H5N5O 152.0567 3 2.83 0.001 1.325 0.073 
Guanosine C10H13N5O5 284.0989 1 2.89 0.003 1.119 0.527 
6-pyruvoyltetrahydropterin 
(6-PTP) , biopterin C9H11N5O3 238.0935 5 3.03 4.10E-09 1.576 5.18E-04 
Dihydrobiopterin C9H13N5O3 240.1091 3 5.47 1.20E-06 5.188 1.2E-07 
Dihydropterin  C7H9N5O2 196.0829 1 0.13 0.013 0.214 0.006 
Inosine C10H12N4O5 269.088 2 4.69 0.005 2.023 0.011 
AMP C10H14N5O7P 348.0704 2 1.46 0.055 1.075 0.43 
Tryptophan pathway Metabolites    
Tryptophan  C11H12N2O2 205.09715 2 0.53 0.005 0.36 6.4E-07 
Hydroxytryptophan C11H12N2O3 221.0921 1 1.87 0.028 0.509 0.004 
Kynurenine C10H12N2O3 209.921 1 3.35 5.5E-08 0.64 0.004 
Hydroxykynurenine C10H12N2O4 225.0921 1 0.405 2.5E-07 0.345 7.1E-07 
Osmolytes   
Choline glycerophosphate  C8H21NO6P 258.1101 1 14.57 4E-11 9.56 1.8E-11 
Glycerophosphoethanolamine  C5H14NO6P 216.1101 1 16.16 2E-10 9.672 8.7E-08 
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Choline C5H14NO 104.107 1 1.33 0.006 0.792 0.09 
Pyrimidines 
           
Cytosine C4H5N3O 112.0505 1 14.31 0.002 2.571 0.016 
Uracil C4H4N2O2 113.0346 1 0.921 0.6 0.402 0.002 
Uridine C9H12N2O6 245.0768 2 0.9 0.617 0.5 0.209 
Arginine Pathway Metabolites  
Citrulline C6H13N3O3 176.103 1 0.299 0.004 0.348 0.042 
Ornithine  C5H12N2O2 133.0972 1 0.376 0.147 0.128 0.036 
L-Homocitrulline C7H15N3O3 190.11862 1 0.011 1.9E-07 0.00009 0.00031 
Misc Metabolites 
Alanine C3H7NO2 90.055 2 1.93 8.4 X 10-8 1.259 0.075 
Glutamic acid C5H9NO4 148.0604 4 1.75 3.14E-04 0.871 0.094 
Glutamine  C5H10N2O3 147.0764 5 1.32 5.66E-04 1.11 0.233 
Threonine C4H9NO3 120.0655 2 0.526 0.000032 0.578 2.21 E-04 
Nicotinamide C6H6N2O 123.0553 1 1.55 1.60E-04 0.732 0.081 
Valine C5H11NO2 118.08613 5 1.06 0.494 0.76 0.016 
As well as finding what was expected from metabolomic studies in the rosy mutant, 
many further changes in metabolites were obtained, some of which were quite 
unexpected, and not known from the extensive classical literature on rosy. I will now 
focus on each affected pathway in detail. Red colour readings indicate conflict between 
male and female.  
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3.3.7 Purine metabolism pathway 
As can be seen in (Figure  3-14), the changes shown in (Table  3-3) are very sensible. 
Significantly, changes in metabolite levels can be detected several metabolites further 
from the genetic lesion than had been detected by classical analytical biochemistry. This 
means that the Orbitrap technology can provide more information in a single experiment 
than can be obtained by classical techniques. 
 
 
Figure  3-14. Part of purine metabolism pathway in Drosophila, with significant changes 
in whole-fly metabolite levels shown (Kamleh et al., 2008). 
 
3.3.8 Tryptophan pathway metabolites 
It was, also found that 3-hydroxykynurenine levels were lower in ry (Table  3-2) and 
(Table  3-3), while kynurenine was elevated. This suggests that the enzyme responsible 
for converting 3-hydroxykynurenine to kynurenine is reduced in activity; and so 
explains how the ry eye red-dull colour is generated. Generally, the Drosophila eye 
colour is constituted as a result of a mixture of two pigment colours, namely, brown 
(xanthommatin or ommochrome) and red (drosopterin). Each colour is generated from a 
distinct pathway (Figure  3-15). Thus, any disruptions in either pathway will impact on 
the Drosophila eye colour. The ommochromes are metabolites of tryptophan pathway, 
via kynurenine and 3-hydroxykynurenine. 
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(A) 
 
(B) 
Tryptophan 
↓ 
N-formylkynurenin 
↓ 
Kynurenin 
↓ 
3-hydroxy kynurenin 
↓ 
Xanthommatin 
 
 
 
Figure  3-15 (A) Overview of eye pigment formation in insects. (B) Detailed view of 
conversion of tryptophan to xanthommatin. 
 
 
How could Xanthine dehydrogenase impact on the tryptophan metabolism pathway? 
One possibility is through a reduction in cofactors necessary for enzymatic metabolism 
of tryptophan. The structure of flavin adenine dinucleotide (FAD) is shown in (Figure 
 3-16). Adenosine is linked through two phosphate units to a riboflavin; so the idea here 
is that flavin is very important part in the FAD; so when it is defective, vital metabolic 
biosynthesis, like hydroxylation of kynurenine will be disrupted. It was observed that 
levels of riboflavin (vitamin B2), which is necessary for the biosynthesis of the FAD co-
factor required for hydroxylation of kynurenine, were much lower in ry. This may be 
due to malabsorption of the vitamin in ry and could provide an explanation for the 
important of XO on the kynurinine pathway.  
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Figure  3-16 Chemical structure of FAD. 
The black molecule is adenosine dinucleotide, The red is ribitol, and the blue flavin.  
 
3.3.9  Osmolyte biosynthesis 
Changes were also observed in the glycerophospholipid pathway. Both choline 
glycerophosphate (CGP) and glycerophosphoethanolamine (GPEA) -related to osmolyte 
biosynthesis- were elevated.  
In other organisms, this pathway is triggered or activated when excessive amounts of 
NaCl or nitrogenous wastes (urea) accumulate in the mammalian renal medullary cells. 
This occurs as a result of the animal trying to maintain the osmotic balance. How are 
these metabolites changing in rosy? Rather than a direct enzymatic effect on 
phospholipids, it is possible that defective purine metabolism may result in osmotic 
stress – as outlined below – and so induce osmolyte biosynthesis. 
Nitrogenous waste products are highly toxic and need to be eliminated immediately 
from insects. To do so these wastes are must be metabolized to lesser toxic products, 
like uric acid in Drosophila. Uric acid is water insoluble so its excretion is sparing of 
organismal water (Chapman and Chapman, 1998). However, if urate formation is 
blocked, purine metabolism may result in the accumulation of water-soluble 
metabolites, thus they must be diluted to reduce its toxicity until they excreted. As ry 
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mutants are unable to make uric acid in the absence of XDH, they excrete the nitrogen 
waste in other forms, perhaps as water-soluble xanthine. This process would be wasteful 
of water, leading to osmotic stress. This could explain the observation of CGP and 
GPEA in higher levels in comparison to WT fly in the osmolyte biosynthesis (Figure 
 3-17).  
 
 
 
 
Figure  3-17. Osmolyte biosynthesis: extract from the KEGG pathway map, with fold 
changes superimposed. 
 
Thus all previous effects of on the osmolyte pathway are not directly an effects of ry, it 
is rather a secondary impact of the XDH enzyme on phospholipid synthesis.  
A corollary of this model is that rosy flies might be under baseline osmotic stress, and 
so might be more susceptible to external stress – for example – hyperosmotic diets. It 
would be interesting to test this model experimentally, if time allowed. 
 
3.3.10 Arginine metabolism  
Arginine metabolism (the urea cycle) is also affected in ry, with significantly lower 
levels of ornithine, citrulline and L-homocitrulline (Table  3-2). L-homocitrulline does 
not actually feature on a KEGG map; but it is synthesised from carbamoyl phosphate (a 
precursor of citrulline), and lysine. So its depression could link to the observed 
reduction in levels for citrulline (Figure  3-19).  One explanation could be that an 
observed accumulation of dihydrobiopterin (DHBT) causes an inhibition of 
tetrahydrobiopterin (THBT) recycling (Figure  3-18). One of the isomers of DHBT is 
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known to be an inhibitor of THBT regeneration (Thony et al., 2000) and THBT is 
required as a co-factor in arginine oxidation which results in the formation of NO and 
citrulline. Accumulation of DHBT in vascular tissue may have a role in insulin 
resistance where it inhibits vasodilation through inhibiting NO production (Shinozaki et 
al., 1999). 
 
 
Figure  3-18 Impact of rosy mutation on the purine and biopterin metabolic pathway. 
Although the primary lesion is a disruption of xanthine dehydrogenase, the impact on 
the dehydrobiopterin pathway might be explained by the increase in guanosine levels. 
Red arrows denote significantly changed metabolites; fold changes are shown alongside 
each arrow. After (Kamleh et al., 2008).  
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More simply, a lesion in purine metabolism increases the pressure on other routes for 
nitrogen excretion, and urea production is a key by-product of the arginine (urea) cycle 
(Figure  3-19). Even if rosy exerted a relatively focused effect on purine metabolism, it 
could still perturb this remote part of the metabolic map. 
 
 
 
Figure  3-19. Arginine pathway: extract from the KEGG pathway map, with fold 
changes superimposed. 
 
3.3.11 Pyrimidine metabolism 
Cytosine is strongly increased, and uracil decreased in rosy compared to wild-type, 
although the uracil depression was male specific (Table  3-2). Cytosine and uracil are 
neighbouring metabolites in the pyrimidine metabolic pathway (Figure  3-20). By 
contrast, their neighbours (cytidine and uridine) are not significantly changed. The 
pyrimidine compounds can also be degraded into urea. For example cytosine can be 
catabolized into uracil and then catabolized further to β-Alanine.  
The reason why cytosine is the only metabolite elevated is not clear, however – as for 
the arginine explanation above-  this could be possibly as a secondary effect of the fly 
x 0.004 
x 0.15 
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trying to compensate for a shortfall in nitrogenous compound excretion through the 
purine metabolism pathway. 
 
Figure  3-20. Pyrimidine pathway: extract from the KEGG pathway map, with fold 
changes superimposed. 
 
3.4 The mutant rosy, allopurinol and gout 
3.4.1 Introduction 
Gout is an inflammatory disease condition characterized by a recurrent attacks of 
inflammatory arthritis, redness, tenderness and swollen joints, as a result of sodium 
urate or uric acid crystals precipitating in joints and soft tissues (Figure  3-21) and 
(Figure  3-22).   
For example, in the UK it is estimated 1.4 % of the adult population are affected with 
gout. The disease is mainly seen in the elderly people over 65 years (Patel et al., 2010).  
Gout can be caused by either dietary habits; high sugar and protein intake, or could be 
happens as a result of secondary effects of metabolic syndrome. It may also result from 
renal failure.  
The exquisitely painful nature of gout has been described by several prominent writers: 
“People wish their enemies dead, but I do not; I say give them the gout, give them the 
stone!” (Mary Worley Montagu) 
x 0.4 
x 14 
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“Be temperate in wine, in eating, girls, and sloth; Or the gout will seize you and plague 
you both” (Benjamin Franklin) 
 
 
Figure  3-21. A cartoon illustrating the painful inflammatory effects of gout in man can be.  
(From: The Gout, James Gillray, 1799.)  
(A) (B) 
 
 
Figure  3-22 (A) Diagram of disruption of the big toe (the most common locus for gout) by 
urate crystals. (From medicinenet.com) (B) an affected joint, with a tophus of urate 
crystals clearly visible through the distended skin. (From news.bbc.co.uk). 
 
At first sight, therefore, it would seem that urate formation is undesirable, and that 
circulating levels of urate should be kept as low as possible (Figure  3-23). However, 
(Hilliker et al., 1992) suggested that urate is an important antioxidant agent; as urate-
null mutants, like ry, are extremely sensitive to oxidative stress agents like paraquat and 
die quicker than wild types. Thus they suggested that urate is playing an important role 
in longevity (this will be discussed further in the uro chapter). The human body is thus 
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likely actively maintain a preferred level of circulating urate, and gout can be seen as an 
unfortunate long-term side-effect of setting this level too high.  
 
Figure  3-23. Part of purine metabolism showing the key role of Xanthine 
oxidoreductase in urate formation, and thus in gout. 
   
Nonetheless, treatments for gout have been found, and revolve around reducing urate 
levels, by reduced nitrogen in the diet (low protein), higher fluid intake, and allopurinol, 
a pseudosubstrate inhibitor of XOR. 
Hypoxanthine 
 
Allopurinol 
 
Figure  3-24 Hypoxanthine vs. allopurinol chemical structures. 
 Its chemical structure is very similar to hypoxanthine with a slight difference in the 
carbon and nitrogen atoms arrangement (Figure  3-24). Furthermore, the enzyme does 
not differentiate between the two chemically similar compounds: allopurinol is rapidly 
metabolized byxanthine oxidase, to its active metabolite oxypurinol (Figure  3-25), 
which is also an inhibitor of xanthine oxidase. Allopurinol is almost completely 
metabolized to oxypurinol within two hours of oral administration, whereas oxypurinol 
is slowly excreted by the kidneys over 18-30 hours. For this reason, oxypurinol is 
believed to be responsible for the majority of allopurinol's effect. 
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Oxypurinol  
 
Xanthine  
 
Figure  3-25 Xanthine vs. oxypurinol chemical structure. 
 
 
Crucially, however, oxypurinol can interact with XOR to block urate production from 
xanthine (Spector, 1988).  
GuanosineInosine
GuanineAdenine Hypoxanthine
Xanthine
Uric Acid
XDH
XDH
Allopurinol
 
Figure  3-26. Allopurinol drug effect. 
 
Consequently, free hypoxanthine concentration will feedback inhibit the XOR 
production and oxypurinol prevent urate production. Consequentially producing lesser 
amount of uric acid and accumulating of the precursors, hypoxanthine and xanthine. 
The accumulation of these two metabolites will lead to accumulation of adenine and 
guanine, precursors of hypoxanthine and xanthine respectively. Increased levels of 
adenine and guanine have an inhibitory feedback effect on a rate-limiting enzyme in the 
purine biosynthesis pathway. So allopurinol not only reduces uric acid by inhibiting its 
conversion from its precursor, xanthine, but also by inhibiting the purine biosynthesis 
(Figure  3-26). Allopurinol is also used with cancer patients as prophylaxis treatment 
with chemotherapy as a treatment for stomatitis (mouth ulceration), though its mode of 
action is unclear (Yokomizo et al., 2004). 
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The effect of allopurinol is not only to reduce urate formation, but it could also lead to 
accumulation of the urate precursors, xanthine and hypoxanthine to high levels. It might 
thus be predicted that high levels of, or sustained treatment with, allopurinol could lead 
to xanthinuria; and indeed, xanthinuria type I can arise as a secondary effect of therapy 
with allopurinol. In Drosophila, allopurinol was reported to phenocopy the rosy mutant 
(Keller and Glassman, 1965). So we wanted to validate this concept by using the 
Orbitrap (Figure  3-27). Importantly, allopurinol has the potential to allow the acute 
effects of XDH inhibition to be studied over time; by contrast studies of ry mutants can 
only follow relatively long-term adaptations to the lesion in XDH.   
3.4.2  Experimental procedure 
 
 
Figure  3-27. Allopurinol experiment overview. Was drawn by me. 
 
Allopurinol-treated flies were tested in a time-course experiment. Keller and Glassman, 
(1965) found that 110 µg/ml allopurinol was sufficient to give ry phenotype. Three 
different times were selected to conduct the experiment; zero, 6, 24 or 72 hours. 
Replicate samples were taken for microarray analysis.  
3.4.3 Results 
Initially, the treatment of Oregon (WT) with allopurinol led to dramatic changes in 
metabolite concentration of hypoxanthine, xanthine, allantoin, uric acid and oxypurinol 
when compared with the control group (Table  3-4). Expressed graphically  (Figure 
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 3-28), it can be seen that levels of hypoxanthine and xanthine increase immediately 
upon exposure to allopurinol, but build steadily to maximum levels over two days. 
Urate, however, declines only very slowly. This is probably because the tubules, fat 
body and eyes of the fly contain major deposits of urate as insoluble uric acid crystals. 
Accordingly, these deposits are likely to have very long half-lives and so deplete very 
slowly. By contrast, allantoin decreases quickly and rather erratically, perhaps reflecting 
that its major pool is as soluble allantoin in the tubules. Accordingly, there is a dynamic 
sub-pool of urate and allantoin in tubules (independent from the insoluble urate pool) 
which is more sensitive to the activity of XDH, and thus the instantaneous metabolism 
of xanthine. 
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Figure  3-28 Timecourse of major metabolites in the purine metabolism pathway after 
feeding allopurinol to Oregon R (WT) flies at t=0. In this log scale graph, dramatic 
changes in metabolite concentration of hypoxanthine, xanthine uric acid and allantoin 
are visible. Hypoxanthine and xanthine levels were increased immediately upon 
exposure to allopurinol and then were built steadily to maximum levels over two days 
(blue lines). By contrast, urate and allantoin (red lines) were both decreased. Urate 
declined very slowly. This is probably because the tubules, fat body and eyes of the fly 
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contain major deposits of urate as insoluble uric acid crystals. Accordingly, these 
deposits are likely to have very long half-lives and so deplete very slowly. By contrast, 
allantoin decreases quickly. Data are shown as mean ±SEM for N=5. Metabolites that 
differ significantly from t=0 are marked with asterisks are analyzed by Student’s t-test 
two tailed. 
 
 
Other pathways are impacted by allopurinol (Table  3-4), though in general the changes 
are less marked than for the purine metabolism pathway. As with the previous 
metabolomic analysis of rosy mutants, there is impact on the pigment precursor 
(kynurinene and typtophan) metabolism pathways, serving to confirm the broad 
accuracy with which allopurinol phenocopies the rosy mutation. 
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Table  3-4. Metabolic pathways significantly affected by allopurinol. (F.C.; Fold change, 
P.V.; P value). Red means down regulated, blue means up regulated. Analyzed by 
Student’s t-test two tailed. 
 6 h 24 h 48 h 72 h 
 
Mr Elution 
time 
F.C. P.V. F.C. P.V. F.C. P.V. F.C. P.V. 
Purines/pterins 
Hypoxanthine 137.0460 11.5 2.3 0.0036 5.2 0.012 3.1 0.0035 6.0 0.0025 
Xanthine 153.0407 10.9 3.2 0.0077 7.8 0.0082 12 0.010 12.3 0.0001 
Urate 169.0357 14.04 1.1 0.38 1.1 0.085 0.85 0.14 0.72 0.002 
Allantoin 159.0514 15.1 0.25 0.00073 0.52 0.007 0.10 0.0011 0.40 0.0028 
Pterin 164.0568 12.7 1.3 0.035 1.7 0.000006 1.6 0.0024 1.4 0.0016 
Isoxanthopterin 180.0517 13.0 1.1 0.32 1.0 0.9 1.2 0.64 1.0 0.70 
Inosine 269.0882 12.7 0.84 0.19 1.0 0.91 0.74 0.0012 0.67 0.0026 
Drosopterin 369.1534 19.2 1.1 0.26 1.1 0.13 1.3 0.012 1.0 0.43 
Oxidative stress 
Methionine S-
oxide 
166.0532 19.1 0.99 0.98 2.77 0.00072 1.5 0.0019 1.4 0.83 
Ascorbic acid 175.0248 13.7 ND - ND - ND - ND - 
GSH 308.91 17.0 0.51 0.0054 0.40 0.01 0.52 0.0077 0.45 0.0059 
Riboflavin 377.1458 10.2 1.0 0.84 0.47 0.0067 0.31 0.0084 0.26 0.0048 
GSSG 613.1592 21.5 1.4 0.12 2.9 0.011 1.8 0.022 1.4 0.06 
Pentose phosphate pathway 
Deoxyribose 133.0506 8.4 0.42 0.033 0.30 0.11 0.6 0.087 0.36  
Sedoheptulose 7-
phosphate 
289.0331 20.3 0.73 0.022 1.0 0.33 0.75 0.0031 0.71 0.0075 
Aldose reductase 
Gulonolactone 177.0405 12.2 0.30 0.029 0.32 0.034 0.26 0.026 0.52 0.090 
glucitol 181.0718 16.3 0.29 0.031 0.50 0.073 0.42 0.048 0.43 0.048 
Gulonic acid 195.0511 16.9 0.46 0.020 0.44 0.020 0.36 0.012 0.42 0.021 
Kynurenine pathway 
Niacin/Nicotinate 124.0393 8.2 0.72 0.029 0.79 0.034 0.44 0.0016 0.44 0.002 
Oxoadipic acid 159.0300 12.2 0.28 0.003 0.31 0.029 0.24 0.0027 0.54 0.1 
dihydroxyquinoline 162.0548 9.1 1.4 0.039 1.7 0.00066 1.2 0.090 0.94 0.65 
Xanthurenic acid 206.0448 11.7 0.86 0.011 0.96 0.47 0.70 0.001 0.80 0.0011 
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L-Kynurenine 209.0922 13.4 0.71 0.00088 0.69 0.012 0.62 0.0019 0.41 0.0019 
3-Hydroxy-L-
kynurenine 
225.0868 15.1 0.90 0.15 0.83 0.027 0.85 0.0006
9 
0.63 0.0006
9 
N-Formylkynurenin 237.0871 13.9 1.1 0.58 0.45 0.30 0.23 0.0027 0.53 0.0027 
Miscellaneous 
L-Tyrosine 182.0812 15.7 0.73 0.024 0.87 0.043 0.61 0.0069 0.75 0.0069 
AHMDHP 196.0831 11.1 5.6 0.029 23.9 0.21 199 0.025 4.0 0.025 
5-Hydroxy-L-
tryptophan 
221.092 13.6 0.41 0.0043 0.18 0.00021 0.19 0.0023 0.32 0.0023 
Linolelyl carnitine 424.3421 10.1 0.66 0.003 0.95 0.5 0.63 0.0023 0.57 0.0013 
oleylcarnitine 426.3576 10.1 0.81 0.0088 1.1 0.21 0.75 0.0084 0.73 0.0020 
 
ND; metabolite not detected in sample group. AHMDHP; 2-Amino-4-hydroxy-6-hydroxymethyl-7,8-
dihydropteridine 
 
3.4.4 Conclusion  
Allopurinol is one of the best inhibitors of XOR and is rapidly converted to oxypurinol 
by oxidation process: both allopurinol and its oxidized metabolite oxypurinol inhibit 
XOR activity (Spector, 1988). Accordingly, as in humans, oral administration of 
allopurinol induced a blockade of the purine pathway in Drosophila. Interestingly, the 
data provide dynamic data on the relative mobility of different pools of purine 
metabolites in the fly; it would be interesting to test the resulting model (that there is a 
dynamic pool of urate and allantoin in the tubules, independent of the insoluble urate 
crystals). It is reasonable to posit a key role for tubules, because –as will be discussed 
later- the enzyme urate oxidase is expressed absolutely specifically in tubules, so this is 
where allantoin formation will occur. 
Inconveniently, oxypurinol has precisely the same molecular weight as xanthine, and so 
the rise in xanthine levels could be attributed to an accumulation of oxypurinol. 
However, the dietary concentration of allopurinol (at 110 µg/ml) is so low that in 
practice, the peak is likely to represent endogenous xanthine. 
Allopurinol use as an inhibitor of XO ramifies into several branches that result in 
several impacts on different biochemical pathways, for following the metabonomic field 
requires a full understanding of biochemistry as well as an open mind. 
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Indeed, the present study is the first to utilize the technique of HILIC-LC-ESI-MS for 
the analysis of allopurinol. 
3.5 General Discussion 
 
The rosy mutation is a triumph of the Drosophila paradigm. It is the second mutation 
ever discovered in Drosophila (almost a hundred years ago) (Dow, 2007), and yet the 
original mutant stocks still exist today. Although many workers in the Drosophila field 
are presently energetically pursuing even tenuous models for human disease, rosy 
recapitulates rather precisely its corresponding human genetic disease (Chintapalli et al., 
2007) . It is even possible to phenocopy the rosy mutations in flies  (Keller and 
Glassman, 1965), and the xanthinuria symptoms in humans (Gok et al., 2003), with the 
XOR inhibitor allopurinol. 
• In this chapter, the Orbitrap technology was brought to bear on Drosophila, and 
there were several key findings: 
• Orbitrap and flies are compatible: a simple homogenate allows the identification 
of hundreds of metabolites in a single experiment 
• The Orbitrap is sufficiently sensitive to allow metabolomes of single fly tissues 
to be measured 
• Single gene mutations have significant impact on the organismal metabolome 
• The Orbitrap not just reproduces findings from years of classical, painstaking 
biochemistry in  a single experiment, but its amazing sensitivity allows these 
classical findings to be greatly extended. 
• The Orbitrap also allows the pharmacological impact of drugs on the 
metabolome to be followed. 
As a result of this work, there are several intriguing lines of further investigation 
suggested. How does XDH knockdown impact on osmolyte biosynthesis? How about 
oxidative stress- is this a result of urate deficiency? And are there separate labile and 
stable pools of urate in specific tissues, like the tubules? Although time did not allow 
the study of these new theories, it is hoped that it will one day be possible to follow 
them up. 
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Chapter 4 Maroon-like (mal) 
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4.1 Introduction 
4.1.1 History 
Similarities among Drosophila mutants have long drawn the attention of Drosophilists. 
Similarities like body size and shape or eye colour, could result from either different 
alleles for the same locus or different genes in the same pathway. There has thus been a 
long tradition of crossing together mutants with similar phenotypes, to test for allelism 
(two mutants in the same gene) or for epistasis (the effects of one gene are modified by 
one or several other genes upstream in an enzyme series). Until the advent of DNA 
sequencing, such complementation analysis and epistatic analysis was a cornerstone of 
experimental genetics (Ashburner, 1990).  
In 1959, it was noted that several Drosophila melanogaster mutants shared a dull red 
eye colour. Those mutants are ry (Forrest et al., 1956), mal (Hadorn and Schwinck, 
1956)   and later cinnamon (cin) (Baker, 1973). 
Similarities between rosy and maroon-like are remarkable. Both of them have the same 
dull red eye colour; and both, also, are deficient in uric acid and have excesses of 
hypoxanthine and xanthine. Mutants in either are unable to convert 2-amino-4-
hydroxypterdine to isoxanthopterin, or to oxidise hypoxanthine to xanthine then to uric 
acid, reactions catalyzed by the xanthine oxidase. This is due to the absence of the 
enzyme. However, the genetic lesion is different, as the ry gene is located on the third 
chromosome, while mal is on the X chromosome (Glassman and Mitchell, 1959). The 
mal mutant, in addition to the malfunction of XDH, is also defective in aldehyde 
oxidase (Courtright, 1967) and pyridoxal oxidase (Forrest et al., 1961). Thus, this 
suggested a link between the previous two enzymes and XDH, namely that mal was 
essential for the activity of all three different enzymes. As mal is epistatic to those three 
enzymes, it is likely to play a common role in their synthesis or function.   
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It is known that conversion of 4-hydroxypteridine to 2,4-dihydroxypteridine needs an 
oxidative-type reaction. The same reaction type occurs in both wild type and rosy 
mutant flies, but not in the mal. This implies that mal is different from ry by the activity 
of the oxidases, which are suggested to be absent in the mal (Forrest et al., 1961). 
Furthermore, specific antibodies for xanthine dehydrogenase showed that the protein 
was found in higher levels in extracts from mal than ry, which implicates that the 
enzyme in ry is either absent or reduced, 
while in mal it is present but is inactive 
(Glassman and Mitchell, 1959). This was 
subsequently found to be because ROSY is 
one of a small group of enzymes which use 
molybdenum at their active site, and Mal is 
the enzyme which inserts the molybdopterin 
prosthetic group into the maturing XO 
enzyme (Ichida et al., 2001).  
Molybdenum cofactor biosynthesis is a 
conserved pathway among bacteria, fungi 
and humans (Schwarz and Mendel, 2006). 
This synthesis pathway consists of five 
important steps summarized in (Figure  4-1), 
starting with guanosine triphosphate (GTP). 
The GTP is converted to compound 
originally known as precursor Z, later called 
cyclic pyranopterin monophosphate cPMP. 
Then the latter is converted to 
molybdopterin (MPT) and finally to the 
mature molybdenum cofactor, MoCo 
(Figure  4-1).  
Figure  4-1 Molybdenum cofactor biosynthesis. After  
(Schwarz and Mendel, 2006). 
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4.1.2 Molybdenum- containing enzymes of Drosophila and their 
synthesis 
The main molybdenum-containing enzymes; XDH, AD and SO in Drosophila are all 
dependent on MoCo synthesis for their activity. Thus any defects in MoCo production 
leads to multiple Drosophila mutant phenotypes (Kamdar et al., 1997). This is 
summarized in (Figure  4-2). The ry mutant is mutated in the XDH gene, consequently 
no enzyme produced to oxidize hypoxanthine to xanthine and then to uric acid. This in 
human, is called xanthinuria type I. Second, mal mutants suffer from dual enzyme loss; 
in addition to XDH, an AO is also absent. However the XDH enzyme is still present, 
but in inactive form. This is due to failure of an enzyme called sulphurase to add a 
sulphur to the prosthetic site of the MoCo. This enzyme also affect the purine 
metabolism pathway in Drosophila as well as in human and are causing a disease called 
xanthinuria type II. Lastly, cin mutants suffer from the complete absence of the MoCo 
production, thus affecting not only XDH and AO, but also SO. This in human causes 
the MoCo deficiency disease which leads to neurological effects.  
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Figure  4-2 MoCo containing enzymes in Drosophila. This figure was drawn by me. 
GTP; Guanosine triphosphate, MPT; molybdopterin, MoCo; molybdenum cofactor , 
SO; sulphite oxidase, XDH; xanthine dehydrogenase, AO; aldehyde oxidase, cin; 
cinnamon, ry; rosy, mal; maroon-like. This figure was drawn by me. 
 
Because of their similarities in the chemical structures , both XDH as well as AO are 
classified in the same sub-group. Both, in order to be in the active form, are require 
post-translational sulphuration of the MoCo. On the other hand this post-translational 
sulphuration is not necessary for the other molybdoenzymes,, i.e. SO. This important 
reaction is carried out by an enzyme called sulphurase, which substitutes one of the oxo- 
groups of the MoCo with a sulpho double bond (Figure  4-3). 
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Failure in this  sulphuration with sulphurase enzymes leads to defects in both enzymes , 
XDH and AO that leads to the rare inborn error of metabolism, xanthinuria type II 
(Garattini et al., 2008).  
 
 
 
 
 
 
Figure  4-3. The effect of the 
sulfurase enzyme. 
substitution of an oxo group 
of MoCo with sulpho-  
double bond (red). 
 
 
Figure  4-4. Instead of 
sulphuration, a Cys is added. 
 
So deficiencies in any of the molybdopterin biosynthetic enzymes should produce a 
maroon-like phenotype, which is a super set of the rosy phenotype as all 
molybdoenzymes will be defective. 
So in flies, mal should produce a phenotype more severe than ry because more than one 
metabolic pathway is impacted.  
 
4.1.3 Links to human molybdoenzyme deficiency 
The molybdenum cofactor (MoCo) is an essential component of molybdoenzymes. So 
deficiency in MoCo is known, but rare in humans. It is autosomal recessive inborn error 
of metabolism, caused by defects in the biosynthesis of molybdenum-complexed pterin 
cofactor (Ichida et al., 2001).  
This defects lead to deficiency of the previously mentioned three molybdenum-
requiring enzymes: sulphite oxidase (SO), xanthine dehydrogenase (XDH) and aldehyde 
oxidase (AO). Affected individuals typically display severe neurological dysfunction in 
the newborn period or at early infancy along with renal impairment and high plasma 
concentration of xanthine.  
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Figure  4-5. This chart show the metabolic pathways affected by molybdenum deficiency 
in human. SO; sulphate oxidase, XO; xanthine oxidase, MoCo; molybdenum cofactor 
deficiency. Due to absence of the MoCo, activity of XO and SO will be decreased. 
Figure after (Ngu et al., 2009) 
 
Affected individuals typically display intractable seizures, metabolic acidosis, 
intracranial haemorrhage, feeding difficulties, dysmorphic facial features, profound 
developmental delay, alterations in muscle tone, microcephaly, lens dislocation and 
renal stones. Because of these varied features and the very rare occurrence, the disease 
can be easily misdiagnosed. The prognosis is poor: most of the infants die in the first 
days or weeks of their lives, and this could be the reason why it is rarely diagnosed: not 
because it is rare but because the it shares many of the clinical features with other 
diseases and its onset  is in the early infancy period and it is also fatal, so newborn 
babies die before proper diagnosis. 
As mal is a clear homologue of the human sulphurase, it is likely that it recapitulates to 
some extent the human disease. It may thus provide (as rosy does for xanthinuria type 
I), a model for xanthinuria type II. This chapter seeks to study the closeness of the 
model using metabolomics to profile the broader metabolic impact of the mutation.  
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4.2 Aims 
So, we selected mal for metabolomic analysis study because, we wanted to have better 
understanding of this mutant as human homolog xanthinuria type II animal model.  
In humans, xanthinuria type II produces additional defects and is more severe than type 
I. Would additional metabolic pathways also affected in Drosophila? 
All previous studies and research indicated that the molybdenum cofactor is deficient, 
thus all molybdoenzymes are present but are not functioning. Could this investigation 
lead to discovery of novel effects of the molybdenum co-factor deficiency?  
In addition in this chapter, I compare two different major wild type strains to compare 
inter-strain differences with mutant phenotypes.  
 
4.3 Results 
We conducted another comprehensive metabolic analysis profiling for mal using the 
methods described in the previous chapter. The investigation took place between the 
maroon-like mutant as a sample and as a control we used the wild type flies, Oregon R 
(OR). The impact of the mal mutation can be seen summarized in (Table  4-1).  
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Table  4-1. Major metabolomic differences between mal and OR. Reduced metabolites 
are in red coloure while blue colour indecates the incresed metabolite level. The test 
was repeated twice, separated by five months and with N=5 biological replicates. . 
Analyzed by Student’s t-test two tailed. 
Compound m/z Ratio 1 P value Ratio 2 P value 2 
I. Purine metabolism pathway 
GABA 104.0707 0.53 0.00000030 0.731 0.00963 
Adenine 136.0759 3.7 0.00045 5.138 0.0019 
Hypoxanthine 137.0459 6.4 0.000014 21.816 0.079634 
Guanine 152.057 0.43 0.0019 0.656 0.086113 
Xanthine 153.041 75.0 0.000032 18.051 0.016686 
Allantoin 159.0516 0.027 0.00026 0.134 0.071928 
Uric acid 169.0358 0.0010 0.00028 0.021 0.001168 
Guanidine 284.0993 0.57 0.025 0.262 0.000145 
II. Eye pigmentation pathway 
Drosopterin 369.1531 0.22 0.000280 0.466 0.002149 
Xanthopterin 180.0518 0.0030 0.0030 0.021 0.018049 
Xanthommatin (met of 
Drosopterin) 424.0648 12 0.0057 2.165 0.000374 
Pterin (Benzene ring) 
the cofactor 164.0568 6.2 0.011 6.911 0.030468 
III Melanin pigments 
Tyrosine (is a precursor 
of melanin pigments) 182.0814 3.2 0.00056 11.586 0.006997 
Dihydrobiopterin 236.0783 2.0 0.058 3.330 0.001336 
IV Arginine and proline metabolism 
Proline betaine 144.1022 0.12 0.000034 0.572 0.0346 
Acetyl arginine 217.1297 2.8 0.0035 3.658 0.020833 
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4.3.1 Purine metabolism pathway  
As with rosy (and with allopurinol treatment), changes are observed in the purine 
metabolism pathway, consistent with the inhibition of XDH (Figure  4-6) not (Fig. 4-7). 
 
 
Figure  4-6. Major metabolite changes in purine metabolism pathway using the mal 
mutant. 
 
Accordingly, mal behaves as expected, and the Orbitrap technique is implicitly 
validated for identifying common metabolic fingerprints between mutants of related 
genes. But are there further, or more severe, changes, consistent with the pathology of 
human xanthinuria type II? 
 
4.3.2 Eye pigmentation 
 The normal Drosophila eye pigments are composed of two important pathways, 
ommochrome and pteridines. The ommochromes, which are synthesized from the 
tryptophan pathway, give rise to the brown pigments. By contrast, the pteridines are 
synthesized from guanine and produce the red pigments. Thus, any mutation to the 
ommochrome pathway will affect the Drosophila eye colour, and by reducing the 
amount of brown pigments, make the eye appear redder. Conversely, mutations 
affecting the pteridine pathway will make the brown colour in the eye predominant so 
the eye will appear darker.   
The ommochrome biosynthesis pathway is well understood, and is less complicated 
compared to the pteridine pathway. Three pteridine pigment types are present in the 
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Drosophila eye, Drosopterin, isoxanthopterin and sepiapterin  (Evans and Howells, 
1978). Drosopterin in particular is produced from two precursors; pyrimidodiazepine 
PDA and dihydropterin DHP (Wang et al., 2008).  
 
 
Figure  4-7. Visual pigment biosynthesis. (is the enzyme converting 7, 8 dihydropterin to 
Drosopterin is the same that converting  pterin to xanthopterin? And this could be why 
both Drosopterin and xanthopterin are reduced? Even though their precursors are high 
in concentration?) 
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4.3.3 Major metabolites differences between OR and CS wild types 
As a further control, two widely-used wild type lines, namely Oregon-R and Canton-S, 
were compared to each other. The full list of metabolites resolved in Oregon R is 
presented in (Table  4-2). 
 
Table  4-2 Metabolites in Drosophila OR strain observed by HILIC chromatography in 
combination with LC-MS 
Metabolite Observed 
Mass 
Rt 
min 
Metabolite Observed 
Mass 
Rt 
min 
Linoleamide 280.264 5 Oleoamide 282.28 5.4 
Hydroxy phenylacetic 
acid 
151.04 6.3 *Pyruvic acid 87.0088 6.9 
*Hydroxyketoglutaric 
acid 
161.009 6.4 Niacin 124.039 7.4 
*Lactic acid 89.0244 6.8 Succinic acid* 117.019 7.6 
Pantothenic acid 220.118 6.8 Fumaric acid* 115.004 7.7 
N-acetylglutamate 190.071 6.9 Ketobutyric acid* 101.025 8.1 
Aminohexadecanediol 274.274 7.7 Pyroglutamic acid 130.05 8.3 
* Ascorbic acid 175.025 7.8 Dihydrobiopterin 1 236.078 8.4 
Dopa quinone 196.061 8 Kynurenic acid 190.05 8.5 
Diacetyl ornithine 217.118 8 Formyl val-gly 203.103 8.7 
Hydroxybutyric acid* 103.04 8.1 Deoxyadenosine 252.109 8.9 
4-amino-4-
deoxychorismate 
226.071 8.8 Myristamide 230.248 9 
*Ribose 133.051 9.1 N-acetylaspartate 176.056 9.1 
Pyridoxate 184.06 9.3 Riboflavin 377.146 9.4 
Xanthurenate 206.045 9.5 Linolenylcarnitine 424.343 9.8 
Linolylcarnitine 426.359 9.8 Oleoylcarnitine 428.374 9.8 
Pyrimidodiazopterin 222.099 9.9 Dihydrobiopterin 1 240.109 9.9 
Dihydrobiopterin 2 236.078 9.9 Biopterin 1 238.094 10.2 
Histidine lipid 338.244 10.6 Xanthine 153.041 10.3 
Hypoxanthine 137.046 10.7 Hydromethyldeoxyhydrop
terin 
196.047 10.5 
Succinyladenosine 384.115 10.7 Uridine 245.077 10.5 
Xanthosine 1 285.083 10.8 Uracil 113.035 10.6 
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Metabolite Observed 
Mass 
Rt 
min 
Metabolite Observed 
Mass 
Rt 
min 
Butoctamide 
semisuccinate 
316.212 10.9 Histidine lipid 362.244 10.6 
Acetylcholine 1 146.118 11.6 Histidine lipid 364.26 10.6 
Inosine 269.088 11.6 C12 sphinganine 218.212 10.7 
Pterin 164.057 11.9 Glycolic acid* 105.019 10.8 
Leucineproline isomer 1 229.155 11.9 Methylguanosine 298.115 10.8 
Ethyl n-acetylarginate 245.161 11.9 Valineleucine 231.171 11.3 
*Malic acid 133.014 12 Leu-leu 245.186 11.3 
Xanthopterin 180.052 12.1 Xanthosine 2 285.083 11.8 
Dihydroxanthopterin 182.068 12.1 Methyl tyrosine 196.097 12 
§*Hexose isomer1 179.056 12.2 Guanine 1 152.057 12.2 
Propylcarnitine 218.139 12.2 Cyclothionine 206.048 12.2 
*Deoxyhexose 163.061 12.4 Narigenin 273.075 12.2 
Phenylalanine 166.086 12.4 *Hexitol 181.072 12.4 
Butanedione 87.0441 12.5 Indospicine 174.124 12.6 
Kynurenine 209.092 12.7 Glycyl-dopa 255.098 12.6 
Biopterin 2 238.094 12.7 Adenosine 268.104 12.6 
Xanthommatin 424.079 12.7 Hydroxyindole acetic acid 192.066 12.7 
Tetrahydrofolate 446.179 12.7 Hydroxytryptophan 221.092 12.7 
Leucine 132.102 12.8 Hydroxyketoglutaric 163.06 12.9 
Guanine 2 152.057 12.8 Leucineproline isomer 2 229.155 12.9 
*Ketoglutaric acid 145.014 12.9 Isoleucine 132.102 13 
Leu-ala 203.139 12.9 Tryptophan 205.098 13.1 
Uric acid 169.036 13 §*Hexose isomer 2 179.056 13.2 
Dihydromethylguanosine 300.13 13 N-succinyl-2,6-
diaminoheptanedioate 
291.119 13.6 
Acetyl carnitine 204.124 13.1 Acetyl choline 1 146.118 13.7 
Pyridoxal 168.066 13.3 Tetrahydrothiophene 
carboxylic acid 
133.032 13.8 
Dihydrobiopterin 2 240.109 13.3 Aminoadipic acid 162.076 13.8 
Guanosine 1 284.099 13.3 *Gluconolactone 177.04 13.9 
Methylproline 1 130.086 13.4 Allantoin 159.052 14 
Acetyl serine 148.097 13.4 N2-(d-1-carboxyethyl)-l-
lysine 
219.134 14 
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Metabolite Observed 
Mass 
Rt 
min 
Metabolite Observed 
Mass 
Rt 
min 
Acetyllysine 189.124 13.5 Guanosine 2 284.099 14.1 
Methionine 150.059 13.8 * Erythrose 119.035 14.2 
N2-acetyl-l-aminoadipate  
semialdehyde 
188.092 13.8 Adenine 136.062 14.2 
Formylkynurenic acid 237.087 13.8 *Pentose 149.046 14.2 
Spermidic acid isomer 1 176.092 13.9 Hydroxy kynurenine 225.087 14.2 
Pro-val/dethiobiotin 215.139 14 Valine 118.086 14.4 
§*Hexose isomer 3 179.056 14.2 Thioproline 134.027 14.4 
Leucineproline isomer 3 229.155 14.2 Proline betaine 144.102 14.4 
Camp  1 330.06 14.4 Tyrosine 182.081 14.5 
Ectoine 143.082 14.5 Spermidic acid isomer 2 176.092 14.8 
Guanidine butanoate 146.093 14.6 Ala-pro 187.108 14.8 
Propionylarginine 231.146 14.6 Methylproline 2 130.087 14.9 
N-acetyl-l-glutamate 5-
semialdehyde 
174.076 14.7 Camp 330.06 15 
Oxidized biopterin 254.089 15.1 Methyladenine 150.078 15.1 
Ala-glu 219.098 15.2 Methionine s-oxide 166.053 15.1 
N-acetylhistamine 154.098 15.3 Thymine 127.05 15.2 
Octopine 247.14 15.3 Gsh 308.092 15.3 
Proline 116.071 15.4 N-acetylhistamine isomer 154.098 15.8 
Uridine monophosphate 325.043 15.4 Cgmp 346.055 15.8 
Glycine betaine 118.086 15.5 Imp 349.054 15.8 
Carnitine 162.113 15.5 N6-(1,2-dicarboxyethyl)-
amp 
464.082 15.9 
Methylphosphate 113 15.6 Carnitine isomer 162.113 16 
Dihydrothymine 129.066 16.1 Acetylarginine 217.13 16 
Hydroxyproline 1 132.066 16.1 Ornithine acetate 175.108 16.2 
Taurine 126.022 16.3 Methyl adenosine 1 282.12 16.2 
Alanine 90.0549 16.4 Glutamic acid 148.061 16.3 
Meso-2,6-
diaminoheptanedioate 
191.102 16.5 4-
hydroxyphenylacetylglyci
ne 
210.076 16.3 
Acetylhydroxylysine 205.119 16.5 GABA 104.071 16.4 
Threonine 120.066 16.6 Glu-gln 276.119 16.7 
 121 
Metabolite Observed 
Mass 
Rt 
min 
Metabolite Observed 
Mass 
Rt 
min 
Amp 348.071 16.6 Hydroxyproline 2 132.066 16.8 
* Gluconic acid 195.051 16.7 Glucosamine phosphate 260.053 16.8 
Aspartic acid 134.045 16.8 Phosphoethanolamine 216.064 16.9 
Dopa 198.076 16.8 Glutamine 147.077 17 
Phosphoric acid 98.9843 16.9 Beta-alanine 90.055 17.1 
Aminopentanamide 117.102 17.1 Methylguanidino inositol 236.125 17.1 
Asparagine 133.061 17.4 Diaminocyclohexane 
tetraol 
179.103 17.2 
Nicotinate d 
ribonucleotide 
335.064 17.4 Guanidino inositol 222.109 17.3 
Glycine 76.0393 17.5 *Pentose-hexose 311.098 17.3 
Choline 104.107 17.5 Cytosine 112.051 17.6 
Serine 106.05 17.5 Hydroxyguanine 168.049 17.7 
Cytidine 244.093 17.6 Tyrosine phosphate 262.048 17.9 
Methyl adenosine 2 282.12 17.6 Phosphoethanolamine 142.026 18.2 
Citrulline 176.092 17.7 Cytidine monophosphate 324.059 18.4 
*Methoxyhydroxyphenyle
thyleneglycol 
185.08 17.7 Glutathione disulphide 615.13 18.8 
Arginylglycine 232.141 17.7 Methylhydroxyproline 146.081 18.9 
Drosopterin 369.153 17.7 *Citric acid 191.02 19.6 
Nad 664.117 17.8 Cysteine 241.031 20 
Glucose phosphate 261.037 17.9 Phosphocholine 184.073 20.1 
Gmp 364.065 18.1 *Tetrahexose 665.212 20.4 
Glycerophosphocholine 258.11 18.3 Acetylhydroxylysine 205.119 20.8 
* Trihexose 503.162 19.6 Arginine related 229.13 21 
Cystathione 223.075 20.2 Dimethylarginine 203.15 21.3 
Methyldihydroinosine 285.12 20.6 Histidine related 
compound 
168.077 22 
*Pentahexose 863.242 20.6 Methylhistidine 170.092 22 
Phosphoarginine 255.086 20.8 Aminobutyraldehyde 88.0756 22.7 
Argininosuccinate 291.13 21 Ornithine 133.097 23 
Histidine 156.077 22 Galactosylhydroxylysine 325.161 23.3 
Arginine 175.119 22.7 S-adenosylmethionine 399.145 24.3 
Lysine 147.113 22.9 N-acetylspermidine 188.176 25.2 
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Metabolite Observed 
Mass 
Rt 
min 
Metabolite Observed 
Mass 
Rt 
min 
Fructosyl lysine 309.165 23 Putrescine 89.1072 26.2 
Thiamine 265.112 24.5 Phenol phosphate 171.992 28 
Histamine 112.087 25.9    
Glyceraldehyde 
phosphate 
171.006 28      
 
* Observed in negative ion mode 
 
These data, reflecting increased resolution as our skill in analysis increased, shows that 
the Orbitrap is clearly a very powerful machine for global metabolomic analysis. 
Investigations showed that both strains are fairly similar, however a few metabolites 
showed differences (Table  4-3).  
 
Table  4-3. Significant metabolite differences between OR and CS wild type flies.   
The test was repeated twice, separated by five months and with N=5 biological 
replicates. 
Metabolite m/z Ratio 1 P value 1 Ratio 2 P value 2 
aminooxopentanoate 132.0656 3.5 0.0000048 9.3 0.067221 
ornithine 133.0972 1.6 0.0002134 3.3 0.037372 
Indospicine isomer 174.1239 12 0.0000033 10 0.000749 
N-acetylornithine 175.1079 23 0.0000706 87 0.000807 
Arginine 175.1191 0.77 0.0067336 0.59 0.000039 
Spermidic acid ? 176.0919 2.4 0.0000778 0.4 0.014783 
Spermidic acid? 176.0919 185 0.0000224 ND  
citrulline 176.1031 3.8 0.0005660 14.8 0.005540 
Hydroxyindole acetic acid 192.0657 0.62 0.0082408 0.22 0.000725 
Kynurenine 209.0923 0.62 0.0088140 0.17 0.000245 
Dihydrobiopterin 240.1094 0.59 0.0180132 0.48 0.001517 
AMP 348.0707 0.55 0.0034903 0.83 0.032279 
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The results are spread fairly broadly across the metabolic map, and there does not 
appear to be a particular concentration of metabolic changes within a particular part of 
the map. It is thus possible that some of these changes are false positives; at P<0.05, one 
would expect one false positive per 20 metabolites, and with more than 250 metabolites 
determined in each run, there is scope for most of these to be false positives. This is 
why in our earlier analysis, it was important to look for more than one change in a 
particular metabolic pathway. 
In principle, further experimentation and more replicates could resolve the issue, and 
increase confidence in the changes observed. One change, however, that did seem 
consistent, and that survived repeated sampling, was in the arginine metabolism 
pathway (Figure  4-8). 
 
Figure  4-8 Metabolic signatures of OR and CS showing variations in the extracted ion 
chromatograms representing compounds in the arginine/ornithine pathway. A, 13C 
isotope peak of ornithine acetate; SA, spermidic acid. After (Kamleh et al., 2009). 
 
Arginine levels are slightly lower in CS. Assuming that the urea cycle is not fully 
functional in Drosophila, in that conversion of arginine to ornithine via the loss of urea 
does not occur, citrulline and ornithine function as the precursors of arginine. Ornithine, 
ornithine acetate and citrulline are all elevated in CS. In addition to functioning as a 
precursor of arginine, ornithine enters the polyamine pathway, and two compounds, 
which are isomers of the spermidine metabolite spermidic acid (Kawase et al., 1994) are 
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present in high abundance in CS. Only one of these compounds could correspond to 
spermidic acid; the other would have to be a compound such as aminoheptadioic acid. 
Neither of these compounds appears in the Metlin or KEGG databases, although 
spermidic acid has been reported as a metabolite of spermine (Kawase et al., 1994). 
Although further experimentation would be required to validate this theory, the data 
show that the Orbitrap has the potential to resolve and identify entirely new metabolites. 
 
4.4  Discussion and conclusion 
4.4.1 How similar are different wild-type strains of Drosophila? 
All previously carried out experiments were done along with control samples. The fly 
wild type lines are the OR and CS. These fly lines are considered as the wild type flies 
and are used extensively, world wide. Despite all the years, no studies have been 
conducted to investigate the deference or the similarities between them. 
It has been observed from the previous ry experiment that the Orbitrap is a powerful 
analyser in which can be applied to generate new hypothesis in investigating new 
mutants or even wild types. As it has not been reported before, a comparison between 
the two wild type strains are not exactly the same. This dose not mean they are both not 
wild types. The differences among the OR and CS are much fewer than comparing any 
of them to ry  or any other mutant. Furthermore, the significant difference in metabolites 
are not consistently in the same pathway which suggested the increase in false positive 
results. In any dataset with hundreds of data points, their will be some false positives. 
However, changes that occur in nearby metabolites are more likely to represent real 
changes than false positives. 
 
4.4.2 How similar are the metabolomic footprints of lesions in ry 
and mal? 
Similarities between ry and mal are not only in the phenotypes, but also in some 
metabolites. The main affected pathway is in the purine metabolism pathway, where the 
impact of XDH is clearly revealed.  This is reflected in the excessive levels of 
hypoxanthine and xanthine and their precursors, like adenine and inosine. By contrast, 
downstream metabolites such as urate and allantoin are both sharply reduced or 
sometimes even not detected.  While the ry mutant mimics the xanthinuria type I inborn 
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error of metabolism, mal mimics the xanthinuria type II. Although ry and mal are 
phenotypically similar, they are genetically very different; the lesion in ry is in 
chromosome 3 whereas in mal it is in the X chromosome. In rosy only one enzyme is 
defective namely, XDH. While in mal the lesion is due to deficiency in both XDH and 
AO. This is attributed to a defect in sulphurase enzyme which adds a sulphur atom to 
the cofactor binding site.   
What was interestingly different from the ry mutant is on the tyrosine levels.  
The cause of defect in the purine pathway in mal mutant is that the lesion is not because 
the absence of the XDH enzyme, it is rather present, but the molybdopterin co-factor, 
which is require for the XDH functioning is defective. This co-factor is required not by 
the XDH only, but by a wide range of enzymes like aldehyde oxidase and sulphite 
oxidase.  And this may explain the secondary effects on the tyrosine metabolism.  
Also, the aldehyde oxidase enzyme oxidises pyridoxal to pyridoxate. Accordingly, 
pyridoxate was seen in both OR and ry, but not in mal  (Figure  4-9).  Thus this is clear 
indication that this must be due to the molybdopterin co-factor defect.  
 
Figure  4-9 This diagram shows the electrogram of the traces of pyridoxate in OR, ry and 
mal. After  (Kamleh et al., 2009). 
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4.4.3 Maroon-like as a model for xanthinuria type II 
This work also allows the comparison of the models offered by Drosophila mutants ry 
and mal, for the human diseases xanthinuria type I and type II, respectively. Both types 
are characterised by lower plasma uric acid concentrations, and higher plasma xanthine 
concentrations; whereas urinary excretion of uric acid is low or undetectable, and that of 
xanthine is elevated. As discsussed above, both fly mutants recapitulate these symptoms 
rather closely.  
 
 
Figure  4-10 This picture shows darker eye colour in mal mutant compared with WT. 
This picture was taken by me. 
 
 
Although both types of hereditary xanthinuria in human are clinically similar, but there 
are some differences. Whereas patients with type I can metabolise allopurinol to 
oxypurinol, those with type II cannot. Unfortunately, we did not test this finding in 
maroon-like flies. 
 
4.4.4 How consistent are metabolomes over time? 
The wild-type flies OR and CS were compared at two time points, 5 months apart. On 
both occasions, there were a number of differences in the metabolites listed in (Table 
 4-3); however, the differences were not the same on each occasion. Thus, variation in 
time must be a criterion for establishing stable differences. In addition, there is variation 
mal 
WT 
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which occurs on extraction, as it is virtually impossible to stop biologically labile 
metabolites altering, because metabolism cannot be stopped instantaneously. There are 
of course some instrumental variations, but analysis of batches, e.g. 5 × OR against 5 × 
CS, in randomized order eliminates these. Biological variations are a difficult area and 
represent a major challenge in the extraction of useful metabonomic data. At best, all 
that is possible at the moment is to state that significant differences must be observed on 
at least two occasions to be considered significant. 
 
4.4.5 Conclusions 
• The Orbitrap is capable of resolving over 250 metabolites in even a small sample, 
and of identifying potentially novel metabolites. 
• The two wild-type strains, Oregon R and Canton S, show highly similar 
metabolomes, but with consistent differences in arginine metabolism. 
• Metabolomes are very labile, and repeated biological replicates need to be taken 
over an extended period to minimise variation. 
• The rosy and the maroon-like are both excellent models of xanthinuria types I and 
II, respectively. Maroon-like shows changes in a wider range of metabolites, 
reflecting the impact on more than one enzyme.  
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Chapter 5 Urate oxidase (uro) 
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5.1 Introduction 
As any living organism nitrogenous waste products can be highly toxic and need to be 
eliminated immediately either in the form of UA or other forms of metabolic forms 
(Vogels and Van der Drift, 1976). To do so these wastes are must be metabolized to 
lesser toxic products, like uric acid in Drosophila. Uric acid is also water insoluble, so 
its excretion wastes less water volume.  Such uricotelic excretory systems are found in 
terrestrial insects and birds. Excretion of urea or ammonia is found in large animals and 
water living animals.  
In some cases the wastes are metabolized to water soluble metabolites, thus they must 
be diluted to reduce its toxicity until they excreted. Consequently, excessive water 
volume is highly demanded in this process. 
Uro encodes a structural gene for urate oxidase enzyme (URO); this enzyme is 
important in oxidation of urate to 5-hydroxyisourate (5HIU) or allantoin in Drosophila 
melanogaster (Kral et al., 1986). It is exclusively expressed in the Drosophila 
Malpighian tubules, and only in the third-instar larvae and adults (Friedman, 1973) and 
(Chintapalli et al., 2007). Its activity is rapidly reduced in the late period of the third-
instar larvae and disappears in the pupal stage; then it regains its activity again at the 
early adult stage as shown in (Figure  5-2) (Friedman, 1973). This disappearance is 
controlled by an intercellular clock-like mechanism which at specific life period stops 
the expression of uro (Friedman and Johnson, 1977). Although others have different 
opinion (Jackson, 1978), this remarkable disappearance of the enzyme activity does not 
apply to all Drosophila species. For example the uro gene in Drosophila virilis is 
expressed only in the MT and the enzyme activity is shown in the third-instar larvae 
only. Whereas in Drosophila pseudoobscura the mRNA abundant is also in the MT but 
the enzyme activity is shown only during the adult stage (Figure  5-1) (Wallrath and 
Friedman, 1991).  
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Figure  5-1 Comparison between three different species of Drosophila showing the URO 
enzyme activity during different life span. Dark circles represents males, whereas 
opened circles represent females (Wallrath and Friedman, 1991). 
 
 It is puzzling that this gene should be controlled so precisely, and so differently, in 
three closely related species. The reason is not known; but it could be because the need 
for the protective antioxidant properties of urate differs between the species. 
The end product of purine metabolism varies between human and Drosophila. In 
Drosophila, like other insects, the final purine product is a mixture of uric acid and 
allantoin, depending on expression levels of urate oxidase. On the other hand, urate 
oxidase is absent in human; and as a result, urate is not metabolized into allantoin (as in 
Drosophila) as the end product of purine metabolism. The absence of this enzyme has 
some beneficial effect on mammals (Chapman and Chapman, 1998), as UA, plays an 
important role as an antioxidant of ROS in plasma and excreted through urine as urate. 
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5.2 Urate and oxidative stress 
Several diseases have been suggested to be caused by toxicity due to free oxygen 
radicals, like cancer, heart diseases and aging.  
It has been shown that an increased lipid peroxidation is found in heavy exercise and is 
accompanied by increased levels of urate. Free oxygen radicals rise as a result of the 
aerobic metabolism of metabolic reactions. Consequently, exposure to these active 
oxygen species will react with electrons from lipids in cell membrane, varieties of 
important molecules like DNA, RNA, proteins and leading to cell damage. Ultimately, 
such products will lead to products that are able to be cytotoxic, mutagenic, and 
carcinogenic and may be lethal to the organism.  
Antioxidants are thus important defences against oxidative stress, and have been 
asserted to protect against cancer and ageing. Urate is a potent free radical scavenger 
(Ames et al., 1981), which binds to these radicals and keeps them in a more stable form 
and causing less cellular damage (Hilliker et al., 1992).  
 
5.3 Urate and gout 
Although urate plays a vital role in detoxification and free radicals scavenging in 
disease and normal status (Ames et al., 1981), high levels of uric acid, by contrast can 
be damaging and lead to inflammatory disease. Gout is an inflammatory human disease 
that arises due to excessive uric acid levels in blood, and also due to the lack of urate 
oxidase enzyme to further metabolise uric acid to 5HIU (Maloley and R.Westfall, 
2000). 
The levels of circulating urate are thus a compromise between two opposing needs. As 
humans lack a urate oxidase enzyme, they are predisposed to higher levels of urate. By 
contrast, in Drosophila melanogaster, uric acid, is not always not end product of purine 
metabolism, and can be further metabolized to 5-hydroxyisourate (5HIU), by urate 
oxidase, and then to allantoin by 5-hydroxyisourate hydrolase (Figure  5-3). 
Nonetheless, a potential role for urate as a protection against oxidative stress in 
Drosophila can be inferred from the discovery that rosy mutants are hypersensitive to 
oxidative stress, induced by the weed killer paraquat. Paraquat is a redox cycling 
compound, it is reduced by NADPH to form a relatively stable radical species 
(Pq+)which then racts with O2 to generat ROS (Hilliker et al., 1992), it is also inhibites 
microchnodrial electron transport (Franco et al., 2010). 
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5.4 Control of urate oxidase expression 
Unlike microorganisms, uric acid oxidase enzyme in Drosophila melanogaster is not 
induced by uric acid, since ry and mal mutants have higher URO enzyme concentration 
higher than the Oregon-R wild type mutant. This interest, in both ry and mal mutants, 
came from the fact that both of them lack detectable levels of the xanthine 
dehydrogenase enzyme, which is responsible for hypoxanthine to xanthine then to uric 
acid conversion (Friedman and Johnson, 1977). 
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Figure  5-2 The uro activity pattern in wild-type mal and ry in Drosophila. Modified 
after (Friedman, 1973). 
 
Urate oxidase activity is not detected in the first, second instar larvae and pupal stages. 
However, it is present in third instar larvae and adults. So it seems there is a temporal 
control of the enzyme activity during different fly stages. However, molecular 
mechanism of reactivation of the uro gene in the adults Drosophila is poorly 
understood. However, (Friedman and Johnson, 1977) have proposed two phenomena for 
urate oxidase activity. First an inducing factor, closely located to the gene that stimulate 
the production of enzyme, suggested to be found in the haemolymph. The second is that 
an autonomous intracellular clock-like mechanism, found in the adult Malpighian 
 
Ore-R 
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ry 
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tubules, may be responsible for controlling the time of changes to take place (Friedman 
and Johnson, 1977).  
The inducing factor was found in ry and mal 5-10 times higher than uro -mRNA and 
uro proteins than in wild type adult. (Wallrath et al., 1990). However, studies by 
(Ramazzina et al., 2006) and (Tipton, 2006) suggested that urate oxidase is converting 
UA to 5HIU but not allantoin, as it was thought.  
 
 
Figure  5-3 Part of purine metabolism pathway, emphasising the downstream 
metabolism of urate. 
 
5.4.1 Principle of Polarizing microscope assay for uric acid crystals 
As well as using metabolomic approaches, it is possible to visualize urate directly, as it 
is birefringent (Ainsworth et al., 2000). The polarized light microscope is designed to 
observe and capture specimens that are visible primarily due to their optically 
anisotropic character. In order to accomplish this task, the microscope must be equipped 
with both a polarizer, positioned in the light path somewhere before the specimen, and 
an analyser (a second polarizer; Figure  5-4), placed in the optical pathway between the 
objective rear aperture and the observation tubes or camera port.  
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Figure  5-4. The light polarizing microscope. 
http://www.microscopyu.com/articles/polarized/polarizedintro.html  
 
 
This polarizing effect depends on the properties of the specimen, including the thickness 
difference between the refractive index and the birefringence of the two mutually 
perpendicular beams, which has a maximum value dependent on the specimen and on 
the direction of light propagation through the specimen. 
As the analyzer plate is rotated, the intensity of the polarization light varies cyclically, 
from zero (extinction; Figure  5-5 (d)) up to a maximum brightness at 45 degrees (Figure 
 5-4 (a), and then back down to zero after a further 90-degree rotation.  
That is why rotating the plate is crucial in polarized light microscope for determining of 
the specimen.  
 
 
 135 
 
Figure  5-5. Principle of polarizing imaging of birefringent crystals. From: 
http://www.microscopyu.com/articles/polarized/polarizedintro.html  
One of the most common medical applications for polarized light microscopy is the 
identification of gout crystals (monosodium urate). Thus, shiny urate crystals are 
indicated as high levels of crystals under polarizing microscope (e.g. Figure  5-6). 
 
5.5 Aims 
We aimed to perturb the uro in the Drosophila melanogaster specifically in the 
Malpighian tubules in order to investigate the effects of this gene. As the uro is involved 
in complex biological activities in the human as well as in the Drosophila, we wanted to 
see the effects on longevity, response to oxidative stress and changes in the 
metabolome. Another interesting point is to investigate whether the nitrogen was being 
shunted to other pathway, for example proline and glutamine pathways.   
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5.6 Results 
5.6.1 RNAi 
The RNAi is a method widely used as a powerful tool for reverse genetics in gene 
silencing. The method first was used in C. elegans, was quickly adopted for gene 
silencing in Drosophila melanogaster (Kennerdell and Carthew, 2000).  
In order to intervene a specific gene in the Drosophila, an inverted repeat DNA 
sequence must be constructed to target a specific gene, in our case, uro, and to be placed 
under the control of the UAS promoter. This was carried out with help of the pRISE II 
transgenic vector (Kondo et al., 2006). Then this construct was sent to be injected into 
white background fly embryos, w1118 and was balanced over the homozygous lethal 
CyO on the second chromosome.  
 
5.6.2 Testing the effectiveness of RNAi against urate oxidase 
UAS-uro (RNAi) flies were crossed to uro -GAL4 virgin flies. Then 5 to 7 day old adult 
progeny were dissected in a Petri dish containing Schneider’s medium. Once the MT 
were separated, they were carefully transferred with a glass rod to be screened for both, 
uric acid crystals precipitation using the polarizing microscope (Figure  5-6) and gene 
expression knockdown with both quantitative expression analysis (Figure  5-7) and 
Orbitrap metabolomics (Figure  5-8).  
 
5.6.3 Polarizing microscope assay  
5-7 days old adult progeny of a cross between UAS-uro RNAi line and uro -GAL4 
driver, were selected for the analysis. Dissected MT were immediately transferred using 
a glass rod onto a microscope slide which also containing a few drops of Schneider’s 
medium. A coverslip was applied, using four dots of high vacuum grease to maintain a 
gap. This slide was then immediately inspected under the polarizing filter microscope.  
As a result of knocking down uro, UA crystals would be expected to accumulate in the 
Drosophila MTs. These crystals should be visible as birefringent under the polarizing 
filter.  
In (Figure  5-6), two pictures are shown for the same tubule. The one in the left, used as 
control as it was taken under the classical light microscope. It was shown the 
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background is lighter than the object and it is not signs for crystals precipitations. 
Whereas in the right side picture, the background was dark as well as parts of the 
tubules as they do not contain crystals. However, the main segments were full of the 
uric acid crystals; thus they were seen as shining under the polarizing filter.  
This provides us with a clear indication that polarizing microscopy is capable of 
visualizing urate crystals effectively.  
 
A  B  
  
 
Figure  5-6. Demonstration of uric acid accumulation in tubules. The same picture is 
shown what it looks like the uric acid crystals under the polarizing microscopy. 
Transmitted (A) and polarizing (B) views of uro knockdown tubules. White arrows 
denotes uric acid crystals precipitations, while red arrows pointing to areas where no 
crystals were seen.  Wild type  vs mutant comparison pictures are shown in Figure  5-9. 
 
5.6.4 Validation by qPCR 
As the polarization test suggested that the uro knockdown was working, gene 
expression validation was taken place in order to measure the efficiency of the 
knockdown. For this MT from parents and the progeny were dissected in a Petri dish 
containing Schneider’s medium. Then the MT were immediately transferred by a glass 
rod into RLT buffer in preparation for RNA extraction. In the case when the extraction 
was not going to be immediate, RLT buffer containing the MT were preserved at the -80 
ºC. After mRNA extraction, quality and quantity of mRNA were measured. Then after, 
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cDNA were generated, using the mRNA as a template, and again were checked to 
quality and quantity.  
As a statistical control, four technical replicates were applied for each of three 
biological replicates. Each tube contained 12.5 µl SYBR green, 2 µl primer set, 
approximately 500 ng cDNA template and finally made up to 25 µl of nuclease-free 
water.  
As can be seen (Figure  5-7) there is a substantial decrease in the amount of expressed 
uro gene in knockdowns when compared with the other two parents. Approximately 
80% gene expression reduction was seen in the dissected MT as compared to the same 
number of parental tubules dissected. It must thus be concluded that this is a relatively 
successful knockdown. 
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Figure  5-7 This figure shows uro RNAi knockdown validated by qPCR. It shows uro 
gene knockdown expression dissected from the MT compared to uro GAL4 and uro 
UAS-RNAi parental lines. Approximately eighty per cent uro lower expression was 
seen as determined by Student’s t-test. Data are expressed as a percentage, compared 
with the average parental expression levels. 
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5.6.5 Validation by Orbitrap 
Further studies were performed to determine key metabolites as a result of the uro 
knockdown on MT using the Orbitrap. The UAS-uro RNAi lines with their parents 
were used. Around 20 adult flies aged between 5 to 7 days old were used for the MT to 
be dissected. Fly dissection took place in a Petri dish containing Schneider’s medium. 
After the desired number of tubules was dissected, they were immediately transferred 
into ice-cold 50% methanol/ 50% water solvent. Samples were kept at -20 ºC for short-
term less than one week, or at -80 ºC for longer periods, until the day of analyses. Each 
fly line was repeated in three biological replicates.  
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Figure  5-8. Impact of uro knockdown on purine metabolite levels in tubule using the 
Orbitrap.  Data are shown as mean +/- SEM of three biological replicates.  A) Plotted by 
genotype. B) The same data plotted by metabolite. UAS may show some leaky 
expression even when not driven. This would explain why the UAS-uro resembles uro-
GAL4 x UAS uro.   
A) 
B) 
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It is nice to note that these results also show the ability to produce good metabolic data 
from isolated single tissues, rather than whole flies. 
 
 
5.6.6 Crystals under the polarizing microscope 
As another validation method in the uro knockdown we used the polarizing filter 
microscope. Usually uric acid crystals shine when seen under crossed polarizing filters, 
allowing their rapid visual identification in the MT. The MT from the uro -RNAi 
progenies and their parental lines were dissected under the light microscope in a Petri 
dish containing Schneider’s medium. After dissection, a glass slide was marked with the 
designated line’s name and one drop of Schneider’s medium added; then with a glass 
rod the whole tubules were carefully transferred to the slide. As the eye view field was 
limited, and the whole MT was relatively wide, several pictures were taken then were 
merged together to form composite pictures showing the whole tubules (Figure  5-9). 
In this figure tubules in A and B were for uro -GAL4 parent and UAS-uro RNAi parent 
respectively; consistent with normal expression of uro, only sparse uric acid crystals 
were seen. Whereas in C, the UAS-uro RNAi progeny, an obvious and aberrant 
accumulation of uric acid crystals was seen.  
 
Although there was no significant difference in the levels of urate between the three 
lines in the metabolomic analysis, it was clear in the polarizing microscope and in the 
quantitative PCR. The results from the three techniques are thus slightly contradictory, 
but could be explained if most of the uric acid crystals were spun down into the pellet 
during methanol/water extraction for metabolomic sampling. The protocol used would 
favour sampling of the soluble urate.  
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Figure  5-9. Impact of uro knockdown on uric acid accumulation in adult tubules. Uro -
GAL4 parent (A), UAS-uro (RNAi) parent (B) and progeny of uro -GAL4>uro 
(RNAi) (C). The RNAi knockdown of uro  was functionally effective, and resulted in an 
abnormal accumulation of uric acid. 
A 
B 
C 
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5.7 Survival assay 
Furthermore, this line was used to determine the effects on the fly survival and see the 
effects on aging and longevity.  
 
5.7.1 No additive to the fly food 
Longevity has been linked directly to urate concentration. Thus the Malpighian tubule 
specific gene, uro, was tested to see if it has an effect on fly survival. So experiments 
involved several fly lines were conducted including both the uro -GAL4 and UAS-uro 
(RNAi) parents and their progeny. Adult flies were collected and transferred to newly 
prepared fly food vials, and kept under medium crowding (10 males +10 females per 
vial). The number of dead flies were recorded twice a week. Flies were tipped weekly 
into newly-prepared vials. As seen in (Figure  5-10), survivorship curves were plotted. 
The UAS-uro RNAi cross fly line showed a slight improved in longevity compared to 
both parents, which differed markedly in their survivorship. The UAS-uro (RNAi) 
parent line was the fastest to die, while the other parent, uro -GAL4, was very similar to 
the progeny.  
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Figure  5-10 Survival assay for uro RNAi lines under normal conditions. When uro is 
knockdown it shows more urate, which is antioxidant, this means the fly is better 
protected, this suggested the flies are healthier. Significant changes were seen P-value 
0.0018, Log-Rank (Mantel-test). 
 
.  
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5.7.2 Survival assay under oxidative stress 
Unfortunately, our UAS-uro RNAi line was lost, so the oxidative stress experiments 
were performed with the uro insertional knockdown line from Bloomington  
w1118; {w+mC=WH}PBac urof04888 (Mamer et al., 1971).  
 
 
It is important to increase the efficiency of transposon mutagenesis in D. melanogaster, 
to emphasis on generating stronger loss-of-function alleles.  In this line the most 
promising, pBac transposon was used for more effective gene disruption.  When this 
technique was discovered  by (Thibault et al. 2004) eighty-nine percent of the lines 
yielded unique flanking sequence by inverse PCR. In addition, 97 of 100 pBac lines 
analyzed by genomic Southern blotting had single insertions. And the unlinked 
background mutations screens of pBac stocks contained only 0.3 -0.5 %. Finally, they 
also found the insertion and transposase strains have been stable for 4 years with no 
observed breakdown. Taken together, these data support the conclusion that pBac acts 
as an effective mutagen and that the mutations observed are directly caused by the 
transposon insertion.  
 
The uro gene contain only one small intron (60 bp) in the middle of the gene, and the 
pBac is 7.2 kb is large enough  which was landed in the middle of the gene, and so is 
highly likely have disrupted the gene reducing the transcription of the normal mRNA as 
seen in Figure  5-11.   
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Figure  5-11 The pBac transgenic insertion site on the uro gene. 
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Figure  5-12 Survival assay showing the effects of parquat on male specific into three 
different mutants. Three tubes of 10 flies. 
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Figure  5-13 Survival assay showing the effects of parquat on female specific into three 
different mutants. Three tubes of 10 flies. 
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Figure  5-14 A survival assay showing the effects of 20mM parquat on three different 
lines w1118; {w+mC=WH}PBac urof04888 , rosy506 and w1118. No significant changes were 
seen, P-value 0.25, Log-Rank (Mantel-test). 
 
5.8 Discussion 
From the interfering RNA work (Figure  5-7), it can be seen that a significant < 0.001 
knockdown, of approximately 80% of the uro expression, was achieved. This can be also 
confirmed by the condensation of the uric acid crystals in the MT of the organism as 
compared to the other parents (Figure  5-9). This gave enough confidence that it worked. 
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However, when applying metabolomics, the results were a puzzling and confusing (Figure 
 5-8 A and B). The explanation to this could be that although there were an approximately 
80% knockdown, the other 20% perhaps was enough to produce enough UA to be seen by 
the Orbitrap. This small percentage (20%) is the residual expression, or what is sometimes 
called leaky expression, would be capable of producing some protein.  An alternative 
explanation for the UA crystals seen in the MT, are that these are of insoluble urate. This 
insoluble urate was pulled down in the sample preparation for the metabolomic experiment. 
So, even if urate production had ceased entirely, carry-over of insoluble urate would result 
in a relatively slow depletion of urate levels, much as was observed.  
Then the effects of uro on the Drosophila lifespan was also needed to be investigated, thus a 
survival assays were important to be carried out. 
Thus a survival assay was conducted to investigate the uro effects on Drosophila’s lifespan 
in comparisons with uro-GAL4 parental line and UAS-uro RNAi parental line as it can be 
seen in (Figure  5-10). Lifespan was significantly increased, P-value 0.0018 in the progenies 
of the uro-RNAi line crossed with the uroGAL4. 
Moreover, these interesting results have encouraged us to further survival testing using an 
oxidative stress agent. Sadly, the UAS-uro parental line were lost and this rendered us from 
carrying out the experiments. However, a Bloomington stock of uro knockdown insertional 
line were used (w1118; {w+mC=WH}PBac urof04888). 
This time survival assay under the 20 mM oxidative stress parquat was conducted. Beside 
the uro  w1118; {w+mC=WH}PBac urof04888  line, rosy506 and w 1118 were also 
compared. (check if there is Oregon-R) 
The limited time during my PhD and the family bereavement happened have prevented me 
to test the uro w1118; {w+mC=WH}PBac urof04888  line to validate the gene knockdown 
by qPCR or to visualize the uric acid crystals under the polarizing microscopy. 
If the time allowed, it would be nice to continue these experiments in order to get insights in 
the future for the effect of parquat on the Drosophila lifespan. 
In particular, it would have wanted to confirm these exciting results by : 
• Re-transforming Drosophila with my RNAi construct. 
• Validating knockdown of w1118; {w+mC=WH}PBac urof04888  line by QPCR. 
• Validating knockdown of the  w1118; {w+mC=WH}PBac urof04888 line by 
visualising uric acid crystal accumulation (as seen in Figure  5-9); and perhaps 
• Validating knockdown of the  w1118; {w+mC=WH}PBac urof04888   line by 
Orbitrap analysis. 
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In addition, it would be interesting to test the hypothesis that there are both soluble and 
insoluble pools of urate in tubule.   
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Chapter 6 Drosophila microarray analysis 
investigation 
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6.1 Introduction 
Gene-expression microarrays have become widely used as measurement tools in 
biological research (Lamy et al., 2011). Designing the experiment has a direct impact on 
the efficiency of the results interpretations and test validity (Leung and Cavalieri, 2003). 
From the experimental and technical point also, the biological replicates of samples are 
another important point must be carefully considered. In microarray analysis, two types 
of replication can be carried out: the technical replication, is when mRNA sample is 
used on multiple microarrays, and the biological replication, is when measurements are 
taken from multiple sample (Kerr et al., 2000).  
However, data analysis is considered the most challenging part of it. A wide range of 
methods for microarray data analysis have been used . 
 
Microarrays are considered among the most attractive techniques for high-throughput 
transcriptional profiling with metabolomics. This technique draws its power from the 
simultaneous detection of tens of thousands of genes at the same time. The cost is 
dropping constantly and it is not only being used exclusively in the research field, but in 
screening for cancers, and for disease diagnosis and monitoring. In time, next 
generation sequencing (NGS) technologies are likely to supplant microarrays for 
expression profiling; but at present microarrays are the mature platform of choice.  
 
6.1.1 General principle  
 
Generally in any microarrays, probes are fixed to a surface, usually glass. Each probe is 
complementary to a particular cognate mRNA. From each biological sample, mRNA is 
used to generate cRNA in order to hybridize to the probes. These cRNAs are usually 
labelled with fluorescent dyes for hybridization.  
 
After hybridization, laser light is used to excite the fluorescent dye; the amount of 
florescence is proportional to the intensity of the hybridization, thus reflects the 
abundance of transcript (Figure  6-1).  
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Figure  6-1 Schematic overview of the Affymetrix GeneChip, taken from 
www.affymetrix.com. 
 
 
 
6.1.2 Affymetrix 
Affymetrix one of the most popular microarray platforms used (Figure 1.21). In only a 
small square (1.28 cm2) glass, more than 1,000,000 different probes are synthetically 
attached (Lipshutz et al., 1999).  
Each probe is 25 nucleotide long, between 16-20 probe pairs representing one particular 
gene. These probes are synthesized in a basis of perfect match (PM) and mismatch 
(MM) basis.  The PM is designed to complementary hybridized to cRNA, while the 
MM is the same sequence as the PM except that only one single base in the middle is 
changed. 
Drosophila GeneChip 
array 
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The probe lengths should not be exceeded 25 nucleotides as problem of  non specific 
hybridization are expected to be found (Fodor et al., 1991) and (McGall et al., 1996).  
 
 
6.1.3 RNA quality control 
All RNA extracted samples should meet the highest quality standards to ensure the best 
hybridization on the gene-chip array to be achieved. In order to inspect the RNA quality 
a small amount of  each sample must be assessed by the RNA 6000 Nano assay on the 
Agilent Bioanalyzer (Agilent Technology UK. Ltd) to examine the ribosomal RNA 
bands. The more intact the ribosomal RNA, the less RNA degradation has occurred.  
Sample absorbance should also be read at 260/280: acceptable readings are between 1.8 
to 2.1 for RNA. Readings below 1.8 indicate possible protein contaminations while 
readings above 2.1 indicate likely RNA degradation.  
 
6.2  Affymetrix microarray experiment  
Total 2 µg of RNA was reverse-transcribed and in vitro transcribed according to the 
standard Affymetrix protocol to produce biotinylated complementary RNA (cRNA). 
Prior to the reverse transcription, poly-A RNA controls were added into the RNA 
samples before target labeling. Poly-A controls (lys, phe, thr and dap) function is to 
monitor the target labeling process from the beginning of the experiment to finish. They 
act as indicators of target preparation and labeling efficiency.  The cRNA was then 
purified and checked for integrity (see section  6.1.3 RNA quality control) and 
fragmented. Fragmented cRNA was hybridized to Drosophila genome 2 expression 
arrays (4 biological replicates per tissue). Hybridized probes were then stained using 
streptavidin phycoerythrin conjugate and scanned with an Affymetrix GeneChip 
Scanner 3000 7G. The overview of the GeneChip 3’ IVT express kit labelling assay is 
shown in Figure  6-2. An additional amplification step was used as necessary for RNA 
samples less than 2 µg in the two-round amplification protocol; the starting amount of 
RNA for the two-round amplification was typically 100 ng. 
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Figure  6-2 Overview of the GeneChip 3' IVT express labelling assay (taken from 
www.affymetrix.com). 
 
6.2.1 Statistical analysis 
Experimental trascriptomes compared against the relevant controls to obtain t-test P-
values for the statistical significance for differential expression.  
For the advanced analysis and annotation, GeneSpring GX10 (Agilent UK) was used. 
Raw data (signal intensity) CEL files were obtained from the Affymetrix GCOS and 
uploaded into the GeneSpring for further data processing and analysis. In GeneSpring, 
data was analyzed in several sequential steps which include data processing, 
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normalization, grouping, interpretation, quality control, statistical analysis and 
functional annotation. 
6.2.2 Functional annotation 
The DAVID Gene Ontology (GO) package was used to represent the data on an 
intuitive heat map and to functionally annotate using ontology terms. 
6.2.3 Fold change (FC) analysis 
Fold Change Analysis was used to identify genes with expression ratios or differences 
between a treatment and a control that are outside of a given cut-off or threshold. Where 
Fold change was used, it was calculated between a condition (Condition 1) and one or 
more other conditions (Condition 2) treated as an aggregate. The ratio between 
Condition 2 and Condition 1 is calculated (Fold change = Condition 1/Condition 2). 
Fold change gives the absolute ratio of normalized intensities (no log scale) between the 
average intensities of the samples grouped. The entities satisfying the significance 
analysis are passed on for the fold change analysis. 
6.3 Allopurinol drug  
Allopurinol, was one of the drugs discovered at Burroughs Wellcome program that 
started in 1940s and was awarded the Nobel Prize in Physiology and Medicine in 1988 
(Pacher et al., 2006). The drug discovery project was meant to find potential antitumor 
drugs. However, subsequent experiments showed effective control of serum and urinary 
uric acid by allopurinol; and its direct metabolite, oxypurinol, showed promise for the 
treatment of hyperuricemia. In 1966, allopurinol was Food and Drug Administration 
(FDA) approved as treatment for gout and until now it is an important cornerstone in 
primary and secondary hyperuricemia management (Pacher et al., 2006).  
Many researchers have also suggested additional important roles for that XO in different 
types of ischemic and tissue and vascular injuries, inflammatory diseases, and chronic 
heart failure. Beneficial effects on the previously mentioned conditions were seen not 
only due to allopurinol but also from its metabolite, oxypurinol. Reviewed in (Harrison, 
2002) , (Harrison, 2004) and  (Berry and Hare, 2004).  
 
 
6.3.1 Pharmacokinetics 
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When administered orally, allopurinol is rapidly absorbed and reaches peak 
concentration in plasma within 30 to 60 min. On the other hand oxypurinol has lower 
oral bioavailability than allopurinol. 
In terms of half-life, allopurinol has relatively short time in plasma approximately (2–3 
h), whereas the half-life of oxypurinol is much longer (14–30 h) due to renal 
reabsorption (Pea, 2005). 
Gastrointestinal pain, hypersensitivity reactions as well as skin rash are the most 
common side effects  of allopurinol and it may vary from individual to individual 
(Pacher et al., 2006).  
 
6.3.2 Mechanism of action 
 
Allopurinol is known inhibitor for the enzyme xanthine oxidase, which blocks the 
metabolism of hypoxanthine and xanthine to uric acid.  It acts by interfering with the 
catabolism of purines resulting in lowering  uric acid production.  
Also its metabolite, oxypurinol acts as in a competitive inhibitor as it is an isomer of 
xanthine. Thus preventing the conversion of xanthine to uric acid. Also as indirect 
inhibition , oxypurinol inhibits the purine biosynthesis by stimulating negative feedback 
(Pacher et al., 2006).  
 
6.4 Aim 
We applied the Affymetrix Gene-chip array in a way to identify the effects of 
allopurinol drug on the MT of wild type OR Drosophila melanogaster in a time-course 
experiment.  
Allopurinol was intended used to phenocopy the rosy mutant and to test any metabolic 
effects on the Drosophila melanogaster tubular transcriptome.  
Furthermore, the classical rosy mutant MT was also analyzed in comparison with the 
WT OR tubules.  
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6.5 Results 
6.5.1 Microarray results for rosy compared to wild type 
The main purpose of the microarray experiment was to compare the transcriptome of 5-
7 day adult Drosophila melanogaster wild type against rosy Malpighian tubules. The 
total numbers of genes significantly (P-value 0.05) changed were 8720, where 3368 
were up regulated while 5352 genes were down regulated. In order to narrow down the 
list, only genes two times fold changed up and/or down were selected. This gave a list 
of total 1189 on both directions. To focus the analysis more tightly, only genes 
significantly changed five times were only listed in ( Table  6-1 and Table  6-2). 
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Table  6-1 Genes significantly down regulated in rosy compared to wild type.  Genes 
shown here are ranked by their fold changed down regulated expression in MT 
compared to WT, P< 0.05. 
 
Gene Symbol P-value 
FC 
Absolute Gene ontology biological process 
ry 7.3E-20 160.1  Determination of adult life span 
CG13313 8.2E-18 159.4   
CG14957 3.4E-06 37.3  Chitin metabolic process  
CG2781 2.9E-16 30.4  Fatty acid elongation  
DnaJ-1 6.0E-07 29.3  Protein folding  
CG9981 3.7E-16 19.9  Atp biosynthetic process  
Hsp70Ba, Bb, bb and Bc 4.3E-02 18.4  Response to stress  
RFeSP 1.6E-12 18.3  Mitochondrial electron transport 
Map205 3.1E-10 17.6  Microtubule-based process  
Hsp27 2.3E-02 14.2  Response to stress  
CG10924 4.8E-12 12.6  Gluconeogenesis  
CG18673 4.6E-06 12.5  One-carbon compound metabolic process  
CG12910 9.4E-12 11.6   
Hsp26 3.5E-02 11.2  Response to stress  
 1636495_at 4.7E-08 10.7   
CG13397 3.2E-15 10.5  Metabolic process  
Pepck 2.8E-05 10.4  Gluconeogenesis  
ninaD 1.7E-03 10.3  Defense response  
CG9149 2.8E-21 9.8  Metabolic process  
CG4288 7.0E-11 9.7   
CG32103 2.9E-06 9.1  Transport  
CG7968 2.6E-04 8.9   
alpha-Est7 1.6E-09 8.6   
CanA1 1.1E-08 8.3  Protein amino acid dephosphorylation  
CG3292 4.9E-08 8.0  Metabolic process  
CG14688 4.8E-11 7.7   
CG10657 1.2E-06 7.2  Transport  
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CG14872 1.1E-04 7.0  Transport  
CG9360  1.2E-09 7.0  Metabolic process  
 1624819_s_at 2.1E-13 6.9   
CG15202 1.5E-13 6.6   
 1623349_x_at 1.4E-13 6.5   
CG14298  1.3E-11 6.4   
CG12734  2.0E-05 6.2   
CG14120 2.7E-07 6.1  Metabolic process  
 1639729_s_at 1.6E-13 5.9  RNA-dependent DNA replication  
Cyp4e1 8.3E-08 5.9  Oxidation reduction  
Ugt86Dd 3.7E-10 5.8  Metabolic process  
Hsp22 5.4E-03 5.7  Response to stress  
CG6495 5.0E-11 5.6   
CG32750 2.0E-06 5.5  Nitrogen compound metabolic process  
Lox 3.4E-06 5.4  Protein modification process  
Nha1 9.7E-05 5.4  Transport  
CG8147 4.6E-02 5.2  Metabolic process  
CG6448 3.5E-15 5.2   
mthl8 3.0E-11 5.0  Response to stress  
CG9989 2.9E-07 5.0   
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Table  6-2 Genes were up regulated in rosy compared to WT. 
 
Gene Symbol p-value FC Gene Ontology Biological Process 
CG10140 3.8E-16 72.7 Chitin metabolic process  
Cht4 6.3E-10 60.0 Carbohydrate metabolic process  
AttD 2.4E-06 59.9 Antibacterial humoral response  
CG12009 1.6E-23 56.4 Chitin metabolic process  
CG30031  2.4E-07 55.3 Proteolysis  
Arc1 2.7E-07 38.4   
Adh  2.6E-15 36.1 Cellular alcohol metabolic process  
CG30090 9.7E-20 35.5 Proteolysis  
RpL35 1.1E-22 28.0 Mitotic spindle elongation  
TyrR 5.4E-25 27.8 Signal transduction  
regucalcin 2.3E-19 23.5   
CG6330 6.7E-13 22.4 Nucleoside metabolic process  
CG5091  3.5E-20 22.0 Protein amino acid N-linked glycosylation  
His4r 1.9E-20 20.0 Chromatin assembly or disassembly  
Act42A 3.6E-08 19.6 Cytokinesis  
Arc1  2.4E-19 18.9   
CG30154 6.3E-19 18.7   
CG14687 3.9E-11 17.5   
lectin-37Db 8.6E-06 17.0   
CG31997 8.1E-09 16.7   
CG9336 5.2E-10 16.4   
Rab40 1.0E-16 16.3 Intracellular signaling cascade  
CG9691 3.6E-09 15.2   
CG11671 6.0E-08 14.7   
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cib 6.6E-14 14.5 Cytoskeleton organization  
CG15210 4.8E-07 14.0   
alpha-Man-I 2.1E-15 13.9   
yellow-d 7.5E-07 13.8 Protein amino acid N-linked glycosylation  
CG5541 1.6E-15 13.6   
CG8768 3.9E-13 12.9   
 1625050_s_at 5.6E-09 12.7 Metabolic process  
CG7191 9.3E-10 12.7   
CG6643 2.2E-06 12.6   
insc 2.0E-15 12.2 RNA localization  
unc-13 1.6E-16 12.2 Intracellular signaling cascade  
norpA 3.7E-23 11.7 Lipid metabolic process  
Tsp42Eh 2.7E-09 11.7   
 1627236_s_at 3.0E-16 11.6   
Mlp60A 2.4E-11 11.5 Multicellular organismal development  
CG7447 9.6E-19 11.4   
RpS29 3.4E-16 11.3 Translation  
CG9072 1.1E-22 11.0 Tubulin complex assembly  
CG7778 3.9E-06 10.6   
cib 7.4E-14 10.5 Cytoskeleton organization  
CG5011 2.3E-09 10.0   
Idgf1 4.9E-05 9.6 Carbohydrate metabolic process  
CG30026 6.3E-06 9.5   
fau 2.1E-13 9.5 Response to stress  
Pvf2 2.1E-07 9.0 Salivary gland morphogenesis  
CG13075 7.1E-07 9.0 Chitin metabolic process  
CG12780  1.1E-07 8.9   
CG5910 6.4E-05 8.7   
Sema-2a 1.5E-09 8.7 Multicellular organismal development  
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Nrg 3.4E-11 8.4 Cell adhesion  
Bsg 4.2E-05 8.4 Spermatid development  
DptB 4.1E-04 8.4 Antibacterial humoral response  
Hsp60B  1.5E-16 8.2 Protein folding  
Cht8 3.4E-17 8.1 Carbohydrate metabolic process  
CG3973  4.8E-14 8.1 Cell cycle arrest  
CG7267 4.5E-15 8.1   
Mef2 8.3E-15 8.0 Transcription  
CG4757 4.3E-04 7.7   
fax 1.9E-08 7.6 Axonogenesis  
CG13117 5.2E-09 7.6   
CG12310 8.6E-06 7.5   
RpII215 2.1E-15 7.5 Transcription  
CG16743 9.3E-06 7.2   
Tsp42El 1.1E-09 7.1   
CG9784 5.3E-12 7.1 Dephosphorylation  
CG1077 1.4E-13 7.0   
CG1572 2.2E-07 7.0   
Akt1 2.0E-09 6.7 Protein amino acid phosphorylation  
CG1146 3.8E-07 6.5   
CG31158 6.9E-12 6.3 Regulation of ARF protein signal transduction  
PGRP-SA 1.9E-06 6.3 Defense response  
Sucb 9.0E-09 6.3 Tricarboxylic acid cycle  
Dcp2 5.2E-13 6.3 Nuclear-transcribed mRNA catabolic process 
trol 4.1E-12 6.2 DNA methylation  
Eip75B 3.7E-07 6.2 Transcription  
CG15347 2.0E-06 6.2   
lea 4.1E-10 6.1 Neuron migration  
smi35A 4.5E-14 6.1 Protein amino acid phosphorylation  
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CG34104  3.5E-11 6.1 Chitin metabolic process  
HLHm3 3.6E-14 6.0 Negative regulation of transcription from RNA polymerase 
W 1.1E-10 6.0 Embryonic development via the syncytial blastoderm  
CG32687 4.9E-10 6.0   
CG9672 4.8E-12 6.0 Proteolysis  
Stlk 2.5E-14 6.0 Protein amino acid phosphorylation  
msn 2.5E-09 6.0 Activation of MAPKKK activity  
Ect4 5.2E-12 5.9 Immune response  
Ste12DOR  1.0E-14 5.9 Spermatogenesis  
Btd 5.4E-04 5.8 Nitrogen compound metabolic process  
CG12112 3.1E-13 5.8   
CG6959 4.6E-10 5.8   
CG9021 6.4E-16 5.8   
eIF-4B 1.1E-11 5.8 Translational initiation  
shi 1.1E-14 5.7 Cytokinesis  
sls 3.1E-07 5.7 Somitogenesis  
 1641367_at 7.9E-09 5.7   
 1635258_s_at 5.9E-10 5.7   
RpS30 1.3E-17 5.6 Mitotic spindle elongation  
CG5804 1.5E-05 5.5 Cellular acyl-coa homeostasis  
Pka-C1 2.4E-06 5.4 Protein amino acid phosphorylation  
Nrg 9.2E-12 5.4 Cell adhesion  
Tm1 3.3E-11 5.4 Muscle contraction  
Flo-2 2.7E-10 5.3 Cell adhesion  
 1625336_s_at 1.2E-15 5.3   
Imp 3.3E-12 5.2 Spermatogenesis  
CG32626 1.2E-10 5.2 Purine base metabolic process  
CG5630 7.0E-08 5.2   
MtnB 1.2E-11 5.2 Cellular metal ion homeostasis  
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Eip93F 5.6E-06 5.1 Phagocytosis, engulfment  
CG7920 1.9E-09 5.1 Acetyl-coa metabolic process  
CG32512 5.0E-14 5.1   
Mctp 1.1E-10 5.1   
Scamp 7.5E-16 5.1 Protein transport  
CG42329 5.8E-15 5.1   
Sox100B 1.4E-18 5.1 Male gonad development  
CG31004 1.9E-10 5.0 Cell-matrix adhesion  
baz 3.1E-10 5.0 Cytokinesis  
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6.5.2 Reconciling array and metabolomic data for rosy 
 
Perhaps the key finding of the thesis is the attempt to reconcile these related, but distinct 
datasets. Metabolite changes were brought from the rosy chapter three, while genes 
annotations and pathway were from the KEGG website and finally the microarray 
datasets from this chapter (Figure  6-3).  
The purine metabolic pathway is shown, along with changes occurring on the levels of 
metabolome and transcriptomic (Figure  6-3).  As it is known that rosy is defective in 
xanthine oxidase, its precursors accumulate, while urate is lowered. Consistent with the 
known lesion in rosy, the array data show, ry was down regulated 160 times, this 
allowed to xanthine to accumulate 25 times. This accumulation has a concomitant 
impact on levels of xanthine precursors; hypoxanthine (15 times) and guanine (3 times).  
 
Upstream expression changes ionclude the guanine deaminase (3.5.4.3) was found 
down regulated 2 and half times. Further above the CG16758 gene was found to be 
twice as normal indicating the perhaps as a result of urate low concentration, demanding 
for more urate. The CG11883 was lowered more than halved time as normal, and that 
could be hypothesized due to increased levels of adenine, hypoxanthine and guanine, 
the activation of the feedback inhibition of the enzyme by APRT and HGPRT (Figure 
 6-3) (Kamleh et al., 2008). 
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Figure  6-3 A combination of different datasets. This novel compined figure represents 
the purine metabolism pathway with respect to integrated metabolomic as well as 
transcriptomic. Triangl shaped denotes or represents gene affeted, while arrows 
represent metabolites changed. Red colour means reduced in level or downredulated and 
blue cloure means incresed in level or upregukated. The impact of rosy on the xanthine 
oxidase, urate is reduced, which proved by orbitrap. Consequently urate oxidase gene 
was 1.4 upregulated, this could be as a masage from allantoin ordering the the fly to 
produce more urate in order to be later converted to allantoin. Futher effect of the 
enzyme are accumulation of xanthine and hypoxanthine which shown by orbitrap to be 
25 and 15 fold increased repectevely. The effects do not soley on xanthine and 
hypoxanthine, it impacted further up the pathway as it reaches their immediate 
precursers, for example adenine and guanin and futher up like adenosine, inosine and 
guanosine with a slightely leasser increas.  
 
 165 
 
 
 
6.5.3 Microarray results for Allopurinol 
 
It has been thought phenocopying the rosy with allopurinol drug might have interesting 
effects on the metabolomic and/or transcriptomic levels. Allopurinol is known to 
phenocopy rosy (Keller and Glassman, 1965). 
In the microarray dataset for allopurinol experiment, although 374 genes showed 
changed expression, there was no clear pattern, and there were no significant effects on 
the key enzymes in the purine metabolic pathway Table  6-3.  
This may be because the effect of the drug was only transient on the metabolic level. By 
contrast, the rosy mutant is lacking xanthine oxidase enzyme since birth. Thus no 
beneficial effect found on the transcriptomic level when applying allopurinol on WT. 
 
Table  6-3 Significantly downregulated grouped genes in six hours allopurinol treated flies. 
Top changed groups  Group 
members  
Changed 
members  
P-value 
changed  
Percent 
changed  
Blood coagulation 3 2 8.9e-05 66.67 
Reduced folate carrier activity 3 2 7.4e-05 66.67 
Determination of adult lifespan 98 2 6.6e-05 2.04 
Response to stress 82 7 5.6e-12 8.54 
Response to unfolded protein 7 3 4.4e-08 42.86 
Heat shock-mediated polytene 
chromosome puffing 
7 3 4.4e-08 42.86 
Response to hypoxia 18 4 3.5e-09 22.22 
Protein refolding 7 2 2.3e-05 28.57 
Cell morphogenesis involved in 
neuron differentiation 
4 4 1.7e-04 100.00 
Folic acid binding 4 2 1.5e-04 50.00 
Response to heat 81 7 1.2e-11 8.64 
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WT vs 6h upregulated 
 
Top Changed Groups  Group 
Members  
Changed 
Members  
P-Value 
Changed  
Percent 
Changed  
Immune response 98 7 9.7e-06 7.14 
RNA-directed DNA polymerase (reverse RT) 12 2 9.6e-05 16.67 
Regulation of protein import into nucleus 10 2 9.4e-06 20.00 
Eclosion rhythm 12 3 8.6e-07 25.00 
Innate immune response 98 8 7.9e-07 8.16 
Glutathione peroxidase activity 9 2 6.8e-05 22.22 
Circadian rhythm 42 4 6.0e-07 9.52 
Antibacterial humoral response 28 6 5.7e-08 21.43 
Gns1/sur4 membrane protein 3 2 5.3e-05 66.67 
Protein import into nucleus 23 2 5.2e-05 8.70 
Regulation of circadian sleep 20 3 4.4e-06 15.00 
Tata box binding protein associated factor 8 2 4.1e-05 25.00 
Negative regulation of oskar mRNA translation 9 3 4.0e-05 33.33 
Structural molecule activity 88 5 3.8e-05 5.68 
Locomotor rhythm 37 4 3.6e-07 10.81 
Rhythmic process 18 3 3.2e-06 16.67 
Vitellogenesis 9 3 3.1e-06 33.33 
Rhythmic behavior 20 4 2.7e-08 20.00 
Protein heterodimerization activity 58 4 2.2e-06 6.90 
Photoperiodism 2 2 2.1e-07 100.00 
Negative phototaxis 2 2 2.1e-07 100.00 
Circadian behavior 5 2 2.1e-06 40.00 
Mating behavior 15 3 1.8e-06 20.00 
Negative regulation of histone modification 2 2 1.5e-06 100.00 
Entrainment of circadian clock 14 3 1.4e-06 21.43 
Acyl carrier activity 9 2 1.4e-04 22.22 
Regulation of circadian sleep/wake cycle 4 2 1.3e-06 50.00 
Defense response to bacterium 20 3 1.3e-04 15.00 
L-phenylalanine catabolic process 4 2 1.3e-04 50.00 
Copulation 13 3 1.1e-06 23.08 
Perinuclear region of cytoplasm 27 3 1.1e-05 11.11 
Sleep 11 2 1.1e-05 18.18 
Sex differentiation 27 3 1.0e-04 11.11 
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6.6 Conclusion 
 
As it can be seen in this experiment, allopurinol did not elicit consistent significantally 
reliable effects on the wild type fly in the microarray experiment. However, when 
microarray data were analyzed using the MT of rosy mutant against the MT wild type , 
as expected the rosy gene came on the top of the list of the upregulated.  
 
What needs to be addressed here is the question why does allopurinol induce changes in 
the metabolome, but not in the transcriptome under the same conditions?. Experimental 
error or high variability in analysis are possibilities. Alternatively, the short-term 
blockade of the purine metabolism pathway may not induce the same transcriptomic 
changes as the lifelong knockdown associated with rosy506 deletion. 
 
Several genes and metabolites were affected as a direct impact of rosy, both in the 
transcriptomic and on the metabolomic levels respectively. These changes are shown in 
Table  6-1, Table  6-1 and Table 3-2 and Figure  6-3. Pleasing, to my knowledge it was 
first time a mutant has been studied with both techniques. 
 
The ‘list of genes’ resulting from a microarray analysis should not be viewed as an end 
in itself; its real value increases only as that list moves through biological validation, 
ranging from the numerical verification of expression levels with alternative techniques. 
Sadly, time has limited us from further array analysis. 
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Chapter 7 Summary and discussion 
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7.1 Introduction 
IEMs are a group of diseases with a much higher incidence in some areas more than 
others, due to factors like consanguinity. Because of their early onset, severity and 
frequently devastating consequences, good animal models are highly demanded. 
Investigations of IEMs in animal models might be very helpful in exploring insights in 
these types of diseases, mode of transmission and the way of tackling them and finding 
the best screening and / or efficient diagnosis methods. However, most IEMs have 
vanishingly low incidence in the Western world, and so are considered ‘orphan 
diseases’ – the investments in mammalian models or in drug therapy research is not 
considered justified. Simpler models, and rapid and efficient development pipelines, are 
thus highly important goals. Drosophila melanogaster is well known as a powerful 
genetic model, and has excellent genetic tools - for example RNAi, UAS-GAL4 system. 
Other key benefits include its small size, the short reproduction time and fully 
sequenced genome.  
Another bottleneck is provided by screening technologies in humans, which historically 
have been ad hoc, and based on single disease diagnoses. The newly developed mass 
analyzer, the Orbitrap, has great potential in neonatal screening, because of its ability to 
identify 300-500 small metabolites in a single run from a single sample. This provides 
the opportunity both to streamline neonatal testing, and to expand the range of diseases 
that can be screened.  
In this thesis, I addressed both issues, by using the new Orbitrap to test Drosophila 
mutants homologous to IEM genetic loci in humans, for example xanthinuria type I.  
7.2 What was achieved? 
At the outset of the project, the Orbitrap was a brand-new instrument, and metabolomics 
was almost unknown in Drosophila. A pilot experiment was performed on extracts 
pooled from 10 flies, male and females using the ry506 mutant. Initially we were testing 
the validity of the technology by looking for key metabolite changes in the purine 
metabolic pathway which was a targeted rather than global metabolomic validation.  
As expected, the rosy mutant revealed what was historically was found. Having 
obtained the expected results, the analyzer was challenged further, to see to what extent 
that it would be useful in specific fly tissues. Consequently, we carried out another 
experiment using different fly tissues, like heads and Malpighian tubules. Empirically, 
15-20 heads and tubules for 20-30 flies were found to give informative results. 
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Findings were again consistent with microarray expression data, as ry is expressed in 
the whole fly, with higher levels particularly in MT.  
Then we decided to take one step forward in the analysis, after validating the 
technology, the approach was extended to all metabolites that could be resolved in the 
Orbitrap. Thus, 
all significantly changed metabolites detected were arranged into putative metabolic 
pathways. Changes shown in (Table 3-3) were very sensible. Significantly, changes in 
metabolite levels can be detected several metabolites further up from the genetic lesion 
than had been detected by classical analytical biochemistry. This provided that the 
Orbitrap technology with great confidence has provided more information in a single 
experiment than could be obtained by classical techniques.  
Remarkably, some of significantly metabolic changes were quite unexpected, and not 
known from the extensive classical literature (over 500 papers) on rosy. For example, 
effects on the tryptophan pathway, which involved in Drosophila eye pigmentation, 
were also noticed. This explained how the ry eye red-dull colour is generated. 
Generally, the Drosophila eye colour is constituted as a result of a mixture of two 
pigment colours. Each colour is generated from a distinct pathway. Thus, any 
disruptions in either pathway will impact on the Drosophila eye colour.  
 Another unexpected finding, was the impact on osmolyte biosynthesis.  This was 
explained on the basis that ry mutants are unable to make uric acid in the absence of 
XDH, they excrete the nitrogen waste in other forms, perhaps as water-soluble xanthine. 
This process would be wasteful of water, leading to osmotic stress.  
These results were extended to a second mutant, maroon-like, which is necessary for the 
activation of both rosy and other molybdoenzymes. Maroon-like is thus epistatic to 
rosy, and we accordingly observed a broader range of metabolic changes than in rosy. 
The work thus showed that it was possible not just to characterize a known mutant in 
Drosophila, but to extend the phenotypic description usefully, and to follow an epistatic 
series. 
We also applied the Orbitrap technology to characterise a genetic lesion for which the 
underlying gene was not known – the eye and tubule colour mutant chocolate. In the 
limited time available, a definitive metabolomic fingerprint was not identified. 
However, with more work, it should be possible to perform such identifications more 
easily, and thus to provide a useful phenotype for reverse genetics of novel genetic loci. 
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In summary, then, Drosophila is highly compatible with Orbitrap technology, and the 
results are highly informative for analysis of both known and novel loci. 
7.3 Drug action  
This technology was also challenged not only with mutants or specific tissues, but also 
to follow and unravel the pharmacological effects of drug actions. It again proved 
successful. We used the anti-gout drug allopurinol, which is considered to phenocopy 
the rosy mutant both in humans and flies. Confidently, effects on purine pathway were 
seen, however we also uncovered interference with isomers - an important issue in 
metabolic analysis.  We found unexpected behaviour of what was believed to be 
hypoxanthine and xanthine levels. However, later on we concluded these changes were 
as results of the hypoxanthine and xanthine isomers, the original drug allopurinol and its 
oxypurinol metabolite, respectively.  
7.4 Utility of Drosophila 
All of those experiments would not be conducted without the availability of an excellent 
genetic animal model like Drosophila melanogaster. It has clear advantages for 
studying some human disease genes, based on the rich information available for 
researchers. For example, availability of the completed Drosophila genome sequence 
(Adams MD, 2000), the tens of thousands of available classical mutants in stock 
centres, RNAi stocks for nearly every gene (Dietzl et al., 2007), and the FlyAtlas.org 
(Chintapalli et al., 2007) and Homophila (Reiter et al., 2001) websites. 
A transgenic fruit-fly line can be made for approximately $500 in only three months and 
costs $30 per year to maintain (Dow, 2007). It is also one of the best and powerful 
genetic animal models being used; this is due to its short life cycle, which allows 
multiple generations to be screened quickly. The small size of the insect makes it better 
than many other animal models in terms of space in the lab and food requirements.  
At the molecular level, balancers and P-elements provide powerful genetic tools for 
gene transformation and phenotype selection. Interfering RNA is also one of the 
important molecular genetic tools which helps in field of functional genomics, 
specifically reverse genetics. 
Also, these findings have encouraged us to think of applying the technology to unlock 
the mysteries for thousands of Drosophila mutants in captivity in stock centres. Thus, 
we subjected the chocolate mutant to for further metabolic investigations. Moreover, the 
list could be expanded widely to other mutants in stock centres world wide.   
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This new technology had helped us in addressing scientific questions fairly quickly and 
easily. It costs few dollars to run the samples which takes the technician less than 30 
minutes in sample preparations and analyzers set-up. Then the analyzer might be left 
overnight to carry the job. Then a few days of further analysis (depending on the depth 
of the needed detail) can finalize the results.  
The Drosophila, as genetic model, has its limitations as it is not mammalian; however 
with all the new technology and techniques continually emerging, the Orbitrap with 
great certainty will help in closing the phenotype gap between human and Drosophila. 
In particular, this thesis has shown the usefulness of Drosophila in modelling rare, 
Mendelian diseases of humans that might otherwise be considered too rare to attract 
major research funding. 
Moreover in the utility of this technology, one can integrate the wealth of Drosophila 
genetics and metabolomics in other branches that will be great impact to it. This is to 
measure the changes in development, drugs mode of actions and newly discovered drug 
usages and might also be used in insecticide and detoxifications studies.  
 
7.5 Utilization in humans 
 Certain inborn errors of metabolism (IEM) are far more common in some parts of the 
world than other places in the world, and neonatal screening must thus be more 
comprehensive. These inborn errors of metabolism, which are recessively inherited, are 
attributed to the consanguineous marriages practiced in the Arab world, especially in a 
country like Saudi Arabia (Al-Odaib et al., 2003).  
In Saudi Arabia, in particular, consanguinity rates are about 50%, of which 60% are at a 
first-cousin level of consanguinity (El Mouzan et al., 2008); furthermore, the Kingdom 
is considered to have one of the highest birth rates in the Middle East and North Africa 
(Saadallah and Rashed, 2007). 
So premarital screening programmes for congenital diseases could help significantly to 
limit the incidence and impact of inborn errors of metabolism. 
Although premarital screening is an ideal solution, it is not always practical, socially 
acceptable or economic; so in practice both diagnosis and treatment must also be 
researched. In order to have better understanding, and to improve management of 
human genetic disorders, good metabolic screening and fairly fast and reliable analyzer, 
like the Orbitrap, is desirable. Although we did not assay human samples in this project, 
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we showed that the Orbitrap is ideal for detecting the metabolic changes associated with 
such mutations, and in samples far smaller than are likely to be available from human 
patients. 
 
The consanguinity has played an essential role which made the genetic diseases are 
certainly important, if not, the most important health problem in this part of the World. 
The most sensible way to combat this problem is prevention. Thus we found the 
Orbitrap is very sensitive, quick, and cost-effective when applied to investigate 
Drosophila mutants in metabolic detections. So we concluded that the analyzer is a 
powerful technique that could be applied in the routine and as a screening for genetic 
diseases preventions in the Arab world where consanguinity constitutes a major 
problem especially in country like Saudi Arabia where it reaches up to 50% of all 
marriages.  
Usually, inborn errors of metabolism causing clinical manifestations in the neonatal 
period are severe and often lethal if early detection was not done and proper therapy is 
not initiated. Clinical findings in this period are usually non-specific and similar to those 
seen in infants with sepsis. However, it has been shown that if detected early, 
complications in these disorders could be easily prevented with restricted dietary 
programmes or with early drug intervention.  
With the advanced mass spectrometer analyzers available today, like tandem MS and  
GC-MS , a proper diagnostic revolution may not be far away. The tandem MS alone can 
detect 35-40 metabolic disorders and has revolutionized the concept of newborn 
screening in the developed countries (Roa. et al, 2009). 
It is now possible to screen rapidly, simultaneously, and inexpensively for a number of 
very rare disorders with the use of tandem mass spectrometry, but some metaboloites 
would missed with such lower sensitivity when compaired to Orbitrap.  
For this reason, assessment for the diagnostic potential of this technology is required. 
To evaluate the technology fully, studies of the clinical effectiveness of screening and a 
detailed cost analysis will be necessary, compared with what already available  in the 
medical field. 
Recently, new techniques involving the IEM are creating many possibilities for clinical 
applications. Although theses techniques might still be years away from practical use, it 
certainly will join the field of expanding genetic applications. These technologies, will 
have a great impact on carrier screening, which is an integral part of preventive genetics 
 174 
programs. However, before commencing such programs, diseases should be carefully 
selected.  
For example, in Saudi Arabia ( Table  7-1 ) various rare metabolic diseases are screened 
at King Faisal Specialist Hospital and Research Centre, Riyadh, KSA (Al Odaib. et al 
2003). In the last year, standard Guthrie cards (heel prick blood samples) collected from 
every newborn in Saudi Arabia (200 000+ annually), are sent to King Faisal, and 
subjected to a battery of tests (including two MS runs), specifically to identify IEMs. If 
the Orbitrap could simplify or streamline this testing, it could have a major impact. 
 
Table  7-1 Major IEMs seen at the King Faisal Specialist Hospital and Research Centre. Riyadh, Kingdom 
of Saudi Arabia (1998-2002) 
Disease category 
 
Disease name 
 
Organic acidemias 
(n= 294) 
 
Methylmalonic acidemia (n=72) 
Propionic acidemia (n= 56) 
Glutaric aciduria type 1 (n= 29) 
3-Hydroxy-3-Methyl Glutaryl CoA Lyase Deficiency (n=26) 
Other organic acidemias (n=111) 
 
Amino acid disorders 
(n= 223) 
 
Maple syrup urine disease (n=58) 
Classical phenylketonuria (n=33) 
Biopterin dependent phenylketonuria (n=29) 
Homocystinuria (n=33) 
Other amino acid disorders (n=70) 
 
Lysosomal storage 
disease (n=172) 
 
Niemann-Pick disease type B (n=36) 
Multiple sulfatase deficiency (n=30) 
Morquio’s disease (n=25) 
Sandhoff’s disease (n=19) 
Hurler-Scheie disease (n=18) 
Gaucher disease (norbottnian type) (n=8) 
Other lysosomal storage disease (n=36) 
 
The medications required for the management of certain inborn errors of metabolism are 
so costly that few can afford them. For example, the available injectable enzymes for 
Gaucher and Niemann-Pick diseases cost approximately $30,000 per year for an infant. 
Since the dose is according to body weight, it increases proportionally with growth. The 
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same is true for the tetrahydrobiopterin cost for biopterin dependent PKU and for the 
Betaine required for homocystinuria (Al Odaib. et al 2003).  
Thus, the carrier screening for rare genetic screening with a powerful analyzer like the 
Orbitrap, should take the lead over others in the Arabian Peninsula, especially in society 
like Saudi Arabia. 
7.6 Metabolic modelling and systems biology 
Although the Orbitrap is important in diagnosis, the other aim is to improve treatment. 
How could Drosophila, and the easy availability of mutants, help here? Firstly, mutant 
flies could provide a sensitized background for a genetic screen to identify modifiers of 
the severity of the disease – this is a very standard Drosophila technique. Secondly, the 
same sensitized background could be used to screen for compounds which improve 
survival .Although this is not a high-throughput screen, it is much less expensive than 
working with mice or humans. Thirdly, our work in Drosophila could allow us to build 
systems biology metabolic models that could predict the impact of mutations, and 
potentially predict possible therapies. 
This lead us to integrate the metabolites, viewed in different tissues with gene 
expression level in those individual tissues (Chintapalli et al., 2007), suggesting that it 
may ultimately be possible to build models linking transcriptome and metabolome. 
However, this is not easy as it sounds, as metabolomic analysis consists of different 
stages. The hardest part is the data analysis; it requires up-to-date speedy computers as 
well as continuously cutting-edge computational skills along with very strong 
biochemistry background knowledge.  
7.7 Recommendations 
The metabolomic studies are very helpful and a powerful method, along with what is 
available from the transcriptomic datasets, in the biological fields, in the normal as well 
as in the disease status. There are tens of thousands of Drosophila mutants in stock 
centres all over the world. Many of these fly lines are kept for several years without 
knowing the genetic makeup or the metabolomic profiling.  
Thus we argue that using the power of the metabolic analysis (especially using the 
Orbitrap analyser) along with the transcriptomic data, scientists would be able to unlock 
the genetic mystery of many of the lines and perhaps human genetic diseases. 
Furthermore, there is a huge pressure for cost-effective programmes for rare but lethal 
genetic diseases (like IEMs) in the neonatal and perhaps the premarital periods, 
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especially in a society like the Kingdom of Saudi Arabia. For this we argue that the 
Orbitrap analyzer is sensitive, fast, cost effective and high throughput enough analyzer 
that could be applied both in diagnostics as well as in screening; it is not yet been used 
in the Kingdom. 
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Chapter 8 Appendices 
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8.1 Drosophila media 
Reagent composition 
Standard fly food Per 1 litre of water  
10 g agar 
15 g sucrose 
30 g glucose 
35 g dried yeast 
15 g maize meal 
10 g wheat germ 
30 g treacle 
10 g soya flour 
S.O.C Medium 2% Trypton 
0.5 % Yeast Extract 
10 mM NaCl 
10 mM Mg Cl2 
10 mM MgSO4 
20 mM glucose 
Schneider’s medium   
 
8.2 Plasmids and vectors 
Item Conceteration 
pENTR/D TOPO vector 15-20 ng/µl linerized plasmid DNA in : 
50 % glycerol 
50 mM Tris-HCL, Ph 7.4 
1 mM EDTA 
2 Mm ddt 
0.1 % Triton x-100 
100 µl / ml BSA 
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30 µM bromophenol blue    
dNTP Mix 12.5 mM dATP 
12.5 mM dCTP 
12.5 mM dGTP 
12.5 mM dTTP 
In water , pH 8 
TE buffer is a commonly used buffer solution in molecular biology, especially in 
procedures involving DNA or RNA. "TE" is derived from its components: Tris, a 
common pH buffer, and EDTA, a molecule chelating cations like Mg2+. The purpose of 
TE buffer is to protect DNA or RNA from degradation.  
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8.3 Primers used in this thesis  
 
no 
Plasmid 
used 
Gene 
name 
F or R 
Primer name to 
paplo 
Full primer seqence incl res.t site Restic. Enzyme used 
Ann. 
Temp 
Seg. 
Size 
1 pWIZ ry F ROSY F1 GCATTCTAGACTACACAGATGACATTCCCCGC  Xba I 
2 pWIZ ry R ROSY R1 GCATTCTAGAAAACGCTTGGCACGACAGAC Xba I 
58.6 556 
3 pWIZ ry F ROSY F2 GCATTCTAGATCGGAACTGATTCACATTTCGG Xba I     
4 pWIZ ry R ROSY R2 GCATTCTAGATTCACCCACTGCCTTGGAAGAG Xba I     
5 pWIZ uro F URO pWIZ F1 GCATTCTAGATCACAATGTTTGCCACGCCC  Xba I 
6 pWIZ uro R URO pWIZ B1 GCATTCTAGATGAAGTCGCAGTTCCCTTGGAC Xba I 
58.6 489 
7 pRISE uro F URO pRISE F1 TCACAATGTTTGCCACGCCC   
8 pRISE uro R URO pRISE B1 CACCTGAAGTCGCAGTTCCCTTGGAC   
58.6 489 
9 pWIZ uro F URO pWIZ F2 GCATTCTAGAGCAAAAAGGATTACTACCAGGGC Xba I     
10 pWIZ uro R URO pWIZ B2 GCATTCTAGAACCACGGTGCTAAAGATGCG  Xba I     
11 pRISE uro F URO pRISE B2 GCAAAAAGGATTACTACCAGGGC        
12 pRISE uro R URO pRISE F3 CACCACCACGGTGCTAAAGATGCG        
13 pRISE ry F ry_pRISE F1 CTACACAGATGACATTCCCCGC       
14 pRISE ry R ry_pRISE B1 CACCAAACGCTTGGCACGACAGAC       
   F M13 Forward  5’-GTAAAACGACGGCCAG-3’    
   R M13 Reverse   5’-CAGGAAACAGCTATGAC-3’    
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8.4 Metabolomics of cho, an uncharacterized mutant 
The field of metabolomics has proven to give more insights in mutants for either novel 
or unknown metabolites (Kamleh, 2008). Previous studies have been done on 
Drosophila were done based on observational analysis, like variation in eye color 
pigmentation. This time we tried to use the metabolomic profiling in a way to reveal the 
cover for historically known mutants without exactly knowing what is the genetic 
lesion, like the cho mutant fly. In this contest, we tested the cho mutant against the 
Oregon R to elucidate the genetic lesion causing this pigmentation variation.  
 
 
 
8.4.1 Cho Phenotypes 
 
 
Figure  8-1 Part of Malpighian tubule from cho mutant.This picture shows the 
pigmentations in the MT in the cho mutant. 
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Figure  8-2 Four different flies showing different phenotypes. 
 
8.4.2 Metabolomic comparisons between cho  and Oregon R 
 
Table  8-1 The major metabolite differences between cho and OR. 
Sampled on two occasions (n=5) separated by five months (cho/OR). 
 
Compound m/z Ratio 1 P value 1 Ratio 2 P value 2 
Hydroxyproline 132.0656 1.92 0.010003 9.10 0.002113 
Proline betaine 144.102 0.17 0.000793 0.17 0.000094 
N-acetyl histamine 154.0976 0.42 0.011233 0.31 0.027323 
Xanthurenic acid 206.045 0.60 0.008469 0.43 0.000107 
Kynurenine 209.0923 0.49 0.001686 0.46 0.001774 
Hydroxytryptophan 221.0922 0.19 0.009653 0.28 0.000405 
Pyrimidodiazepine 222.0988 2.20 0.000021 1.50 0.024299 
Hydroxykyurenine 225.0872 0.27 0.000457 0.43 0.000116 
Dehydrobiopterin 236.078 3.06 0.000365 2.73 0.000104 
Formylkynurenine 237.087 0.34 0.007335 0.46 0.029471 
Biopterin 1 238.0937 1.72 0.013539 1.40 0.042726 
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Biopterin 2 238.0937 3.73 0.000013 2.68 0.001068 
Drosopterin 369.1533 0.37 0.002922 0.19 0.000215 
Xanthomattin 424.0647 1.61 0.157908 3.33 0.001808 
 
 
 
 
 
8.5 Metabolites List 
 
Formula Compounds MZ Time Ionization 
mode 
C2H3NO2 Iminoglycine 74.02365 19.47 positive 
C2H5NO2 Glycine 76.03931 19.92 positive 
C4H6O2 butanedione 87.04408 16.3 positive 
C4H6O2 butanedione 87.04409 18.82 positive 
C4H8O2 Butanoic acid 89.05979 8.299 positive 
C3H7NO2 Alanine 90.05495 19.85 positive 
C3H7NO2 Alanine 90.05498 18.84 positive 
C4H9NO2 GABA 104.0706 18.82 positive 
C5H14NO Choline 104.107 19.4 positive 
C3H7NO3 L-Serine 106.0499 19.92 positive 
C4H11NO2 Diethanolamine 106.0863 20.91 positive 
C8H10 Ethylbenzene 107.0856 5.152 positive 
C6H4O2 p-Benzoquinone 109.0284 19.08 positive 
C4H5N3O Cytosine 112.0506 20.22 positive 
C5H9N3 Histamine  112.087 29.12 positive 
CH5O4P Hydroxymethylphosphonate 112.9999 17.44 positive 
C4H4N2O2 Uracil 113.0346 11.63 positive 
C6H8O2 cis-1,2-Dihydrobenzene-1,2-diol 113.0598 8.223 positive 
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C5H9NO2 L-Proline 116.0704 17.75 positive 
C8H7N Indole 118.0652 14.67 positive 
C5H11NO2 valine 118.0862 18.03 positive 
C5H11NO2 glycine  betaine 118.0863 16.56 positive 
C4H9NO3 L-Threonine 120.0655 18.94 positive 
C8H9N Indoline 120.0808 14.4 positive 
C3H7NO2S L-Cysteine 122.0271 17.08 positive 
C8H11N Phenethylamine 122.0966 14.86 positive 
C6H5NO2 Niacin/Nicotinate 124.0394 8.266 positive 
C2H7NO3S Taurine 126.0218 18.28 positive 
C6H6O3 1,2,3-Trihydroxybenzene 127.039 20.34 positive 
C6H9NO2 2,3,4,5-Tetrahydropyridine-2-carboxylate 128.0708 6.455 positive 
C5H7NO3 Pyrroline-4-hydroxy-2-carboxylate 130.0499 18.49 positive 
C5H7NO3 Pyrroline-4-hydroxy-2-carboxylate 130.05 19.52 positive 
C6H11NO2 methylproline3 130.0863 25.43 positive 
C5H11N3O guanidino butanal 130.0974 17.47 positive 
C6H10O3 beta-Ketoisocaproate 131.0703 8.223 positive 
C5H9NO3 Glutamate 5-semialdehyde 132.0656 18.42 positive 
C6H13NO2 L-Leucine 132.1018 14.92 positive 
C6H13NO2 L-Leucine 132.1019 15.96 positive 
C4H8N2O3 L-Asparagine 133.0608 19.92 positive 
C4H7NO4 L-Aspartate 134.0448 19.14 positive 
C4H7NO4 L-Aspartate 134.0449 5.472 positive 
C5H5N5 Adenine 136.0618 14.66 positive 
C5H4N4O Hypoxanthine 137.0458 11.82 positive 
C5H4N4O Hypoxanthine 137.0459 17.84 positive 
C8H8O2 Phenylacetic acid 137.0597 8.049 positive 
C10H16 alpha-Pinene 137.1326 5.028 positive 
C7H7NO2 4-Aminobenzoate 138.055 17.75 positive 
C6H6N2O2 Urocanate 139.0503 15.99 positive 
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C2H8NO4P Ethanolamine phosphate 142.0264 21.28 positive 
C7H13NO2 Proline Betaine 144.1019 16.58 positive 
C8H16O2 Octanoic acid 145.1224 5.964 positive 
C6H11NO3 Amino-3-oxohexanoic acid 146.0812 25.45 positive 
C5H11N3O2 guanidino butyric acid 146.0923 17.17 positive 
C7H16NO2+ acetylcholine 1+ 146.1176 17.28 positive 
C7H16NO2+ acetylcholine 1+ 146.1177 16.27 positive 
C5H10N2O3 Glutamine 147.0764 19.48 positive 
C6H14N2O2 L-Lysine 147.1129 25.41 positive 
C5H9NO4 glutamate 148.0604 18.62 positive 
C5H9NO4 N-Acetyl-L-serine 148.0606 5.364 positive 
C6H12O4 (R)-Pantoate 149.0806 19.48 positive 
C8H7NO2 Indole-5,6-quinone 150.055 14.65 positive 
C5H11NO2S L-Methionine 150.0583 15.82 positive 
C6H7N5 Methyladenine 150.0774 17.67 positive 
C6H6N4O Methylhypoxanthine 151.0617 15.82 positive 
C5H5N5O Guanine  152.0567 13.3 positive 
C8H9NO2 (Z)-4-Hydroxyphenylacetaldehyde-oxime 152.0706 16.19 positive 
C5H4N4O2 Xanthine 153.0407 11.23 positive 
C7H11N3O N-acetylhistamine  154.0974 18.21 positive 
C6H9N3O2 L-Histidine 156.0766 24.7 positive 
C6H7NO4 2-Aminomuconate 158.0448 9.729 positive 
C6H12N3O2+ Guanidine proline+ 158.0925 16.48 positive 
C4H6N4O3 (S)(+)-Allantoin 159.0513 15.31 positive 
C8H17NO2 2-amino octanoic acid 1 160.1332 16.56 positive 
C8H17NO2 2-amino octanoic  acid 2 160.1332 12.85 positive 
C9H7NO2 indole carboxylic acid1 162.055 10.01 positive 
C6H11NO4 O-Acetyl-L-homoserine 162.0762 15.9 positive 
C7H16NO3 Carnitine 162.1123 18.42 positive 
C6H10O3S Dihydroxy-5-(methylthio)pent-1-en-3-one 163.0423 9.162 positive 
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C6H10O5 3,3-Dimethylmalate 163.0601 18.29 positive 
C6H5N5O pterin 164.0566 13.09 positive 
C5H11NO3S L-Methionine S-oxide 166.0532 19.44 positive 
C9H11NO2 L-Phenylalanine 166.0863 14.38 positive 
C5H4N4O3 Urate 169.0356 14.33 positive 
C7H11N3O2 1-Methylhistidine 170.0925 24.9 positive 
C3H9O6P Glycerolphosphate 173.0209 18 positive 
C10H8NO2 Quinaldic acid 174.0551 14.65 positive 
C6H14N4O2 L-Arginine 175.1187 25.47 positive 
C6H9NO5 N-Formyl-L-glutamate 176.0554 9.753 positive 
C7H13NO4 Spermidic acid 176.0918 15.85 positive 
C6H13N3O3 L-Citrulline 176.1029 20.19 positive 
C6H5N5O2 Isoxanthopterin 180.0517 13.16 positive 
C6H13NO5 D-Galactosamine 180.0867 20.39 positive 
C6H7N5O2 Dihydroxanthopterin 182.0673 13.25 positive 
C9H11NO3 L-Tyrosine 182.0811 16.61 positive 
C5H15NO4P+ Choline phosphate+ 184.0734 24.33 positive 
C8H14N2O3 Ala-Pro 187.1078 19.08 positive 
C9H21N3O N-acetylspermidine 188.1758 28.15 positive 
C8H16N2O3 N6-Acetyl-L-lysine 189.1233 15.62 positive 
C9H20N2O2 7,8-Diaminononanoate 189.1597 25.89 positive 
C10H7NO3 Kynurenic acid 190.0499 8.743 positive 
C7H11NO5 N-Acetyl-L-glutamate 190.0711 8.793 positive 
C7H14N2O4 meso-2,6-Diaminoheptanedioate 191.1027 19.15 positive 
C10H9NO3 5-Hydroxyindoleacetate 192.0656 14.73 positive 
C9H11NO4 DOPA 198.0761 18.94 positive 
C12H25NO Dodecanamide 200.201 5.401 positive 
C12H25NO Dodecanamide 200.201 12.9 positive 
C9H17NO4 O-Acetylcarnitine 204.1227 15.43 positive 
C11H12N2O2 L-Tryptophan 205.0973 15.07 positive 
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C8H16N2O4 Val Ser 205.1183 19.04 positive 
C8H16N2O4 Val Ser 205.1184 23.99 positive 
C10H7NO4 Xanthurenic acid 206.0447 10.18 positive 
C10H12N2O3 L-Kynurenine 209.0921 14.73 positive 
C10H11NO4 4-Hydroxyphenylacetylglycine 210.0761 17.11 positive 
C13H10O3 Dihydroxyfluorene-9-one 215.0696 18.7 positive 
C2H8NO4P phosphoethanolamine 216.0633 19.44 positive 
C9H16N2O4 gamma-Glutamyl-gamma-aminobutyraldehyde 217.1185 8.269 positive 
C8H16N4O3 Acetylarginine 217.1295 18.62 positive 
C10H19NO4 Propionyl carnitine 218.1388 14.43 positive 
C9H17NO5 Pantothenate 220.1177 8.169 positive 
C9H17NO5 Pantothenate 220.1181 6.523 positive 
C11H12N2O3 5-Hydroxy-L-tryptophan 221.0921 14.63 positive 
C8H15NO6 Pyrimidodiazopterin 222.0985 12.09 positive 
C7H14N2O4S L-Cystathionine 223.0747 23.35 positive 
C10H12N2O4 3-Hydroxy-L-kynurenine 225.087 16.2 positive 
C13H20O3 Methyl jasmonate 225.1487 5.266 positive 
C14H29NO Myristamide 228.2322 5.372 positive 
C11H20N2O3 Leu-Pro 229.1547 16.56 positive 
C11H20N2O3 Leu-Pro 229.1547 15.19 positive 
C11H20N2O3 Leu-Pro 229.1548 14.14 positive 
C14H31NO Dodecyldimethylamine oxide  230.2479 11.62 positive 
C11H21NO4 Butyrylcarnitine 232.1544 13.72 positive 
C10H22N2O4 1,1,3-tris(ethoxymethyl)urea 235.1653 17.98 positive 
C9H9N5O3 dehydrosepiapterin 236.0777 10.75 positive 
C11H12N2O4 N-Formylkynurenine 237.087 14.86 positive 
C9H11N5O3 Biopterin1 238.0936 14.33 positive 
C9H11N5O3 Biopterin2 238.0936 11.21 positive 
C9H13N5O3 Dihydrobiopterin 240.1091 15.21 positive 
C12H20N2O3 Pirbuterol 241.1547 16.69 positive 
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C6H11O8P Inositol cyclic phosphate 243.0265 19.14 positive 
C6H11O8P Inositol cyclic phosphate 243.0265 20.32 positive 
C9H13N3O5 Cytidine 244.0929 20.28 positive 
C9H12N2O6 Uridine 245.0769 11.63 positive 
C10 H20O3 N4 Ethyl-Acetyl-Arginine 245.1609 16.45 positive 
C14H31NO2 N,N-bis(butoxymethyl)-2-methylpropan-2-
amine 
246.2429 12.64 positive 
C6H15N4O5P phosphoarginine 255.0854 23.7 positive 
C11H14N2O5 glycyl-dopa 255.0977 19.86 positive 
C16H33NO palmitamide 256.2632 5.315 positive 
C8H20NO6P GPC 258.1098 21.35 positive 
C6H14NO8P D-Glucosamine 6-phosphate 260.0531 19.17 positive 
C6H13O9P Glucose phosphate 261.0371 19.22 positive 
C6H13O9P Fructose phosphate 261.0371 20.29 positive 
C11H20N2O5 Glutamyl-leucine 261.1445 14.35 positive 
C9H12NO6P Tyrosine phosphate 262.0475 20.68 positive 
C12H17N4OS+ thiamine(+) 2 265.1116 28.17 positive 
C10H13N5O4 Adenosine 268.104 14.59 positive 
C10H13N5O4 Deoxyguanosine 268.1041 13.59 positive 
C10H12N4O5 Inosine 269.0881 12.85 positive 
C15H12O5 narigenin 273.0752 18.45 positive 
C10H17N3O6 Glu-gln 276.1189 19.3 positive 
C18H28O2 Stearidonic acid 277.2161 5.057 positive 
C18H30O2 (9Z,12Z,15Z)-Octadecatrienoic acid 279.2322 5.031 positive 
C11H15N5O4 Methyl adenosine 282.1198 18.88 positive 
C18H35NO Oleamide 282.2794 5.286 positive 
C10H13N5O5 Guanosine1 284.099 14.91 positive 
C10H13N5O5 Guanosine2 284.099 15.93 positive 
C17H37NO2 C17 sphinganine 288.2897 11.83 positive 
C18H30O3 17-Hydroxylinolenic acid 295.2271 5.031 positive 
C11H15N5O3S 5'-Methylthioadenosine 298.0967 11.92 positive 
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C18H37NO2 Dehydrosphinganine(Sphingosine) 300.2893 11.93 positive 
C10H17N3O6S GSH 308.0908 17.55 positive 
C12H24N2O7 Fructosyllysine 309.1657 25.4 positive 
C12H18N6O4 2-aminodimethyladenosine 311.1465 24.85 positive 
C16H29NO5 Butoctamide semisuccinate 316.2113 12.99 positive 
C16H29NO5 Butoctamide semisuccinate 316.2119 14.01 positive 
C19 H43 O2 N C19 sphinganine 316.3209 11.65 positive 
C9H14N3O8P cytidine monophosphate 324.0593 21.01 positive 
C9H13N2O9P uridine monophosphate 325.0434 17.15 positive 
C12H20O10 Difructose anhydride isomer 325.113 17.71 positive 
C12H20O10 Difructose anhydride isomer 325.1131 19.22 positive 
C10H12N5O6P c AMP 330.0602 16.34 positive 
C11H15N2O8P Nicotinamide D-ribonucleotide 335.0638 20 positive 
C10H15N4O7P 2'-Deoxyinosine 5'-phosphate 335.0738 19.09 positive 
C9H14N5O7P Dihydroneopterin phosphate 336.0695 19.9 positive 
C18 H29O3 N3 Histidine lipid 336.2282 12.48 positive 
C11H19N3O7S S-(Hydroxymethyl)glutathione 338.1016 18.08 positive 
C18 H29 O3 N3 Hisitidine lipid 338.2437 12.38 positive 
C22H44ON Dodecamide 338.3414 5.152 positive 
C12H22O11 Sucrose 343.1234 18.3 positive 
C10H13O7N5P cGMP 346.0547 16.2 positive 
C10H14N5O7P AMP isomer 2 348.0703 20.14 positive 
C10H14N5O7P AMP isomer 2 348.0703 19.11 positive 
C10H13N4O8P IMP 349.0544 17.9 positive 
C19H34O5N C19H34O5N 356.2432 5.434 positive 
C18H37N4O3 C18H37N4O3 358.2952 6.526 positive 
C20 H31 O3 N3 guanidinosphingolipid 362.2434 12.29 positive 
C10H14N5O8P GMP 364.0654 19.66 positive 
C20 H33 O3 N3 C20-guanidino phytosphingolipid 364.2586 12.13 positive 
C15H16N10O2 drosopterin 369.1531 20.4 positive 
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C17H20N4O6 Riboflavin 377.1455 10.42 positive 
C12H21PN5O7 C12H20PN5O7 378.1159 19.71 positive 
C14H17N5O8 Succinyladenosine 384.1151 11.89 positive 
C28H42O Ergosta-5,7,22,24(28)-tetraen-3beta-ol 395.3311 5.697 positive 
C23H45NO4 L-Palmitoylcarnitine 400.3422 11.6 positive 
C20H13N3O8 Xanthomattin 424.0776 14.57 positive 
C25H45NO4 Linolenylcarnitine 424.342 11.59 positive 
C25H47NO4 Linolylcarnitine 426.3575 11.56 positive 
C13H22N4O8S2 S-Glutathionyl-L-cysteine 427.0951 22.68 positive 
C10H15N5O10P2 ADP 428.0368 24.42 positive 
C25H49NO4 Oleoylcarnitine 428.3733 11.47 positive 
C11H20N4O11P2 CDP-ethanolamine 447.0678 22.04 positive 
C14H18N5O11P N6-(1,2-Dicarboxyethyl)-AMP 464.0813 17.1 positive 
C21H41O7P DHAP(18:0) 478.2923 10.85 positive 
C18H32O16 Raffinose 505.1765 18.32 positive 
C17H27N3O17P2 UDP-N-acetyl-D-glucosamine 608.0888 20.95 positive 
C21H28N7O14P2+ NAD+ 664.1163 20.58 positive 
C24H42O21 Stachyose 667.229 18.32 positive 
C37H72NO8P PE(18:0/14:1(9Z)) 690.5064 9.469 positive 
C37H72NO8P PE(18:0/14:1(9Z)) 690.5067 6.503 positive 
C40H75O10P PG(16:0/18:2(9Z,12Z)) 747.5167 8.266 positive 
C30H52O26 Cellopentaose 829.2809 20.43 positive 
C3H4O3 pyruvic acid 87.00881 7.547 Negative 
C3H6O3 Lactic acid 89.02444 7.774 Negative 
C3H6O3 beta lactic acid  89.02446 6.755 Negative 
C3 H6 O4 Glycolic acid 105.0194 7.285 Negative 
C4H4O4 Fumaric acid  115.0038 7.513 Negative 
C4H6O4 Succinic acid  117.0193 8.096 Negative 
C4H8O4 Erythrose 119.0351 16.72 Negative 
C5H6O4 Glutaconic acid 129.0194 12 Negative 
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C5H8O4 pentanedioic acid 131.0351 6.239 Negative 
C4H7NO4 2-aminobutanedioic acid 132.0303 19.04 Negative 
C4H6O5 malic acid 133.0143 10.62 Negative 
C5H10O4 Deoxyribose 133.0507 8.16 Negative 
C4H8O5 Erythronic acid 135.03 6.829 Negative 
C5H6O5 Oxoglutaric acid 145.0143 8.493 Negative 
C6 H10O4 Adipic acid 145.0507 6.359 Negative 
C5H8O5 Citramalic acid 147.0299 9.055 Negative 
C6H12O4 Mevalonic acid 147.0663 8.158 Negative 
C5H10O5 pentose 149.0457 12.47 Negative 
C8H8O3 3,4-Dihydroxyphenylacetaldehyde  151.0401 5.445 Negative 
C5H12O5 D-Xylitol 151.0613 15.15 Negative 
C7H12N2O3 Glycylproline 153.067 6.378 Negative 
C5H4N2O4 Orotic acid 155.01 12.4 Negative 
C7H11NO3 Tiglylglycine 156.0667 24.82 Negative 
C5H4O3 Furoic acid 157.0143 9.632 Negative 
C6H8O5 Oxoadipic acid 159.03 11.92 Negative 
C8H16O3 (R)-2-Hydroxycaprylic acid 159.1027 5.557 Negative 
C5H6O6 Hydroxyoxoglutaric acid 161.0092 6.415 Negative 
C5H10O6 Arabinonic acid 165.0406 15.56 Negative 
C9H10O3 Homovanillin 165.0558 5.774 Negative 
C8H8O4 3,4-Dihydroxymandelaldehyde 167.035 5.686 Negative 
C3H6O6P Glyceraldehyde phosphate 168.991 17.8 negative 
C3H9O6P Glycerol 3-phosphate 171.0064 17.81 Negative 
C6H6O6 -Aconitic acid 173.00925 10.166 Negative 
C6H8O6 Ascorbic acid 175.0248 9.632 Negative 
C6H10O6 3-Keto-b-D-galactose 177.04051 11.915 Negative 
C6H12O6 hexose 179.05612 16.717 Negative 
C6H12N2O3 D-Alanyl-D-alanine 181.06035 16.717 Negative 
C6H14O6 hexitol 181.07184 15.92 Negative 
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C4H9NO5S Homocysteic acid 182.01288 9.449 Negative 
C7H8O6 cis-2-Methylaconitate 187.02487 8.392 Negative 
C6H8O7 Isocitric acid 191.01979 12.073 Negative 
C7H12O6 Quinic acid 191.05626 13.916 Negative 
C6H12O7 Gluconic acid 195.05104 16.507 Negative 
C10H11NO Tryptophanol 196.05437 16.378 Negative 
C8H15N3O4 N-a-Acetylcitrulline 198.08852 18.437 Negative 
C8H16N2O5 N-Acetyl-b-glucosaminylamine 201.08812 9.219 Negative 
C8H7NO4 2-Methyl-3-hydroxy-5-formylpyridine-4-
carboxylate 
202.01241 19.827 Negative 
C7H10O7 Homocitric acid 205.03539 10.442 Negative 
C13 H20 O2 4-heptoxyphenol 207.13905 5.244 Negative 
C6H13NO5 Fructosamine 214.04868 19.37 Negative 
C4H11O3PS Diethylthiophosphate 215.01419 11.972 Negative 
C5 H13 O7 P 2-C-methyl-D-erythritol 4-phosphate 215.03276 16.147 Negative 
C5H14NO6P Glycerylphosphorylethanolamine 215.05588 8.008 Negative 
C9H9NO4 3-Hydroxyhippuric acid 216.02798 19.049 Negative 
C3H9O6P Glycerol 3-phosphate 217.01196 17.828 Negative 
C10H12O4 Homoveratric acid 217.04832 15.969 Negative 
C6H10N3O4P 4-Amino-2-methyl-5-phosphomethylpyrimidine 218.03294 16.147 Negative 
C9H17NO5 Pantothenic acid 218.10339 8.135 Negative 
C9H11N5O2 2'-Deoxysepiapterin 220.08405 10.98 Negative 
C11H13NO3 N-Acetyl-L-phenylalanine 228.06442 23.292 Negative 
C3H8NO8P Glycero Phosphoserine 230.00722 19.04 Negative 
C4H10NO8P Glycero Phosphothreonine 244.0229 18.604 Negative 
C15H22O3 2-Ethylhexyl 4-hydroxybenzoate 249.14967 5.123 Negative 
C10H14N2O6 3-Methyluridine 257.07813 7.862 Negative 
C15H14O6 Epicatechin 271.06067 18.41 Negative 
C12H15NO5 Acetylvanilalanine 274.06995 23.288 Negative 
C16H22O4 Alpha-CEHC 277.14453 4.688 Negative 
C7H15O10P Sedoheptulose 7-phosphate 289.03314 19.235 Negative 
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C17H26O4 Gingerol 293.1759 5.266 Negative 
C10H16NO3PS Aminoparathion 306.05798 11.504 Negative 
C9H19O11P 1-(sn-Glycero-3-phospho)-1D-myo-inositol 333.05933 18.967 Negative 
C11H16N2O8 N-Acetylaspartylglutamic acid 349.08893 9.445 Negative 
C15H20O10 3-Methoxy-4-hydroxyphenylglycol glucuronide 359.09836 8.14 Negative 
C12H23NO10 Lactosamine 376.1015 19.595 Negative 
C18H38NO5P Sphingosine 1-phosphate 424.24701 11.056 Negative 
C20H30O5 15-Keto-prostaglandin E2 387.15781 8.115 Negative 
C21H18O8 7-Deoxyadriamycinone 397.09323 16.154 Negative 
C23H37NO5 Columbiananin 406.25998 5.311 Negative 
C22H37NO3 Leukotriene B4 dimethylamide 408.27533 5.255 Negative 
C28H42O2 (R)-gamma-Tocotrienol 409.31128 5.023 Negative 
C23H43NO6 Hexadecanedioic acid mono-L-carnitine ester 410.2908 5.216 Negative 
C30H44O2 Demethylphylloquinone 436.33414 3.995 Negative 
C21H42NO7P LysoPE(16:1(9Z)/0:0) 450.26251 10.86 Negative 
C21H44NO7P LysoPE(16:0/0:0) 452.27805 10.946 Negative 
C22H44NO7P LysoPC(14:1(9Z)) 464.27829 10.82 Negative 
C23H42NO7P LysoPE(18:3(9Z,12Z,15Z)/0:0) 474.26263 10.86 Negative 
C23H46NO7P LysoPE(18:1(9Z)/0:0) 478.29315 10.724 Negative 
C26H22Cl2N2O3 Doconazole 479.09366 18.953 Negative 
C29H42O4 Ubiquinone Q4 489.2774 3.742 Negative 
C12H23NO4 Isovalerylcarnitine 489.31845 13.843 Negative 
C18H32O16 trihexose 503.16193 19.143 Negative 
c ADP C15H21N5O13P2 540.05359 20.522 Negative 
C36H71NO3 Ceramide (d18:1/18:0) 600.51221 5.124 Negative 
C30H60NO6P CerP(d18:1/12:0) 606.41406 9.572 Negative 
C20H32N6O12S2 Oxidized glutathione 611.14362 21.851 Negative 
C33H66NO8P PE(14:0/14:0) 634.44574 9.228 Negative 
C24H42O21 tetrahexose 665.21472 19.558 Negative 
C43 H44O19 pentahexose 863.2428 20.56 Negative 
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C31 H50 O19 N7 
P3 S 
3-Isopropenylpimelyl-CoA 948.20209 19.01 Negative 
C43H83O13P PI(16:0/18:0) 859.53168 8.212 Negative 
C41H75O13P PI(16:2(9Z,12Z)/16:0) 805.48651 8.252 Negative 
C42H70NO10P PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/14:0) 778.46576 8.324 Negative 
C42H74NO10P PS(20:4(5Z,8Z,11Z,14Z)/16:0) 782.49701 8.324 Negative 
C45H76NO8P PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:1(9Z)) 788.52441 5.564 Negative 
C45H78NO8P PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0) 790.53967 5.557 Negative 
C45H76NO7P PE(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-18:1(9Z)) 808.5061 8.272 Negative 
C14H25NO11 N-Acetyllactosamine 811.284 19.439 Negative 
C44H78NO8P PC(18:4(6Z,9Z,12Z,15Z)/18:1(9Z)) 824.54431 11.238 Negative 
C43H81O13P PI(18:1(9Z)/16:0) 857.51697 8.212 Negative 
C43H82O16P2 PIP(18:1(9Z)/16:0) 897.48956 10.044 Negative 
C45H82O16P2 PIP(18:3(6Z,9Z,12Z)/18:0) 921.48926 9.83 Negative 
C47H83O13P PI(22:4(10Z,13Z,16Z,19Z)/16:0) 923.50531 10.061 Negative 
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